<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/228787-pyrrole-compound by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:24:43 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 228787:PYRROLE COMPOUND</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">PYRROLE COMPOUND</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Novel pyrrazole compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (1) is a four, five, or six membered saturated ring and X is C, O or S.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>FIELD OF THE INVENTION<br>
The present invention relates to pyrrole derivative compounds of formula I and their use as<br>
pharmaceutical agents, in particular their use as TCF-beta signal transduction inhibitors.<br>
BACKGROUND AND PRIOR ART<br>
The transforming growth factor-beta (TGF-Beta) ("TGF-β") polypeptides influence growth,<br>
differentiation, and gene expression in many cell types The first polypeptides of this family<br>
that was characterized, TGF- (β1, has two identical 112 amino a single amino acid subunits<br>
that are covalently linked. TGF- (β1 is a highly conserved protein with only a single amino<br>
acid difference distinguishing humans f rom mice. There are two other members of the TGF-|β<br>
gene family that are expressed in mammals. TGF- β2 is 71% homologous to TGF- (β1 (de<br>
Martin, et al. (1987) EMBO J. 6:3673-:i677), whereas TGF- (β3 is 80% homologous to TGF-<br>
(β1 (Derynck, et al. (1988) EMBO J 7::;737-3743). The structural characteristics of TGF- (β1<br>
as determined by nuclear magnetic resonance. (Archer, et al. (1993) Biochemistry 32:1164-<br>
1171) agree with the crystal structure of TGF- (32 (Daopin, et al. (1992) Science 257:369-374;<br>
Schlunegger and Grutter (1992) Nature 358:430-434)<br>
There are atleast three different extracellular TGF- (β receptors, Type I, II and III that are<br>
involved in the biological functions of TGF- β1, - β2, - (β3 (For reviews, see Derynck (1994)<br>
TIBS 19: 548-553 and Massague (1990) Ann. Rev. Cell Biol. 6:597-641) The Type I and<br>
Type II receptors are transmembrane se rine/threonine kinase which in the presence of TGF- P<br>
form aheteromeric signaling complex (Wrana, et al (1992) Cell 71: 1003-1014).<br>
The mechanism of activation of the beteromerie signaling complex at the cell surface has<br>
been elucidated (Wrana, et al. (1994) Nature 370:341-347). TGF- β first binds the type II<br>
receptor that is constitutively active :ransmembrane serine/ threonine kinase. The type 1<br>
receptor is subsequently recruited into complex, phoshorylated at the GS domain and<br>
activated to phosphorylate downstrearr signaling components (e.g. Smad proteins) to initiate<br>
the intracellular signaling cascade. A constitutively active type I receptor (T204D mutant) has<br>
been shown to effectively transduce TGF- β responses, thus bypassing the requirement for<br>
TGF- P and the type II receptor (Wiese •, et al. (1995)<br><br>
EMBO J 14: 2199-2208). Although no signaling function has been discovered for the<br>
type III receptor, it does increase TGF-β2's affinity for the type II receptor making it<br>
essentially equipotent with TGF-β1 and TGF-β3 (Lopez-Casillas, et al. (1993) Cell 73:<br>
1435-1444).<br>
Vascular endothelial cells lack the Type 111 receptor. Instead endothelial cells<br>
express a structurally related protein called endoglin (Cheifetz, et al. (1992) J. Biol.<br>
Chem. 267:19027-19530), which only binds TGF-β1 and TGF-β3 with high affinity.<br>
Thus, the relative potency of the TGF-β's reflects the type of receptors expressed in a cell<br>
and organ system. In addition to the regulation of the components in the multi-factorial<br>
signaling pathway, the distribution of the synthesis of TGF-β polypeptides also affects<br>
physiological function. The distribution of TGF-β2 and TGF-(β3 is more limited<br>
(Derynck, et al. (1988) EMBO J 7:3737-3743) than TGF-pl, e.g., TGF-p3 is limited to<br>
tissues of mesenchymal origin, whereas TGF-βl is present in both tissues of<br>
mesenchymal and epithelial origin.<br>
TGF-β1 is a multifunctional cytokine critical for tissue repair. High<br>
concentrations of TGF-βl are delivered to the site of injury by platelet granules (Assoian<br>
and Sporn (1986) J. Cell Biol. 102:1217-1223). TGF-βl initiates a series of events that<br>
promote healing including chemo taxis of cells such as leukocytes, monocytcs and<br>
fibroblasts, and regulation of growth factors: and cytokines involved in angiogenesis, cell<br>
division associated with tissue repair and inflammatory responses. TGF-βl also<br>
stimulates the synthesis of extracellular matrix components (Roberts, et al. (1986) Proc.<br>
Natl. Acad. Sci. USA 83:4167-4! 71; Sporn, et al. (1983) Science 219:1329-1330;<br>
Massague (1987) Cell 49:437-438) and most importantly for understanding the<br>
pathophysiology of TGF-βl, TGF-βl autoiregulates its own synthesis (Kim, et al. (1989)<br>
J. Biol. Chem. 264:7041-7045).<br><br>
SUMMARY OF THE INVENTION<br>
The disclosed invention relates to compounds of the structure:<br>
wherein <br>
is a four, five, or six membered saturated ring and X is C, O or S;<br>
Rl is unsubstituted or substituted phenyl; unsubstituted or substituted pyridine;<br>
unsubstituted or substituted pyridine N-oxide; unsubstituted or substituted quinoline;<br>
unsubstituted or substituted quinoline N-oxide; unsubstituted or substituted<br>
naphthyridine; unsubstituted or substituted pyrazine; fury I; unsubstituted or substituted<br>
thiazoly); unsubstituted or substituted imidazollyl; unsbustituted or substituted pyrazolyl;<br>
or unsbustituted or substituted thioplhenyl; wherein the substitution may be one or mere of<br>
the following: (Cl-C6)a1kyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (Cl-C6)lkoxy, (C2-<br>
C6)alkenyloxy, (C2-C6)alkynyloxy, (Cl-C6)a]kylthio, (Cl-C6)alkylsulphinyl, (Cl-<br>
C6)alkylsulphonyl, (Cl-C6)alkylamino, di-((Cl-C6)alkyl]amino, (Cl-<br>
C6)alkoxycarbonyl, N-(C1-C6)alkykarbamoyl, N,N-di-[(Cl-C6)lkyl)carbamoyl, (G2-<br>
C6)alkanoyl, (C2-C6)alkanoyloxy, (C2-C6)alkanoylamino, N-(C1-C6)alkyl-(C2-<br>
C6)alkanoylamino, (C3-C6)alkenoyliamino, N-(C1 -C6)alkyl-(C3-C6)alkenoylamino, (C3-<br>
C6)alkynoylamino, N-(C1 -C6)alkyl (C3-C6)alkynoylamino, N-(C1-C6)alkylsulphamoyl,<br>
N,N-di-[(C 1 -C6)alkyl]sulphamoyl, (C1 -C6)alkanesulphonylamino, N-(C 1 -C6)a1kyl-(C 1 -<br>
C6)alkanesulphonylamino, carboxaraide, ethylene, thiophenyl, aminophenyl,<br><br>
trifluoromethyl, halo, trifluoromethoxy, hydroxymethyl, N-pyrrolidino, N-morphoIino,<br>
phenylthio, (Cl-C4)dialkylaminomethyl, methoxyphenyl, amino, hydroxy, carboxyl,<br>
phenyl, arylalky;<br>
R2 is unsubsthuted or substituted quinoline; unsbustituted or substituted quinoline<br>
N-oxide; unsbustituted or substituted phenyl; unsubstituted or substituted naphthalene;<br>
unsubstituted or substituted pyridine; unsubstituted or substituted pyridine N-oxide;<br>
unsbustituted or substituted quinazoline; unsubstituted or substituted cinnoline;<br>
unsubstituted or substituted benzodioxole; unsbustituted or substituted benzodioxane;<br>
unsubstituted or substituted pyrimidine; unsubstituted or substituted benzothiophene; or<br>
unsubstituted or substituted phenanthrolene; wherein the substitution may independently<br>
be one or more of the following: hydrogen, (Cl-C6)alkyl, (C2-C6)alkenyl, (C2-<br>
C6)alkynyl, (C1-C6) aHcylhalide, (Cl-C6)alkoxy, (C2-C6)alkenyloxy, (C2-<br>
C6)alkynyloxy, (Cl-C6)alkylthio, (CI-C6)alky)lsulphinyl, (Cl-C6)alkylsulphonyl, (Cl-<br>
C6)alkylamino, di-[(Cl-C6)alky))ammo, (Cl-C6)alkoxycarbonyl, N-(C1-<br>
C6)alkylcarbamoyl, N,N-di-[(C J-C6}alkyl]carbamoyl, aminooxy, N-(C1-C6)alkyl<br>
aminooxy, N,N-di-[(Cl-C6)alkyl]aminooxy, (C2-C6)alkanoyl, (C2-C6)alkanoyloxy,<br>
(C2-C6)alkanoylamino, N-(C1 -C6)alkyl-(C2-C6)alkanoylamino, (C3-C6)alkenoylamino,<br>
N-(C1-C6)alkyl-(C3-C6)alkenoylamiiio, (C3-C6)alkynoylamino, N-(C I -C6)alkyMC3-<br>
C6)alkynoylamino, sulphamoyl, N-(C1-C6)alkylsulphamoyl, N,N-di-[(Cl-<br>
C6)alkyl]sulphamoyl, (C1 -C6)alkanesulphonyla;mino, N-(C1 -C6)alkyl-(C1 -<br>
C6)alkanesulphonylamino, carboxami de, ethylene, phenyl, thiophenyl, aminophenyl,<br>
phenylthio, halo, cyano, pyridinyl, arylalkyl, hydroxy, N-pyrrolidino, N-morpholino,<br>
carboxyl, [5-phenyI-l,2,4-oxadiazole-3-yl]methoxy, 6-methyl-pyridazin-3-yloxy, (5-oxo-<br>
2-pyrrolidinyl)methoxy, 2-(4,5-dihydro-lH-imidazolyl), N, N-dialkylcarbamoyloxy, 1-<br>
hydroxy-1-methylethyl, 4-fluorophenyl, 3,4-methylenedioxyphenyl, trifluoromethyl,<br>
trifluoromethoxy,<br><br><br>
wherein: X, is O, N, S, SO2.NR,3, C(O), or bond; Qi is hydrogen, phcnyl, 5-(2,2-<br>
difluoro-1,3-benzodioxolyI), C(O)Qs,, or pyridyl when m and n are independently 0-2,<br>
except when one is 0 the other cannot be 0; Qt is ORi i, NR|,R,2, halo, N-morpholino,<br>
N-piperazino-N'Ru, N-imidazolyl, H-pyrazolyl, N-triazolyl, N-(4-piperidinyIpiperidine),<br>
SO2R14, SORu, NHSO2R1S, acetamido, N-phthalimido, N-oxazolidino, N-imidazoIino, N-<br>
benzoxazolidino, N-pyrolidinonyl, N(N'-methylbenzimidazolino), N,N-di(Cl-<br>
C4)alkylamino(Cl-C4)alkoxy, N-beiizimidazolino; when m and n are independently 0-2,<br>
but one or the other of m or n is not 0; Q5 is hydroxy, methoxy, amino, diethylamino,<br>
dimcthylamino; Rio is hydrogen, halo, (Cl-C6)alkyl; Rn and R12 are independently<br>
hydrogen, (Cl-C6)alkyl, (Cl-C6)alkoxy, arylalkyl, (C3-C8)cycloalkyl, (C3-<br>
C8)cycloalkylmethyl, 4-(N-methyIpiperidiriylj, pyridyl, or Rt 1 and Rio can be taken<br>
together to form a 4,5,6, or 7 membered ring, or R| 1 and R12 can be taken together to<br>
form a 3,4, 5,6, or 7 membered ring; Rn is hydrogen, (Cl-C6)alkyl, 2-methoxyphenyl,<br>
2-pyridimidinyl; Ru is 2-pyrimidinyl, N-methyl-2-imidazolyl, 4-chlorophenyl, 2-<br>
pyridylmethyl; R15 is (Cl-C6)alkyl, N-methyl-4-imidazolyl; Rt6 is hydrogen, halo,<br>
arylalkyl, aryl,<br><br><br>
wherein: Q2 is hydrogen, 4-imidazolyl, or C(O)NR24R25 when o and p are independently<br>
0-2; Q2 is OR23, NR24R25, or N-morpholino, when o and p are independently 0-2, but one<br>
or the other of o or p is not 0; R20 is hydrogen, or (Cl -C6)alkyl; R2i is hydrogen, (Cl -<br>
C6)alkyl, or R2| and R20 can be taken together to form a 4,5,6, or 7 membered ring; R22<br>
is hydrogen, (Cl-C6)alkyl, arylalkyl, aryl, or R2i and R22 can be taken together to be a 3,<br>
4, 5, 6, 7 membered ring; R23 is hydrogen or (Cl-C6)alkyl; R24 is hydrogen, (Cl-<br>
C6)alkyl, or R24 and R25 can be takem together to form a 3,4, 5,6, or 7 membered ring, or<br>
R24 and R20 can be taken together to form a 6 or 7 membered ring; R25 is hydrogen, (Cl-<br>
C61alkvl. or acetvl.<br><br>
wherein: R30 is hydrogen, or (Cl-C6)alkyl; R31 is hydrogen, (Cl -C6)alkyl, 2-pyridyl,<br>
pyridylmethyl, amino, or hydroxy,<br><br>
or a group of the formula<br><br>
wherein: R32 and R33 are each independently hydrogen, (Cl-C6)alkyl, acetyl, (Cl-<br>
C4)aIkyIsuJphonyl, or R32 and R33 tan be taken together to form a 4, 5,6, or 7 membered<br>
ring,<br>
or a group of the formula <br>
wherein: X2 is CH2, O, or N; q is 2-3 except when Qj is a bond, q is 0-3; Q3 is NR36R37,<br>
or OR38, and R35 is hydrogen, or R,5 and Q3 can be taken together to form a 5 membered<br>
ring; R36, R37, and R38 are each independently hydrogen, or (Cl-C6)alkyl,<br>
or a group of the formula<br><br>
wherein: X3 is cyano, carboxamide, N,N-dimeihylcarboxamide, N,N-<br>
dimethyhhiocarboxamide, N,N-dimethylaminomethyl, 4-methylpiperazin-lyl-methyl or<br>
carboxylate,<br><br>
or a group of the formula<br><br>
wherein: Q6 is NR41R12; r is 2-3; R40 is hydrogen, or (Cl-C6)alkyl; R41 and R42are<br>
hydrogen, (CI-C6)alkyl, or R41 and R40 can be taken together to form a 6 or 7 membered<br>
ring.<br>
or a group of the formula <br>
wherein: Q7 is hydroxy, methoxy, diniethylamino, or N-piperidinyl;<br>
with the proviso that when one of Rl or R2 is tmsubtituted or substituted phenyl, then<br>
the other cannot be unsubstituted or substituted phenyl or thiophen-2-yl; and with the<br>
proviso that when R2 is quinolin-4-yl, substitution at the quinoline 7-position cannot<br>
include an aryl, heteroaryl, fused aryl, or fused heteroaryl;<br>
k is 1-8; R3 is one or more of the following: hydrogen; (Cl-C4)alkyl; (Cl-<br>
C4)alkylhydroxy; hydroxy; N,N-di(Cl-C4)alkylamino(CI-C4)alkoxy; benzyl oxymethyi;<br>
phenyloxymethyl; oxo; carboxyl; (C1-C4) alkylaryl; benzyloxy; acetoxy, amino(CI-<br>
C4)alkyl; (C2-C4)alkenyl; halo; O-(C1-C4)alkyl; chiorophenethyl; acetonitrile;<br>
unsubsituted or substituted phenyl; wherein the substitution may be one or more of the<br>
following: (Cl-C6)alkoxy, halo, carboxy, or (Cl-C6)alkoxycarbonyl; and the<br>
pharmaccutically acceptable salts, esters and prodrugs thereof.<br><br>
DETAILED DESCRIPTION OF THE INVENTION<br>
The term "effective amount" as used in "an effective amount of a compound of<br>
Formula 1," for example, refers to an amount of a compound of the present invention that<br>
is capable of inhibiting TGF beta.<br>
The general chemical terms used herein have their usual meanings. For example,<br>
as used herein, the teifn "C1-C4 alkyl", alone or in combination, denotes a straight-chain<br>
or branched-chain C1-C4 alkyl group consisting of carbon and hydrogen atoms, examples<br>
of which are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, and the like.<br>
The term "geminal dimethyl" represents two methyl groups attached at the same<br>
substitution position. The term C3-C6 cycloalkyl" refers to cyclopropyl, cyclobutyl,<br>
cyclopentyl, cyclohexyl. The term 'spiro-fused C3-C6 cycloalkyl" refers to a C3-C6<br>
cycloalkyl group as defined above tonded to a carbon atom through a spiro linkage.<br>
The term "C1-C4 alkoxy", alone or in combination, denotes an alkyl group as<br>
defined earlier, which is attached via an oxygen atom, such as, for example, methoxy,<br>
ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, and the like. The term "C1-C4<br>
alkylthio", alone or in combination, denotes an alkyl group as defined earlier and is<br>
attached via a sulfur atom, and includes methylthio, ethylthio, isobutylthio, and the like.<br>
As used herein, the term "halo" or "halogen" represents fluorine, chlorine,<br>
bromine, or iodine. The term "hydroxy," alone or in combination, represents an -OH<br>
moiety. The term "carboxy" or "carboxyl" refers to a carboxylic acid. The term<br>
"carboxamide" refers to a carbonyl substituted with an -NH2 moiety. The term "oxo"<br>
refers to a carbonyl group.<br>
As used herein, the term "heteroaryl" means an aryl moiety, which contains 1 -5<br>
heteroaioms selected from O, S, and N. Examples of heteroaryl groups include pyrrolyl,<br>
pyrazolyl, pyranyl, thiopyranyl, furamyl, imidazolyl, pyridyl, thiazolyl, triaziny),<br>
phthalimidyl, indolyl, purinyl, and benzothiazolyl.<br>
As used herein, the term "aryl" represents a substituted or unsubstituted phenyl or<br>
naphthyl. Aryl may be optionally substituted with one or more groups independently<br>
selected from hydroxy, carboxy, C1-C6 alkoxy, C1-C6 alkyl, halogen, carboxamide,<br>
trifluoromethyl, hydroxymethyl, and hydroxy(C1-C4alkyl. <br><br>
The term "C3-Cg cycloalkyl" refers to cyclopropyl, cyclobutyl, cyclopentyl,<br>
cyclohexyl, cycloheptyl, and cyclooctyl. The term "optionally substituted C3-C8<br>
cycloalkyl" refers to a Cj-Cg cycloa Ikyl as defined herein unsubstituted or substituted<br>
with one or more groups independently selected from hydroxy, carboxy, Cu alkoxy, Ci-e<br>
alkyl, halogen, carboxamide, trifluoromethyl, hydroxymethyl, and hydroxy(C|-C4)alkyl.<br>
As used herein, the term "saturated heierocycle" is taken to be a 4-9 membered<br>
ring containing nitrogen and optionally one other atom selected from oxygen, nitrogen,<br>
and sulfur. The term "optionally substituted saturated heterocycle" is taken to be a<br>
saturated heterocycle as defined herein unsubstituted or substituted with one or more<br>
groups independently selected from hydroxy, carboxy, C14 alkoxy, Cj^ alkyl, halogen,<br>
carboxamide, trifluoromethyl, hydrcocymethyl, and hydroxy(CrC4)alkyl.<br>
As used herein, the term "C]~C6 alkyl" refers to straight or branched, monovalent,<br>
saturated aliphatic chains of I to 6 carbon atoms and includes, but is not limited to,<br>
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, tsopentyl, and hexyl. The<br>
term "C]-C6 alkyl" includes within its definition the terms "C1-C4 alkyl" and "C|-Q»<br>
alkyl."<br>
"C\-C(, alkenyl" refers to a straight or branched, divalent, unsaturated aliphatic<br>
chain of 1 to 6 carbon atoms and includes, but is not limited to, methylenyl, ethylenyl,<br>
propylcnyl, isopropylenyl, butylenyl, isobutylenyl, /-butylenyl, pentylenyl, isopentylenyl,<br>
hexylenyl.<br>
"C]-C6 alkoxycarbonyl" represents a straight or branched d-Q alkoxy chain, as defined<br>
above, that is attached via the oxygen atom to a carbonyl moiety. Typical C]-Co<br>
alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,<br>
isopropoxycarbonyl, butoxycarbonyl, /-butoxycarbonyl and the like.<br>
The term "di(Ci-C6 alkyl)aniino" refers to a group of the formula:<br><br>
wherein each R group independently represents a "C1-C6 alkyl" group, as defined above.<br><br>
An "optionally substituted phenyl" is a phenyl ring that is unsubstituted or<br>
substituted with 1 to 5 substituents, more preferably 1 to 3 substituents, for example: halo,<br>
Ci-Cfi alkyl, C\-C(, alkoxy, Cj-C6 alkylamino, trifluoromethyl, nitro, and cyano.<br>
An "optionally substituted benzyl" is a benzyl ring that is unsubstituted or<br>
substituted with 1 to 5 substituents, more preferably I to 3 substituents, for example: halo,<br>
C i -C6 alkyl, Ci -C6 alkoxy, trifluoromethyl, nitro, and cyano.<br>
"Phenoxycarbonyl" refers to the group: phenyl-O-C(O&gt;. "Aryl" refers to an<br>
unsaturated aromatic carbocyclic group of 6 to 14 carbon atoms having a single ring (e^.,<br>
phenyl) or multiple condensed (fused) rings (e.g., naphthyl or anthracenyl).<br>
Unless otherwise constrained by the definition for the aryl substituent, such aryl<br>
groups can optionally be substituted with 1 to 5 substituents, more preferably 1 to 3<br>
substituents, selected from the group consisting of halo, hydroxy, acetyl, nitro, cyano,<br>
Cj-C6 alkyl, C]-C6 alkoxy, phenyl, di(Cj-C6 alkyl)amino, trifluoromethyl,<br>
trifluoromethoxy, -S(O)m-(Ci-Q alkyl), and - S»(O)m-(phenyl), wherein m can be 0, 1, or<br>
2.<br>
"Arylalkyl" refers to aryl groups attached to alkyl groups, preferably having 1 to 6<br>
carbon atoms in the alkyl moiety and 6 to 10 carbon atoms in the aryl moiety. Such<br>
arylalkyl groups are exemplified by t&gt;enzyl, phenethyl, and the like.<br>
Unless otherwise constrained by the. definition for arylalkyl, such arylalkyl groups<br>
can be optionally substituted with 1 w&gt; 5 substituents, more preferably 1 to 3 substituents,<br>
selected from the group consisting of halo, hydroxy, nitro, cyano, C\-C(, alkyl, C]-C6<br>
alkoxy, di(C]-C6 alkyl)amino, trifluoromethyl, trifluoromethoxy, carbamoyl,<br>
pyrrolidinyl, -S(O)m-(Ci-C6 alkyl), and-S(O)n,-(phenyl), wherein m can be 0,1, or 2.<br>
The arylalkyl groups may be optionally substituted on the aryl moiety, the alkyl moiety,<br>
or both the aryl moiety and the alkyl moiety.<br>
The term "heterocycle" represents an unsubstituted or substituted S- to 7-<br>
membered monocyclic, or 7- to 11-membercd bicyclic heterocyclic ring that is saturated<br>
or unsaturated and that consists of carbon atoms and from one to five heteroatoms<br>
selected from the group consisting of nitrogen, oxygen or sulfur, and including a bicyclic<br>
group in which any of the above-defined heterocyclic rings is fused to a benzene ring to<br>
another heterocycle as defined above.<br><br>
The term "heteroaryls" represents the above-defined heterocylic rings that are<br>
fused to a benzene ring to another lieterocylce as defined above.<br>
Unless otherwise constrained by the definition for the heterocyclic substituent,<br>
such heterocycles can be optionally substituted with I to 8 substituents selected from the<br>
group consisting of halo, nitro, cyano, hydroxy, acetyl, Cj-C6 alkyl, C1-Q5 alkoxy,<br>
C3-C10 cycloalkyl, optionally substituted phenyl, phenethyl, phenoxy, phenoxycarbonyl,<br>
optionally substituted benzyl, 1,1-diphenylmethyl, oxo, C\-C6 alkoxycarbonyl, (C]-Q&gt;<br>
alkoxy)Ci-C6 alkyl-, trifluoromethyl, pyridyl, (pyrrolidinyl)Ci-C6 alkyl-, and<br>
(pyridyl)Ci-C6 alkyl-, di(Ci-C6 alkyl)amino, trifluoromethyl, trifluoromethoxy, -S(O)m-<br>
(C|-Cc, alkyl), and - S(O)m-(phenyI), wherein m can be 0,1, or 2.<br>
Examples of such heterocycles; include azepinyl, azetidinyl, benzazepinyl,<br>
benzimidazolyl, benzoazolyl, benzodioxolyl, benzodioxanyl, benzopyranyl,<br>
benzothiazolyl, benzothienyl, dihydropyrazolooxazinyl, dihydropyrazolooxazolyl, furyl,<br>
imidazolyl, imidazolinyl, imidazolidinyl, indolinyl, indolyl, isoindolinyl, isoquinolinyl,<br>
isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, napthyridinyl,<br>
oxadiazolyl, oxazolyl, oxazolidinyl phlhalimidyl, piperazinyl, piperidinyl, pyrazinyl,<br>
pyridyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridyl, pyrimidinyl,<br>
pyridazinyl, pyrrolidinyl, pyrrolopyrazolyl, p&gt;Trolyl, quinazolinyl, quinolinyl,<br>
quinuclidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydroisoquinolinyl,<br>
tetrahydroquinolinyl, thiazolyl, thiazolinyl, thiazolidinyl, thiadiazolyl, thienyl,<br>
thiomorpholinyl, triazolyl, and the like.<br>
Preferred heterocycles include: benzodioxolyU dihydropyrrolopyrazolyl,<br>
pyridyl, quinolinyl.<br>
Preferred embodiments of the invention include the following:<br><br>
One preferred embodiment of the invention are compounds of the structure:<br>
wherein <br>
is a five or six membered saturated ring;<br>
Rl is defined as in Claim 1;<br>
R2' is hydrogen; (Cl-C6)alkyl; (Cl-C6)a1kylthio; (Cl-C6)alkoxy; halo;<br>
thiophenyl; aminophenyl; N-pyrrolicilino; N-morpholino;<br>
R6' and R7' are independently one or more of the following: hydrogen, (Cl -<br>
C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynylf (C!l-C6)alkylhalide, (Cl-C6)alkoxy, (C2-<br>
C6)alkenyloxy, (C2-C6)alkynyloxy, (Cl-C6&gt;lkyllhio, (Cl-C6)alkylsulphinyl, (Cl-<br>
C6)alky!sulphonyl, (Cl-C6)alkylamino, di-[(CI-C6)alkyl)amino, (Cl-<br>
C6)alkoxycarbonyl, N-<c1-c6 n></c1-c6>
aminooxy, N-(CI-C6)alkyl aminooxy, N,N-di-((Cl-C6)aIkyl]aminooxy, (C2-<br>
C6)alkanoyl, (C2-C6)alkanoyloxy, (<:2-c6 n-></:2-c6>
C6)alkanoylamino, (C3-C6)alkenoylamino, NHC1-C6)alkyl-(C3-C6)alkenoylamino, (C3-<br>
C6)alkynoylamino, N-(CI-C6)alkyl-(C3-C6)alkynoylamino, sulphamoyl, N-(C1-<br><br>
C6)alky!sulphamoy!,N,N-di-[(Cl-C6)alkyl}sulphamoyl,(Cl-C6)alkanesu]phonylamino,<br>
N-(C1-C6)alkyl-(C1-C6)alkanesulphonylarnino, carboxamide, ethylene, phenyl,<br>
thiophenyl, aminophenyl, phenylthio, halo, cyano, pyridinyl, arylalkyl, hydroxy, N-.<br>
pyrrolidino, N-morphoJino, carboxyl, [5-phenyl-l,2,4-oxadiazole-3-yl]methoxy, 6-<br>
methyl-pyridazin-3-yloxy, (5-oxo- 2-pyrrolidinyl)methoxy, 2-(4,5-dihydro-l H-<br>
imidazolyl), N, N-dialkylcarbamoyiloxy, ] -hydroxy-1-methylethyl, 4-fluorophenyl, 3,4-<br>
methyJenedioxyphenyt, trifluorometihyl, trifluoromethoxy,<br>
or a group of the formula<br><br>
wherein: X, is O, N, S, SO2.NR|3, C(O), or bond; Q, is hydrogen, phenyl, 5-(2,2-<br>
difluoro-1,3-benzodioxolyl), C(O)Qs or pyridyl when m and n are independently 0-2,<br>
except when one is 0 the other cannol be 0; Qi is ORJI, NR11R12, halo, N-morpholino,<br>
N-piperazino-N'Rn, N-imidazolyl, N-pyrazolyl, N-triazolyl, N-(4-piperidinylpipcridine),<br>
SO2Ru, SOR14, NHSO2R15, acetamido, N-phfhalimido, N-oxazolidino, N-imidazolino, N-<br>
benzoxazolidino, N-pyrolidinonyl, N(N'-methylbenzimidazolino), N,N-di(Cl-<br>
C4)alkylamino(Cl-C4)alkoxy, N-ben;timidazolino; when m and n are independently 0-2,<br>
but one or the other of m or n is not 0; Q5 is hydroxy, methoxy, amino, diethylamino,<br>
dimethylamino; R)0 is hydrogen, halo, (Cl-C6)alkyl; Ru and Rl2 are independently<br>
hydrogen, (Cl-C6)alkyl, (Cl-C6)alkoxy, arylalkyl, cycloalkyl, cycloalkylmethyl, 4-(N-<br>
methylpiperidinyl), pyridyl, or R1( and Rio can be taken together to form a 4, 5, 6, or 7<br>
membered ring, or Ru and R)2 can be taken together to form a 3,4, 5, 6, or 7 membered<br>
ring; R13 is hydrogen, (Cl-C6)alkyl, 2 methoxyphenyl; Ru is 2-pyrimidinyl, N-methyl-2-<br>
imidazolyl, 4-chlorophenyl, 2-pyridylniethyl; R|- is (Cl-C6)alkyl, N-methyl-4-<br>
imidazolyl; R|6 is hydrogen, halo, arylalkyl, aryl,<br><br>
or a group of the formula<br>
* <br>
wherein: Q2 is hydrogen, 4-imidazolyl, or C(O)NR24R2s when o and p are independently<br>
0-2; Q2 is OR.23, NR24R25, or N-moipholino, when o and p are independently 0-2, but one<br>
or the other of o or p is not 0; R* »s hydrogen, or (C1 -C6)alkyl; R21 is hydrogen, (Cl -<br>
C6)alkyl, or R21 and R20 can be takttn together to form a 4,5,6, or 7 membered ring; R22<br>
is hydrogen, (Cl -C6)alkyl, arylalkyl, aryl, or R2i and R22 can be taken together to be a 3,<br>
4, 5,6,7 membered ring; R« is hydrogen or (Cl-C6)alkyl; R24 is hydrogen, (Cl-<br>
C6)alkyl, or R24 and R2S can be taken together to form a 3,4,5,6, or 7 membered ring, or<br>
R24 and R2o can be taken together to form a 6 or 7 membered ring; R2S is hydrogen, (Cl -<br>
C6)alkyl, or acetyl,<br>
or a group of the formula<br><br>
wherein: R^o is hydrogen, or (Cl-C6)alkyl; RM is hydrogen, (Cl -C6)alkyl, 2-pyridyl,<br>
pyridylmethyl, amino, or hydroxy,<br><br>
or a group of the formula<br><br>
wherein: R32 and Rj3 are each independently hydrogen, (Cl-C6)alkyl, acetyl,<br>
alkylsulphonyl, or R32 and R33 can be taken together to form a 4,5,6, or 7 membered<br>
ring,	*<br>
or a group of the formula<br><br>
wherein: X7 is CH2, O, or N; q is 2-3 except when Q3 is a bond, q is 0-3; Q3 is NR36R37,<br>
OR38, or a bond; R35 is hydrogen, 01 R35 and Q3 (when Q3 is a bond) can be taken<br>
together to form a 5 membered ring; R36, R37, and Rj8 are each independently hydrogen,<br>
or (Cl-C6)alkyl,<br>
or a group of the formula<br><br>
wherein: X3 is cyano, carboxamidc, N,N-dimethylcarboxamide, N,N-<br>
dimethylthiocarboxamide, N,N-dimethylaminomethyl, 4-methylpipera2in-lyl-methyl or<br>
carboxylate,<br><br>
or a group of the formula <br>
wherein: Qft is NR41R42; r is 2-3; R*, is hydrogen, or (Cl-C6)alkyl; R^ and R42 are<br>
hydrogen, (Cl -C6)alkyl, or R41 and R40 can be taken together to form a 6 or 7 membered<br>
ring,<br>
or a group of the formula <br>
wherein: Q7 is hydroxy, methoxy, or N-piperidinyl;<br>
k is 1-8; R3 is one or more of the following: hydrogen; (C1-C4) alkyl; (C1-C4)<br>
alkylhydroxy; hydroxy; N,N-di(Cl-C4)alkyIaimino(Cl-C4)alkoxy; benzyl oxymethyl;<br>
phenyloxymethyl; oxo; carboxyl; (C1-C4) alkylaryl; benzyloxy; acetoxy; amino(Cl-<br>
C4)alkyl; (C2-C4) alkenyl; halo; -O-(C1-C4) alkyl; chlorophcnethyl; acetonitrile; phenyl;<br>
or an optionally substituted phenyl; wherein the substitution may be one or more of the<br>
following: (C1 -C6)alkoxy, halo, cirboxy, or (Cl-C6)alkoxycarbonyl;<br>
with the proviso that R7' cannot be aryl; heteroaryl; fused aryl; or fused heteroaryl.<br>
and the pharmaceutically acceptable salts, esters and prodrugs thereof.<br><br>
Another preferred embodiment of the invention are compounds of the structure:<br>
wherein <br>
is a five or six membered ring;<br>
Rl is defined as in Claim 1;<br>
R3" is hydrogen; halo; trifluoromethyl;<br>
R4" is hydrogen; halo; (Cl-C6)alkyl; (Cl-C6)alkoxy; hydroxy; (Cl-<br>
C6)alkylsulphonyl;<br>
k and R3 are defined as in Claim I;<br>
and the pharmaceutically acceptable salts, esters and prodrugs thereof.<br><br>
Another preferred embodiment of the invention are compounds of the structure:<br>
»<br>
wherein <br>
is a five or six membered ring;<br>
R6 may be one or more of the following: hydrogen, (CJ-C6)alkyl, (C2-<br>
C6)alkenyl, (C2-C6)alkynyl, (C! -C6)alkoxy, (C2-C6)alkenyloxy, (C2-C6)alkynyloxy,<br>
(C1-C6)alkylthio, (Cl-C6)alkyIsulpWnyI, (Cl-C6)alkylsulphonyl, (Cl-C6)alkylamino,<br>
di-[(Cl-C6)alkyl]amino, (Cl-C6)all(oxycarbonyl, N-(C1-C6)alkylcarbamoyl, N,N-di-<br>
[(C1-C6)alkyl]carbamoyl, (C2-C6)alkanoy1, (C2-C6)alkanoyloxy, (C2-<br>
C6)alkanoylamino, N-(C1-C6)alkyt-<c2-c6 n-></c2-c6>
(C1 -C6)alkyl-(C3-C6)a1kenoylamino, (C3-C6)alkynoylamino, N-(C 1 -C6)alkyl-(C3-<br>
C6)alkynoylamino, N-(C1-C6)a!kyhiuiphamoyl, N,N-di-{(Cl-C6)alkyl]sulphamoyl, (Cl-<br>
C6)a!kanesulphonylamino, N-(C1-C6)alkyl-(C1-C6)alkanesxriphonylamino, carboxamtde,<br>
ethylene, thiophenyl, aminophenyl, trifiuoromethy), halo, trifluoromcthoxy,<br>
hydroxymethyl.N-pyrrolidino, N-morpholino, phenylthio, dialkylaminomethyl,<br>
methoxyphenyl, amino, hydroxy, carboxyl, phenyl, arylalky;<br>
R2" is unsubstituted or substituted quinoIine-8-yl; unsubstituted or substituted<br>
quinoline-6-yl; unsubstituted or substituted 1-naphthyl; unsubstituted or substituted 2-<br>
naphthyl; unsubstituted or substituted 3,4-methylenedioxyphenyJ; unsbustituted or<br>
substituted 3,4-ethylenedioxyphenyl; unsubstituted or substituted benzothiophen-2-yl;<br><br>
wherein the substitution may indept ndently be one or more of the following: (C1 -<br>
C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6) alkylhalide, (Cl-C6)alkoxy, (C2-<br>
C6)alkenyloxy, (C2-C6)alkynyloxy, (C1-C6)alkylthio, (Cl-C6)alkylsulphinyl, (Cl-<br>
C6)alkylsulphonyl, (Cl-C6)alkylamino, di-[(Cl-C6)alkyl]amino, (Cl-<br>
C6)alkoxycarbonyl, N-(C1 -C6)alkylcarbamoyl, N ,N-di-[(C 1 -C6)alkyl]carbamoyl,<br>
aminooxy, N-(C1-C6)alkyl aminooxy , N,N-di-[(Cl-C6)alkyl)aminooxy, (C2-<br>
C6)alkanoyl, (C2-C6)a1kanoyloxy) (C2-C6)alkanoylamino, N-(C1-C6)alky!-(C2-<br>
C6)alkanoylamino, (C3-C6)alkenoylamino, N-(CJ -C6)alkyl-(C3-C6)alkenoylamino, (C3-<br>
C6)alkynoylamino, N-(C1-C6)alkyl-(C3-C6)alkynoylamino, sulphamoyl, N-(C1-<br>
C6)alkylsulphamoyl, N,N-di-[(Cl C6)alkyl]sulphamoyl, (Cl -C6)alkanesulphonylamino,<br>
N-(CI-C6)alkyl-(C!-C6)alkanesulphonylamino, carboxamide, ethylene, phenyl,<br>
thiophenyl, aminophenyl, phenylthio, halo, cyano, pyridinyl, arylalkyl, hydroxy, N-<br>
pyrroJidino, N-roorphoJino, carboityl, [5-phenyl-l ,2,4-oxadiazole-3-yl]methoxy, 6-<br>
methyl-pyridazin-3-yloxy, (5-oxo-2-pyrroIidiny1)methoxy, 2-(4,5-ditiydro-l H-<br>
imidazolyl), N, N-dialkylcarbamcyloxy, 1 -hydroxy-1 -methylethyl, 4-fluorophenyl, 3,4-<br>
methylenedioxyphenyl, trifluoromethyl, trifluoromethoxy,<br>
or a group of the formula<br><br>
wherein: X( is O, N, S: SO2,NR|j, C(O), or bond; Qi is hydrogen, phenyl, 5-(2,2-<br>
difluoro-1,3-benzodioxolyl), C(O)Q$, or pyridyt when m and n are independently 0-2,<br>
except when one is 0 the other cannot be 0; Qi is ORn, NRuRi2, halo, N-morpholino,<br>
N-piperazino-N'Ru, N-imidazolyl, N-pyrazolyl, N-triazolyl, N-(4-piperidinylpiperidine),<br>
SOJRM, SORM, NHSO2R15, acctamido, N*phthalimido, N-oxazolidino, N-imidazolino, N-<br>
benzoxazolidino, N-pyrolidinonyl, N(N'-methylbenzimidazolino), N,N-di(Cl-<br><br>
C4)alkylamino(Cl-C4)alkoxy, N-btnzimidazolino; when m and n are independently 0-2,<br>
but one or the other of m or n is not 0; Q$ is hydroxy, methoxy, amino, diethylamino,<br>
dimethylamino; R,o is hydrogen, halo, (CJ-C6)alkyl; Ru and R)2 are independently<br>
hydrogen, (Cl-C6)alkyl, (Cl-C6)all:oxy, arylalkyl, cycloalkyl, cycioalkylmethyl, 4-(N-<br>
methylpiperidinyl), pyridyl, or Rn and Rio can be taken together to form a 4,5,6, or 7<br>
membered ring, or Rn and Rt2 can foe taken together to form a 3,4, 5,6, or 7 membered<br>
ring; R(3 is hydrogen,*(Ci-C6)alkyl, 2-methoxyphenyl; Ru is 2-pyrimidinyl, N-methyl-2-<br>
imidazoly], 4-chloropheny], 2-pyridylmethyl; Ri5 is (Cl-C6)alkyl, N-methyl-4-<br>
imidazolyl; R)6 is hydrogen, halo, arylalkyl, atyl,<br>
or a group of the formula<br><br>
wherein: Q2 is hydrogen, 4-imidazolyl, or C(O)NR24R:&gt;s when o and p are independently<br>
0-2; Q2 is OR2.1, NR24R25, or N-morpholino, when 0 and p are independently 0-2, but one<br>
or the other of o or p is not 0; R2o is hydrogen, or (Cl-C6)alkyl; R21 is hydrogen, (Cl-<br>
C6)aJkyl, or R2] and R20 can be taken together to form a 4, 5,6, or 7 membered ring; R22<br>
is hydrogen, (Cl-C6)alkyl, arylalkyl aryl, or R2i and R22 can be taken together to be a 3,<br>
4,5,6, 7 membered ring; R2j is hydrogen or (Cl-C6)alkyl; R24 is hydrogen, (Cl-<br>
C6)alkyl, or RI4 and R25 can be taken together to form a 3,4, 5,6, or 7 membered ring, or<br>
R24 and R2o can be taken together to form a 6 or 7 membered ring; R2s is hydrogen, (Cl -<br>
C6&gt;lkyl, or acetyl,<br><br>
or a group of the formula<br><br>
wherein: R30 is hydrogen, or (Cl-C6&gt;lkyl; R3t is hydrogen, (Cl-C6)alkyl, 2-pyridyl,<br>
pyridylmelhyl, amino, or hydroxy,<br>
or a group of the formula<br>
i <br>
wherein: R32 and R33 are each independently hydrogen, (Cl-C6)alkyl, acetyl,<br>
alkylsulphonyl, or R32 and R33 can be taken together to form a 4,5,6, or 7 membered<br>
ring,<br>
or a group of the formula<br><br>
wherein: X2 is CH2,0, or N; q is 2-3 except when Q3 is a bond, q is 0-3; Q3 is NR.viR37,<br>
OR38, or a bond; R3S is hydrogen, or R35 and Q3 (when Q3 is a bond) can be taken<br>
) together to form a 5 membered ring; R36, R37, and R38 are each independently hydrogen,<br>
or (Cl-C6)alkyl,<br><br>
or a group of the formula<br><br>
wherein: X3 is cyano,*carboxamide, N,N-dimethylcarboxarnide, N.TM-<br>
dimethylthiocarboxamide, N?N-di!Tieihylaminomethyl, 4-methylpiperazin-lyI-methy! or<br>
carboxylale,<br>
or a group of the formula<br>
) <br>
wherein: Q6 is NR^Ru; r is 2-3, R40 is hydrogen, or (Cl-C6)alkyl; R4( and R42 are<br>
hydrogen, (C1 -C6)alkyl, or R41 and R40 can be taken together to form a 6 or 7 membered<br>
ring,<br>
S<br>
or a group of the formula <br>
wherein: Q? is hydroxy, methoxy, dimethylamino, or N-piperidinyl;<br>
0<br>
k is ) -8; R3 is hydrogen; and the pharmaceutically acceptable salts thereof.<br><br>
aaa)	4-[2-(3-Trifluoromeihoxy-phenyl&gt;4,5,6&gt;7-tetrahydfo-pyrazolo[l,5-<br>
a]pyridin-3-yl]-quinoline,<br>
bbb) 4-[2-(2-Fluoro-phenyl&gt;4,5,6,7-tetrahydro-pyrazolo[l,5-a]pyridin-3-yl]-<br>
quinoline,<br>
ccc)	4-(2-Quinolin-2-y]-44,6,7-tetrahydro-pyrazolo[ 1,5-a)pyridin-3-yl)-<br>
quinoline,<br>
ddd)	4-[2-(l-Ethyl-pyridiu-2-yl)-4,5,6,7-tetrahydro-pyrazolo[ 1,5-a]pyridin-3-<br>
yl]-quinoline,'<br>
eee)	4-(2-Quino1in-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
ffi) 2-(3-Quinolin-4-yl-4,5,6,7-ietrahydro-pyrazolo[ 1,5-a]pyridin-2-yl)-<br>
[ 1,8]naphthyridine,<br>
Sgg)	4-[5-(4-Fluoro-phenyl)-2-pyriclin-2-yl-5,6-dihydro-4H-pyTrolo[ 1,2-<br>
b]pyrazol-3-y4J-quinoline,<br>
hhh)	4-(6-Hydroxymelhyl -2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo{ 1,2-<br>
b]pyrazol&gt;3yl)-quino]ine,<br>
iii) 4-(3-Pyridin-2-yl-5,6-dihydiro-4H-pyrroJo[l,2-b]pyrazol-2-yl)-quinoline,<br>
jjj) 4-(4-Methyl-2-pyridin-2-yl-5»6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline,<br>
kkk)	4-(5-BenzyJ-2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo[ 1,2-b)pyrazol-3-yl)-<br>
quinoline,<br>
111) 4-(5-Phenethyl-2-pyridin-2-y»-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline,<br>
mmm) 4-(5-Phenyl-2-pyridin-2-yl-5,6-dihydro-4HpyiTob[ 1,2-b]pyrazol-3-yl)-<br>
quinoline,<br>
nnn)	4-[2-(3-Trifluoromcthylphenyli)-5,6-dihydro-4H-pyrTolo[ 1,2-b]pyrazol-3-<br>
y]]-quinoline,<br>
ooo)	4-[2-(4-Trifluoromethyl-phenj'l)-5T6-dihydro-4H-pyrrolo[ 1,2-b)pyrazol-3-<br>
yl]-quinolinc,<br>
ppp)	4-(2-Pheny)-5,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
qqq)	2-Chloro-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline,<br><br>
m)6,8-Dimethoxy-4-[2-(6-methyl-pyridin-2-y])-5,6-dihydro-4H-<br>
pyrrolo[ 1,2b]pyra2ol-3-yl]-quinoline,<br>
sss)	4-[2-(6-Bromo-pyridin-2-yl)-5,,6-dihydro-4H-pyrrolo[ 1 ,2-b]pyrazol-3-yl]-<br>
quinoline,<br>
ttt) 6,8-Dimethoxy-4-[2-pyridin -2-yl-5,6-dihydro-4H-pyrrolo[ 1,2b]pyra2ol-3-yJ]-<br>
quinoline,<br>
uuu)	3-(4-FJuorophenyl)-2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo(l,2-b]pyrazoJe,<br>
vvv) 3-(4-Methoxy-phenyl)-2-pyri^n-2-yl-5,6-dihydro-4H-pyiTolof 1,2-<br>
bjpyrazolc,<br>
www) 3-(4-Fluorophenyl)-2 (6-me!hylpyridin-2-yl)-5,6-dihydro-4H-pyrroJo[ 1,2-<br>
b]pyrazole,<br>
xxx) 3-(4-Methoxyphenyl) 2-(6-metbyJpyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazole,<br>
yyy) 4-(2-Thiophen-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yI)quinoline,<br>
zzz)	4-[2-(6-Propylpyridin- 2-yl)-5,6-dihydro-4H-pyrrolo|; 1,2-b]pyrazol-3-y]]-<br>
quinoline,<br>
aaaa) 4-[2-(6-Isopropylpyriclin-2-yl)-516-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-<br>
yljquinoline,<br>
bbbb) 4-[2-(6-Ethy]-pyridin-2-yl)-5v6-dihydro-4H-pyrrolo[ 1,2-b]pyrazoI-3-<br>
yljquinoline,<br>
cccc) 4-[2-(6-Methyl-pyridin-2-yl)-5,6- dihydro-4H-pyrrolo[ 1,2-b]pyrazoI-3-yl]-<br>
quinoiine,<br>
dddd) 4-[2-(3-F]uorophenyl)-5,6-dihydro-4H-pyrrolo[],2-b]pyrazol-3-yl]-<br>
quinolinc,<br>
ecee) 4-[2-
quinoline,<br>
ffff)	4-[2-(4-Fluoro-phenyJ) 5,6-dihydiro-4H-pyrrolo[ 1,2-b]pyrazoJ-3-yl]-<br>
quinoline,<br>
gggg) 4-[2-(3-Trifluoromeihoxy-phenyl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-ylJ-quinolinc,<br>
hhhh) 4-[2-(4-Chloro-pyridin-2-yl)-5,6-clihydro-4H-pyrrolo[l ,2-bJpyrazol-3-y!]-<br>
quinoline,<br><br>
iiii)4-(2-(4-Fluoro-3-trifluoromethyl-phemyl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-yl]quinoline,<br>
jjyj)4-[2-(2-FIuoro-3-trifluoromethyl-pheiiiyl)-5,6-clihydro-4H-pyrrolo[l,2-b]-pyrazol-<br>
3-yl]-quinoline,<br>
kkkk) 4-[5-(3-Methoxy-phcnyI)-2-pyridin-2-yl-5,6-dihydro-4H-pyrTolo[ 1 ,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
Hll)4-[2-(4-FluoA&gt;-3-trifluorom«thyl-pheny])-5-(3-meibx)xy-phenyl)-5,6-dihydro-4H-<br>
pyrrolo[l ,2-b]pyrazol-3-yl] -quinoline,<br>
mmmm) 4-(7-Chloro-quinolin-4-yl&gt;3-(6-methylpyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazole,<br>
nnnn) 4-(7-Ethoxyquinolin-4-yl)-3-(6-meihylpyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[l ,2-b]pyrazole,<br>
oooo) 6-(3-Quinolin-4-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-2-yl)-pyridine-<br>
2-carboxylic acid hydrochloride,<br>
pppp) 6,7-Difluoro-4-[2-(6 methyl-pyridin-2-yl&gt;5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quino1ine,<br>
qqqq) 6,7-Dimethoxy-4-[2-(6-methy]-pyridin-2-y])-5,6-dihydro-4H-pyrrolo[1,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
rrrr)	3-Benzo[ 1,3]dioxol- 5-yl-2-(6-methyl-pyridin-2-yl&gt;5,6-dihydro-4H-<br>
pyrTolo[ 1,2-b]pyrazole,<br>
ssss) 6-(4-Fluoro-phenyI)-4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof ] ,2-b]pyrazol-3-yl]-quinol ine,<br>
tttt)6-Benzo[ 1,3]dioxol-5-yl-4-[ 2-(6-methyl-pyridin-2-yI)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yJ]-quinolinc,<br>
uuuu) 4-[2-(6-Melhyl-pyridin-2-yI)-5,6-dihydro-4H-pyrrolo[1^-b]pyrazol-3-y]]-<br>
6-thiophen-2-yl-quinoline,<br>
vvvv) 4-[2-(6-MethyI-pyridin-2-yI)-5,6-dihydro-4H-pyrTolo[l^-b]pyrazol-3-yl]-<br>
6-phcny)-quinoline,<br>
wwww) 8-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl]-<br>
quinoline,<br>
xxxx) 3-Benzo[b]lhiophen-2-yl-2-(6-methyl-pyridin-2-yI)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazok,<br><br>
yyyy) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-p&gt;Trolo[1,2-b]pyTazol-3-yl)-quinoline-6-<br>
carboxylic acid methyl ester,<br>
zzzz) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl]-<br>
quinoiine-6-carboxylic acid methyl ester,<br>
aaaaa) 4-[2-(6-Methyl-pyricliin-2-yl)-5 (6-dihydro-4H-pyTrolo[ 1,2-b]pyrazol-3-yl]-<br>
quinoline-7-carboxylic acid methyl ester,<br>
bbbbb) 4-[2-Pyridin-2-yl-5,
carboxylic acid methyl ester,<br>
ccccc) 2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo[5,l-c]morpholine,<br>
ddddd) 2-Pyridin-2-yl-3-quiiolin-4-yl-pyrazolo[5,l-c]morpholin-4-one,<br>
eeeee) Dimethyl- {3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yl)-quinolin-7-yloxy]-propyl}-amine,<br>
fTfTf)	{3-[6-Methoxy-4-(2 pyridin-2yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-<br>
yl)-quinolin-7-yloxy]-propyl}-dimethyl-amine,<br>
figg^g) Cyclopropylmethyl-propyl-{3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolofl,2-b]pyrazol-3-yl) quinolin-7-yloxy]-propyl}-amine,<br>
hhhhh) Diethyl- {3-[4-(2-pyridin-2-yl- 5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-y!oxy]-propyl}-amine,<br>
iiiii)	Ethyl-methyl-{3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-yl)-quinolin-7-yloxy]-propyl}-amine,<br>
iijjj)	3-[4-(2-Pyridin-2-yl-5,6-dihydlro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-<br>
7-yloxyJ-propylamine,<br>
kkkkk) 7-[3-(4-Methyl-pip«razin-l-yl)-propoxy]-4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinoline,<br>
11111)	Benzyl-methyl-{3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-<br>
b]pyrazol-3-yl)-quinolin-7- yloxy]-propyl} -amine,<br>
mmmmm) 7-(3-Piperidin-l-yl-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yri-quinoline,<br>
nnnnn) 4-(2-Pyridin-2-yl-5 6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-7-(3-<br>
pyrrolidin-1 -yl-propoxy)-quinoline,<br>
ooooo) 7-(3-Azepan-1 -yl-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br><br>
ppppp) 7-(3-lmidazol-1 -yl propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
qqqqq) 7-(3-Pyrazol-l -yl-|jropoxy&gt;4-(2-pyridin-2-yl-5,6-dihydro-4H-pyTrolo[ 1,2-<br>
blpyrazoW-yO-quinoIine,<br>
rtrrr) I'-{3-[4-(2-Pyridiii.2-yl-5J6-dJhydro-4H-pyrrolo[l,2-b]pyrazol-3-yl&gt;<br>
quinolin-7-y!oxy]-propyI}-ll,4']bipiperidinyl,<br>
sssss) Cyclojtoopyl-( 1 -mcthyl-piperidin-4-yt)- (3-{4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[l^-b]pyrazol-3-yl)-qui!K)lin-7-yloxy]-propyl}-amine,<br>
tint)	4-(2-Pyridin-2-yl- S,6-dihydiro-4H-pyrroio[ 1,2-b]pyrazoI-3-yl)-7-(3-<br>
[ ] ,2,3]triazol-l -yl-propoxy&gt;quinollne,<br>
uuuuu) Dimethyl-(3- {4-[2-(6-inethyl-pyrid in-2-yl)-5,6-dihydro-4H-pynrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinolin-7-yk&gt;xy}-propyl)-amine,<br>
vvvvv) Dicthyl-(3- {4-[2-(6-mcthyJ-pyridin-2-y1)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinolin-7-y^oxy}-propyl)-amine,<br>
wwwww) Cyc]opr<qjylmethyl-></qjylmethyl->
pyrro1o[ 1,2-b]pyrazo)-3- yl]-qu inolin-7-yloxy} -propyl)-propyl-amin,<br>
xxxxx) Ethyl-methyl-(3-{4-[2-(6-rnethy1-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3 yl]-quinolin-7-yloxy) -propyl)-amine,<br>
yyyyy) Dimelhyl-{2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo[l,2-b]pyra2ol-3-<br>
yl)-quinolin-7-yJoxy]-e«hyl}-aminc&gt;<br>
zzzzz) Diethyl-{2-[4-(; -pyiidin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-bJpyrazol-3-yl)-<br>
qu inolin-7-yIoxy]-ethyl} -amine,<br>
aaaaaa) 7-(2-Pipcridin-1 -yl-cthoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazo)-3-yl)-quino]ine,<br>
bbbbbb) Ethyl-methyl- {.!-{4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b)pyrazol-<br>
3-yl)-quinolin-7-yloxy|cthy)}-amine,<br>
cccccc) 4-(2-Pyridin-2- /N5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-7-(2-<br>
pyrrolidin-1-yl-cthoxy&gt;-quir»olJne,<br>
dddddd) 7-[2-(4-Methyl-piperazin-1-yI)-ethoxy]-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol- 3-y!)-quino1ine,<br>
eeeeec) Dimethyl- {3-[ I -oxy-4-(2 -pyrid in-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-<iuinolw-7-yloxy></iuinolw-7-yloxy><br>
ffffff) 7-Methy)su]fany]-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-yJ)-quinoline,<br>
gfigtJgg) 7-Ethylsulfanyl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyra2ol-<br>
3-yl)-quinoline,<br>
hhhhhh) 6-McthyJsulfanyJ-4-( 2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-<br>
3-yl)-quinoline,<br>
iiiiii) 7-Benfylsulfanyl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-yl)-quinoline,<br>
jjjjii)	3-[4-(2-Pyridin-2-yI-.4i,6-dihydro-4H-pyrrolo[l,2-b]pyra2ol-3-yl)-quinolin-<br>
7-ylsulfanyl]-propan-1 -ol,<br>
kkkkkk) Dimethyl- {2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yl)-quinoIin-7-ylsulfanyl]-ethy]}-amine,<br>
llllll)	Dimethyl [6-(3-quinolin-4-yl-5,6-dihydro-4H-pyrrolo[l^-b]pyrazol-2-yl)-<br>
pyridin-2-yl-methyl]amine,<br>
mmmmmm) 7-(2-Propoxy-ethoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
nnnnnn) N,N-Dimethyl-N'-[4-( 2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo[ 1,2-<br>
b]pyrazol-3-yl)-pyridin-2-yl]-ethane-1,2-diamine,<br>
oooooo) N,N-Dimethyl-N'-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyTTolo[l,2-<br>
b]pyrazol-3-yl)-pyridin-2-yl]-propane-1,3-diamine,<br>
pppppp) 3- {3-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy3-propyl}-oxiizolidJn-2one,<br>
qqqqqq) l-{3-[4-(2-Pyridin-2-&gt;l-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-propyl}-im idazolidin-2-one,<br>
mTnr) 3- {3-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxyJ-propyl}-3H-benzooxazol-2-one,<br>
ssssss) Dimethyl-(2- {4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo{ 1,2-<br>
b]pyrazol-3-yl]-pyridin-2-ylsulfanyl}-ethyl-amine,<br>
ttittt)	4-(2-Pyridin-2-yl-5,6-clihydro-4H pyrrolo[ 1,2-b]pyrazol-3-yl)-2pyrroHdin-<br>
1-yl-quinoline,<br>
uuuuuu) 2-Phenylsulfanyl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazol-<br>
3-yl)-quinoline,<br><br>
vvvvvv) 2-Morpholin-4-yl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
wwwwww)	2-Ethylsulfanyl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
xxxxxx) Phenyl-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pynolo[],2-b]pyrazol-3-yl)-<br>
quinol in-2-yl]-amine,<br>
yyyyyy) 2-Meftoxy-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo[l,2-b]pyrazol-3-yI)-<br>
quinoline,<br>
zzzzzz) 2-Ethoxy-4-(2-pyrid«n-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline,<br>
aaaaaaa) 4-[2-(6-Phenylsu1fanyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
bbbbbbb) Pheny}-[6-(3-quinolin-4-yl-5,6~dihydro-4H-pyrrolo[l,2-b]pyrazol-2-yl)-<br>
pyridin-2-yl]-amine,<br>
ccccccc) 4- {2-[6-(4-Melhoxy- phenyl)-pyridin-2-y]]-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl}-quinolinc,<br>
ddddddd) 4-[2-(6-Phenyl-pyridin-2-yl)-5,6-dihydro-4H-pyiTolo[l,2-b)pyrazol-3-yl]-<br>
quinoline,<br>
eeeeeee) 4-[2-(6-Morpholin-4 -yl-pyridin-2-yl)-5,6-d ihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yI]-quinoline,<br>
ffffffl) 4-[2-(6-Pyrrolidin-l yl-pyridin-2-yl)-5,6-dihydro-4H-pyrro!o[1,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
ggggggg) 4-[2-(6-Methoxy-pyi idin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yl]-quinoline,<br>
hhhhhhh) 2-{3-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-propyl}-in5oindole-1,3-^ione,<br>
iiiiiii) 7-(3-Fluoro-propoxy)-4-(2-pyridin-2-yI-5,6-dihydro-4H-pyrrolo[],2-<br>
b]pyrazol-3-yl)-quinoline,<br>
jjjjjjj) 7-(3-Fluoro-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
kkkkkkk) 7-(3-Chloro-propoxy)-4-(2-pyTidin-2-yl-5,6-dihydro-4H-pyrroIo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br><br>
11111)]) 7-(3-Chloro-propoxy)-6-methcocy-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)- quinoline,<br>
mmmmmmm) 7-(3-Chloro-propoxyH-[2-(6-methyJ-pyridin-2-yl)-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-3 yl]-quino)ine,<br>
nnnnnnn) (1 -{3-[7-(2-Chloro-ethoxy)-quinolin-4-yl)-5,6-dihydro-4H-pyrroIo[ 1,2-<br>
b]pyrazol-2-yl}-propeny!)-methylene-amine,<br>
ooooooo) N,N-D^ethyl-2-[4-(2 pyridin-2yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-yl)-quinoMn-7-yloxy]-acctamide,<br>
PPPPPPP) 7-[2-((2R)-1 -Methyl pyrrolidin-2-yl)-ethoxy]-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]p;yrazoI-3-y) )-quinolinc,<br>
qqqqqqq) Dimethyl- {4-[4-(2-p;yridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yJ)-pyridin-2-yloxy]-butyl}-iminc,<br>
mini) 1 -{3-[4-(2-Pyridtn-2 yl-5,6-dihydro-4H-pyrrolo(l,2-b]pyrazol-3-yl)-<br>
pyridin-2-yk»cy]-propyl}-pyrrolidin-2-one,<br>
sssssss) 7-( 1 -Methyl-piperidii-3-ylmethoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-<iuinoline></iuinoline>
ttttttt) 7-(3-N,N-Dimethylainino-2-meihyl-propyloxy)-4-{2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1 ^-b]p&gt;Tazol-3-yl)-quinoline,<br>
uuuuuuu) 4-[2-(6-Mcthyl-pyridin-2-yl):5,6-dihydro-4H-pyn-olo[ 1,2-b]pyrazol-3-yl]-<br>
7-propoxy-quinolinc,<br>
wvvvvv) 4-{6-Benzyloxymethyl-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl]-C|uinol ine,<br>
wwwwwww) {4-[2-(6-Methiyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo( 1,2-<br>
b]pyrazol-3-yl]-quinolin-7-yloxy}-acetic acid methyl ester,<br>
xxxxxxx) 7-lsopropoxy-4-[2-(6 meihyl-p)Tidin-2-yl)-5,6-dihydro-4H-pyn-olo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
yyyyyyy) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl]-<br>
7-(3-morpholin-4-yl-propoxy)-quinoline,<br>
zzzzzzz) 4-(6-Benzyloxymethyl-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-6-yl)-quinoline,<br>
aaaaaaaa) 7-Ben2yloxy-2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo[ 1,5-a]piperidine,<br><br>
bbbbbbbb)2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-<br>
7-yloxy]-acetamide,<br>
cccccccc) 7-(5-Phenyl-[l,2,4]oxadiazol-3-ylmethoxy)-4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
dddddddd) 7-(2,2-Difluoro-benzo[ 1,3]dioxol-5-ylmethoxy)-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]py razol-3-yl)-quino)ine,<br>
eeeeeeee) 7-[2-($S)-1 -Methyl-pyrrolidin-2-yI)-ethoxy]-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
fffiYTR) 5-[4-(2-Pyridin-2-yl-! ,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolin-<br>
7-y1oxymethyl]-pyrrolidin-2-one,<br>
gggggggg) 4-(6-Phenoxymethyl-2-pyridin-2-yl-5,6-dihydro-4H-pyrTolo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
hhhhhhhh) 4-(6-Methylene-2-pyudin-2-yl-5,6-dihydro-4H-pyrrolo( 1 ^-bJpyrazol-3-<br>
yl)-quinoline,<br>
iiiiiiii) 3-(4-Fluoro-phenyl)-6-methyler»e-2-
4H-pyrrolo[ 1,2-b]pyrazole,<br>
jjjjjjjj) 7-(]-Methyl-piperidir-2-ylmethoxy)-4-(2-pyrJdin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[l ,2-b)pyrazol-3-yl)-quinoline hydrochloride,<br>
kkkkkkkk) 7-[2-( 1-Methyl-pyiTolidin-2-yl)-ethoxy]-4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline hydrochloride,<br>
11I11I11&gt; 4-[2-(6-Methyl-1 -oxy-pyridin-2-yl)-5,6-dihydro-4H-pynrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline 1-cxide,<br>
mmmmmmmm) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo(l,2-<br>
b]pyrazol-3-yl]-quinoline I-oxide,<br>
nnnnnnnn) 4-[2-(6-Methyl-1 -oxy-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b)pyrazol-3-yl]-quinoline,<br>
oooooooo)7-(3-Chloro-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl)-quinoline I -oxide,<br>
pppppppp) 7-Methanesulfonyl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyTTolo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
qqqqqqqq) 3-(4-Fluoro-phenyI)-2-(6-methyl-1 -oxy-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazole,<br><br>
rrrrrnT) 4-(Quinolin-N-1 -oxkle-4-yl)-3-(6-methylpyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[l,2-b] pyrazole,<br>
ssssssss) 6-Me1hanesulfonyl-4 (2-pyridiri-2-yi-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
tltttttt) 7-EthanesulfonyI-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo[ 1,2-bJpyrazol-<br>
3-yl)-quinoline,<br>
uuuuuuuu) 4-(2-PyVidin-2-yJ-5,6 dihydro-4H-pym&gt;lo[l ,2-b]pyrazol-3-yl)-7-[3-<br>
(pyrimidine-2-sulfonyl)-propoxy]-quinoline,<br>
wwvwv) 7-[3-( 1 -Methyl-1 H-iimdazole-2-sulfonyl)-propoxy]-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyTazo\-3-y\)-qmno\ine,<br>
wwwwwwww) 7-[3-(4-Chloro-benzene!»ulfonyI)-propoxy]-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrro1o[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
xxxxxxxx) 4-(2-Pyridin-2-yI-5,6- dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-7-[3-<br>
(pyridin-2-ylmcthanesulfonyl)-propoxy]-quinoline,<br>
yyyyyyyy) 4-(2-Pyridin-2-yl-5,6 dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-y1)-7-[3-<br>
(pyridin-2-ylmethanesulfinyl)-propoxy]-quinoline,<br>
zzzzzzzz) 4-(Quinolin-l-N-oxide-4-yl)-3-(6-methylpyridin-2-yl-1 -N-oxide)-5,6-<br>
dihydro-4H-pyrrolo [ 1,2-b]p]/razole,<br>
aaaaaaaaa) 3- {4-[2-(6-Methyl-p&gt; ridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyTazol-3-<br>
yl]-quinolin-7-yl}-acrylicacid methyl ester,<br>
bbbbbbbbb)	3- {4-[2-(6-Methylpyrdin-2-yl-5,6-dihydro-4H-pyrTolo[ 1,2-<br>
b]pyrazol-3-yl]quinolin-7-yl]! -1 -piperidiin-1 -yl-propenone,<br>
ccccccccc) 3- {4-[2-(6-Methyl-pyridin-2-yl&gt;5,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazol-3-<br>
yl]-quinolin-6-yl}-acrylicacid methyl ester,<br>
ddddddddd)	4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo{ 1,2-<br>
b]pyrazol-3-yl]-7-vinyl-quiiH&gt;line,<br>
eeeeeeeee) 4-[2-(6-Benzyl-pyridtn-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazo1-3-yl]-<br>
quinoline,<br>
ffTfffm) 7-Benzyl-4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
eeeggggfig)	4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline-7-c arboxylic acid,<br><br>
hhhhhhhhh)	4-[2-(6-Methyl-pyridim-2-y])-5,6-dihydro-4H-pyrroJo[I^-<br>
b]pyrazol-3-yl]-quinoline-6-carboxylicacid,<br>
iiiiiiiii) 3-{4-[2-(6-MethyJ-pyridin-2-&gt;'l)-5,6-dihydro-4H-pyrrolo[l,2-blpyra2ol-3-<br>
yI]-quinolin-7-yl} -acrylic acid,<br>
Jiiijjjjj) 3" {4-[2-(6-Methyl-pyridin-2-yI)-5,6-dihydro-4H-pyrrolo[1,2-bJpyrazol-3-<br>
yl]-quinolin-7-yl}-propionicacid,<br>
kkkkkkkkk) ' 4-[2-(6-Methyl-pyridim-2-yl)-3-quinolin-4-yl-5,6-dihyd«)-4H-<br>
pyrrolo{ 1,2-b]pyrazol-5-yl] -benzoic acid,<br>
Illllllll) 4-(2-Pyridin-2-yl-5,i5-dihydro-4H-pyrrok&gt;[ 1,2-b]pyrazol-3-yl)-^uinoline-7-<br>
carboxylic acid cyclopentylamide,<br>
mmrnmmrnmnirn)4-(2-Pyridiiv-2-yl-5,6-clihydro-4H-pyrrolo[l,2-b]pyrazoI-3-yl)-<br>
quinoline-7-carboxylic acid (2-moiphoHn-4-yl-ethyl)-amide,<br>
nnnnnnnnn)	4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrro1o[l,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid [2-(l H-imidazol-4-yl)-ethylJ-amide,<br>
ooooooooo)	4-(2-Pyridin-2-yl-5,6-«lihydro-4H-pyrrolo[l,2-b}pyrazol-3-yl)-<br>
quinoline-7-carboxyiic acid (2-methyiamino-elhyl)-amidc,<br>
ppppppppp)	4-(2-Pyridin-2-yI-5,6-<lihydro-4h-pyrrolo></lihydro-4h-pyrrolo>
quinoline-7-carboxylic acid (3-methylamino-propyI)-amide,<br>
qqqqqqqqq)	4-(2-Pyridin -2-yl-5,6-<lihydro-4h-pyitolo t2-b></lihydro-4h-pyitolo>
quinoline-7-carboxylic acid (2-dimethylamino-ethyl)-amide,<br>
rrrrrmT) (4-Methyl-piperazin-l -yl)-[4H&gt;pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-quino1in-7-yl]-methanone,<br>
sssssssss) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<juinoline-7-></juinoline-7->
carboxylic acid cyclobutylamide,<br>
ttttttttt) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yJ)-quinolinc-7-<br>
carboxylic acid cyclopropylamide,<br>
uuuuuuuuu)	4-(2-Pyridin-2-yl-5,6-4lihydro-4H-pyrro1o( 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid (l-ethyl-|3ropyl)-amide,<br>
vvvvvvvvv)	4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid elhylamide,<br>
wwwwwwwww) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b}pyrazol-3-yl)-<br>
quinoline-7-carboxylic acict isobutyl-amide,<br><br>
xxxxxxxxx)	4-(2-Pyridin-:&gt;-yl-5,6-dihydro-4H-pyrrolo[],2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid lert-butylamide,<br>
yyyyyyyyy) 4-(2-Pyridin-:Nyl-5,6HJihydro-4H-pym3lo[1,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxyIic acid i sopropylamide,<br>
zzzzzzzzz) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ ] ,2-b]pyrazol-3-yl)-quinoline-7-<br>
carboxylic acid propylamide,<br>
aaaaaaaaaa) «4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid (2-methyl-butyl)-amide,<br>
bbbbbbbbbb) 4-(2-Pyridin-:!-yl-5,6-dihydro-4H-pynrolo[l,2-b}pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid ((2S)-2-methyl-butyl)-amide,<br>
cccccccccc)	4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrroIo[ 1,2-b]pyra2Ol-3-yl)-<br>
quinoline-7-carboxylic acid (2S)-sec-bulylamide,<br>
dddddddddd) 4-(2-P&gt;Tidin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
qainoline-7-carboxylic acid (2R)-sec-butylamide,<br>
eeeeeeeeee)	4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid ((lR)-1,2-dimethyl-propyl)-amide,<br>
ffffffffff) 4-(2-Pyridin-2-yl-5,6 dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline-7-<br>
carboxylic acid (pyridin-4-ylmethyl)-arnide,<br>
gg86£86ggg) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrTolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid (pyridin-3-ylmethyl)-amide,<br>
hhhhhhhhhh) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazol-3-yl&gt;<br>
quinoline-7-carboxylic acid (pyridin-2-ylmethyl)-amide,<br>
iiiiiiiiii) 6-(3-QuinoIin-4-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazoI-2-yl)-pyridine-<br>
2-carboxylic acid amide,<br>
jjjjjjiijj) l-(4-Methyl-piperazin-l-yl)-2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-ethanone,<br>
kkkkkkkkkk) N-(2-dimethylamino-ethy1)-2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-acetamide,<br>
1111111111) N-(2-dimethylaminoH:ihyl)-N-methyl-2-[4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-acetamide,<br>
mmmmmmmmmm) N,N-Dimethyl-3[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-benzamide,<br><br>
nnnnnnnnnn) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yI)-<br>
quino)ine-7-carboxylic acid amide,<br>
oooooooooo) 4-(2-Pyridm-2-yI-5,6-dihydro-4H-pyrrolo[l,2-H]pyrazol-3-yl)-<br>
quinoline-7-carboxylicacid(2-dimethylamino-ethyl)-methyl-amide,<br>
pppppppppp) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo{ 1,2-H]pyrazol-3-yl)-<br>
quino]ine-7-carboxylicaci<ji></ji>
qqqqqqqqqq) * 4-(2-Pyridin 2-yl-5,6-d!ihydro-4H-pyrrolo[l ,2-H]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid dimethylamide,<br>
nrrrrrrtr) 4-(2-Pyridin-2-yi-5,<:>-dihydro-4H-pyiTolo[ 1,2-H]pyrazoJ-3-yl)-quinoline-<br>
7-carboxyIic acid methylamide,<br>
ssssssssss) 4-(2-PyTidin-2-yl-5,-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quino]ine-7-<br>
carboxylic acid pyridin-2-y) amide,<br>
tttttttttt) N-(2,2-Dimethylamii(K&gt;-ethy0-N-methyl-3-{4-[2-(6-methyJ-pyridin-2-yl)-<br>
5,6-dihydro-4H-pyiTolo[1,2-b]pyrazol- 3-y1)-quinolin-7-yl} -propionamide,<br>
uuumiuuuuu) 2-(6-Melhyl-f»yridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazoI-<br>
3-yl]-quinoline-6-carboxyHc acid (2-dimethy)amino-ethyl)-amide,<br>
vvvvvvvvvv) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline-6-«arboxylicacid(3-dimethylamino-propyl)-amide,<br>
wwwwwwwwww)	4-{2-(t»-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrro}o[ ] ,2-<br>
b]pyrazol-3-yl]-quinoline-6H:arboxylicacid(2-morpholin-4-yl-ethyl)-amide,<br>
xxxxxxxxxx) 1 -[2-(Quinolin-4-yl)-1 -(6-methyJ-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-3-yl] quinoline-7-carboxylic acid N,N-<br>
dimethylaminoethylamide,<br>
yyyyyyyyyy) 4-[2-(6-Methylpyridin-2 -yl)-5,6-dihydro4H-pyrro]o( 1,2-b]pyrazol-<br>
3-yl]quinoJine-7-carbox-y(ic acid (2-pijperidin-l-y)-ethyl)amide,<br>
zzzzzzzzzz)	N-(2-Dimelhylamino-ethyl)-3-{4-[2-(6-methyl-pyridin-2-yl)-5,6-<br>
dihydro-4H-pyrrolo[1,2-b]pyiazol-3-y1]-quinolin-7-yl}-propionamide,<br>
aaaaaaaaaaa) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline-7-carboxylicacid (3-dimethylamino-propyl)-amide,<br>
bbbbbbbbbbb) 4-[2-(6-MeJhy]-pyridin-2-yl)-5,6-dihydro-4H-pyrro]o[I,2-<br>
b]pyrazol-3-yl]-quinoline-7-Ciirboxy1ic acid (3-pyrrolidin-l -yl-propyl)-amide,<br><br>
ccccccccccc) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyn-olo[l,2-<br>
b]pyrazol-3-yl]-quinoline-7-carboxylicacid (3-morpholin-4-yl-propyl)-amide,<br>
ddddddddddd) 3- {4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyiTolo[ 1,2-<br>
b]pyrazol-3-yl]-quinolin-7-yl}-propionamide,<br>
eeeeeeceeee) 4-(2-Pyridin-2- yl-5,6-dihydro-4H-pyrrolo{ 1,2-b]pyrazol-3-yl)-<br>
quinoline-6-cart)oxylic acid (2-dimethylamino-ethyl)-amide,<br>
fffffffiYfT) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline-6-<br>
carboxylk acid (2-morpholin-4-yI-ethyl)-amide,<br>
ggggggggggg) 4-(2-Pyridin-2- yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl&gt;<br>
quinoline-6-carboxylic acid,<br>
hhhhhhhhhhh) 4-(2-Pyridin-2- yI-5,6-dihydro-4H-pyrrolo{ 1,2-b]pyrazol-3-yl)-<br>
quinoiine-6-carboxylic acid hydrazide,<br>
iiiiiiiiiii) 4-(2-Pyridin-2-yi-5,6-<lihydro-4h-pyrrolo></lihydro-4h-pyrrolo>
carboxylic acid amide,<br>
j.ijjiiiijjj) 4-(2-Pyridin-2-y1-5,6-<lihydro-4j-l-pyrrolo></lihydro-4j-l-pyrrolo>
carboxylic acid (3-methylamino-propyI) amide,<br>
kkkkkkkkkkk) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-6-carboxylic acid amide,<br>
11111111)11) 4-(2-Pyridin-2-yl-5,6-<lihydro-4h-pyrrolo></lihydro-4h-pyrrolo>
carboxylic acid (2-hydroxy-ethyl)-amide,<br>
mmmmmmmmmmm) 4-(2-Py ridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yl)-quinoline-7-carboxylic acid hydrazide,<br>
nnnnnnnnnnn) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)--<br>
quinoline-7-carboxylic acid hydroxyamide,<br>
ooooooooooo) 4-(2-Pyridin-2- yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid (2-amino-ethyI)-amide,<br>
PPPPPPPPPPP) 4-(2-Pyridin-2- yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid (2-hydroxy-ethyl)-amide,<br>
qqqqqqqqqqq) 4-(2-P&gt;Tidjn-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-sulfonic acid amide,<br>
inriiiini) 4-(2-Pyridin-2-yl-5,6-cl»ihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline-7-<br>
sulfonic acid methylamide,<br><br>
iiiiiiiiiiii) [4-(2-Pyridin-2-yl-5,6-dihydro-4iH-pyrrolo[1,2-b]pyrazol-3-yl)-quinolin-7-<br>
yl]-carbamic acid methyl ester,<br>
jjjjjjtijjjjj) [4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolin-7-<br>
yl]-carbamic acid 2-hydroxy-clhyl ester,<br>
kkkkkkkkkkkk) [4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yI)-<br>
quinolin-7-yl]-carbamic acid 2-methoxy-ethyl ester,<br>
IllllUlllll) 1,3-Bis-f4-(2-pyridin-:!-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yl]-urea,<br>
mmmmmmmmmmmm) Dimethyl-carbamiic acid 4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[l ,2-b]pyrazol-3-yl)-qiiinolin-7-yl ester,<br>
nnnnnnnnnnnn) 7-Bromo-2-isoj3ropyl-4-(2-pyridin-2-yI-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
oooooooooooo) 2- (4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinolin-6-yl)-propan-2-ol,<br>
pppppppppppp) 7-(3-Chloro-propylsulfanyl)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
qqqqqqqqqqqq) 7-Broino-4-(4- :hIoro-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
n 11 n 11111 r) 8-Chloro-4-(2-pyridin- 2-yI-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yI)-<br>
quinolin-7-ol,<br>
ssssssssssss) 8-Bromo-4-(2-|i)yridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-<br>
3-yl)-quinolin-7-ol,<br>
tttttttttttt) 3-(7-Bromo-quinolin^-yl)-2-pyiidin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-4-ol,<br>
uuuuuuuuuuuu) 7-Bromo-4-(4-iiiethoxy-2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
vvvvvvvvvvvv) [3-(7-Bromo-quinolin-4-yl)-2-pyridin-2-yl-5,6-<lihydro-4h-></lihydro-4h->
pyrrolo[ 1,2-bJpyrazol-4-yl J-methyl-amme,<br>
wwwwwwwwwwww) 3-(7-Bromo-quinolin-4-yl)-2-pyridin-2-yl-5,6-dihydro-<br>
pyrrolo[ 1,2-b]pyrazol-4-one,<br>
xxxxxxxxxxxx) 3-[4-(2-Pyridir -2-yl-5,6-dihydro-4H-pyrrolo[ 1 ^-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-benzamide<br><br>
yyyyyyyyyyyy) W,A^Dimethyl-3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo[l,2-<br>
b]pyrazol-3-yl)-quinolin-7-j'loxy]-thiobenzamide,<br>
ZZZZZZ777777) Dimethyl-{3 [4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrroJo[ 1,2-<br>
b]pyrazol-3-yl)-quinolin-7-yloxy]-benzyl} -amine,<br>
aaaaaaaaaaaaa) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[i,2-<br>
b]pyrazol-3-yl]-1 H-quinolin-2-one,<br>
bbbbbbbbbbbbb)* 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yI)-<br>
quinolin-7-ol,<br>
ccccccccccccc) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazoI-3-yl]-quinolin-7-ol,<br>
ddddddddddddd) 6-Methoxy-4 (2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1J.-<br>
b]pyrazol-3-yI)-quinolin-7-ol,<br>
eeeeeeeeeeeee) 3- {4-[2-(6-M ethyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinolin-7-yI}-propionic acid methyl ester,<br>
ffffffflffiff)	4-(6-Methyl-2-pyridin-2-yl-5?6-dihydro-4H-pyrrolo[ 1 ^-bjpyrazol-<br>
3-yl)-quinoline.<br>
gfiegegggggggg) 3- {4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-<br>
b]pyrazol-3-yl]-quinolin-6-yl}-propionic acid methyl ester,<br>
hhhhhhhhhhhhh) 7-Amino-4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrTolo[l,2-b]pyrazol-3-yl]-(iuinoline,<br>
iiiiiiiiiiiii) N,N-Dimethyl-3-{4-|2-(6-methyl-pyridin-2-yl)-5,6-d!hydro-4H-<br>
pyrrolo[1,2-b]pyrazol-3-yl]-cjuinolin-7-yl}-propionamide,<br>
iiiijjjjjjjjj) N-{3-[4-(2-Pyridin-2 -yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yJoxy]-propyl}-acetamide,<br>
kkkkkkkkkkkkk) N-Acetyi-N- {4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-3-yl]-t|uinoIin-7-yl}-acetamide,<br>
1111111 HillJ&gt; 2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo[l,5-a]piperidin-7-ol,<br>
mmmmmmmmmmmmm)7-Aceioxy-2-pyridin-2-yl-3-quinolin-4-yl-pyrazolo[l,5-<br>
a]piperidine,<br>
nnnnnnnnnnnnn) Methyl-{3-[4(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl)-quinolin-7-yloxy]-propyl}-amine,<br><br>
ooooooooooooo) 7-(Pjperidin-4-yloxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)- quinoline,<br>
PPPPPPPPPPPPP) 4-[2-(6-Methyl-pyridin-2-yJ)-5,6-dihydj^4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl]-quinoline-7-carboxylic acid (2-amino-I,I-dimethyl-ethyl)-amide,<br>
qqqqqqqqqqqqq) {6-[3-(4-Fluciro-phenyl)-5,6-dihydro-4H-f)yrrolo[1,2-b]pyrazol-2-<br>
yl]-pyridin-2-yl} -methanoi,<br>
iinniiinrr) 
pyridin-2-yl]-methanol,<br>
sssssssssssss) 4-[2-{6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyn-olo[ 1,2-<br>
b]pyrazol-3 -yl ] -phenol,<br>
ttttttttttttt) 7-( 1 -MethyJ-pyrroIidin-3-ylmelhoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-i|uinoline,<br>
uuuuuuuuuuuuu) 7-( 1 -Methyl-jiiperidin-4-ylmeihoxy)-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]p&gt;Tazol-3-yl)-quinoline,<br>
vvvvvvvvvvvvv) 4-[2-(6-Mefhyl-pyridin-2-yl)-5,6-dihydr©-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-y]]-quinoline-7-carboxylic acid(2-dimethylamino-l ,1 -dimethyl-<br>
ethyl)-amide,<br>
wwwwwwww^'wwww) (S)-[3-(4-Fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-5,6-<br>
dihydro-4H-pyrro!o[ 1,2-b]pyrazol-6-yl]-methanol,<br>
xxxxxxxxxxxxx) (^?)-[3-(4-Fluoro-phenyI)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-6-j'I}-methanol,<br>
yyyyyyyyyyyyy) (5)-[3-(4-FIuoro-phenyl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-6-)l]-acetonii:rile,<br>
777.7777777777) (/?)-[3-(4-Fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-6-&gt; !]-accionii:rilc,<br>
aaaaaaaaaaaaaa) 4-(3-Pyridin-2yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-2-yl)-<br>
quinoline,<br>
bbbbbbbbbbbbbb)4-(6-Pyridin-2 y]-2,3-dihydro-pyra2olo[5,l-b]oxazol-7-y])-<br>
quinoline,<br>
cccccccccccccc) 3-[4-(2-Pyridhi-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yl]-oxazolidin-2-o»oe,<br><br>
dddddddddddddd) 1 -[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyn-o]o[ 1,2b)pyrazol-3-yl)-<br>
quinoIin-7-yI]-imidazolidin-2-one,<br>
eeeeeeeeeeeeee) 4-(2-Pyridin-2-yl-5,6-diihydro-4H-pyrrolo[ 1,2-b]pyrazoI-3-yl)-7-<br>
(pyridin-4-yImethoxy)-quinoline,<br>
fffffffiffiffi) 4-(2-Pyridin-2-y]-5,6-dihydro-4H-pyrrolo[ 1,2-b}pyrazol-3-yl)-7-(3-<br>
pyridin-3-yl-propoxy)-quiiKi(line,<br>
gggggggggggggg) 7-(4,5-Dihydifo-1 H-imidazol-2-yl)-4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrro]o{ J ,2-b]pyrazol-3-yl)-quinoliine,<br>
hhhhhhhhhhhhhh)4-[5-(4-Fluor.o-phenyl&gt;2-(6-methy]-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolofl ,2-b]pyrazol-3-yl]-
iiiiiiiiiiiiii)4-[5-(4-Fluoro-pheny4)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-ylJ-
jjjjjjjjjjiljjj) 2-Pyridin-2-yl-3-quwK&gt;lin-4-yl-pyrazolo[5,1 -cjmorpholine,<br>
kkkkkkkkkkkkkk)4-[2-(6-Vinyl-pyridin-2-yl&gt;5,e-dihydro-4H-pyrrotofl.2-b}pyrazol-<br>
3-yl]-quinoline,<br>
lllllllllinil) 3-{4-[2-(6-Methyl-pjTidin-2-yl)-5,6-dihydro-4H-pyrro]o[ 1,2-b]pyrazol-3-<br>
yl]-quinolin-6-yl}-acrylic acid,<br>
mmmmmmmmmmmmmm) 7-(6-Mcthyl-pyridazin-3-yloxy)-4-(2-pyridin-2-yl-<br>
5,6-dihydro-4H-pyrrolo[ 1,2-lajpyrazol- 3-yl)-quino] ine,<br>
nnnnnnnnnnnnnn) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-7-[4-<br>
(4-pyrimidin-2-yl-piperazin-1 -yl)-butoxyj-quino1ine,<br>
oooooooooooooo) 7- {3-[4-(2-Mt:thoxy-phcnyl)-piperazin-1 -yl]-propoxy} -4-(2-<br>
pyridin-2-yl-5,6-dihydro-4H- pyrrol^ 1,2-b]pyrazol-3-yl)-quinoIine,<br>
pppppppppppppp) Pyridin-2-yl- {3-[4-(2-pyTidin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-quinolin-7-yloxy]-pKq3yl}-ainine,<br>
qqqqqqqqqqqqqq) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline-7-tarboxylic acid (2-dimethylamino-1 -methyl-ethyl)-<br>
amide,<br>
iiiniiiiinii) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoIine-7-carboxylic acid amide,<br>
ssssssssssssss) 4-(2-Pyridin-2-yI-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid (J-dimethyllamino-propyl)-amide,<br><br>
tttuttmtttt) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl]-<br>
quino)ine-7-carboxylic acid f2-dimethylamino-ethyl)-methyl-amide,<br>
uuuuuuuuuuuuuu)N,N-Dimeth&gt;l-3-{4-[2-(6-methyl-pyridin-2-yl)-5,6-dJhydro-4H-<br>
pyrTolo[l,2-bJpyrazol-3-yl]-quinolin-7-yl}-acrylamide,<br>
vvvvvvvvvvvvvv) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yI)-<br>
quinoline 1-oxide,<br>
wwwwwwwwww«wwww)7-BenEyloxy-4-[2-(6-niethyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl]-quinoline,<br>
xxxxxxxxxxxxxx) 4-[2-(6-Chlor*&gt;6-dihydro-4H-pyrrolo loro-pyridin-2-yl)-5 [ 1,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
yyyyyyyyyyyyyy) 6-(3-Quinolin-4-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b)pyrazol-2-<br>
yl)pyridine-2-carboxylic acid methyl ester,<br>
zzzzzzzzzzzzzz) 4-(7-Chloroquinolin-4-yl)-3-(pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2 Dbjpyrazole,<br>
aaaaaaaaaaaaaaa) 4-(2-Furan-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline,<br>
bbbbbbbbbbbbbbb)	3-{4-[H6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyiTolo[l,2-b]pyrazoI-3-yl]-C|uinolin-6-yl}-acrylic acid methyl ester,<br>
ccccccccccccccc) 4-[2-(2-Meth&gt;l-thiazol-4-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
ddddddddddddddd)	3-(4-Fluoro-phenyl)-2-(2-methyl-thiazol-4-yl)-5,6-dihydro-<br>
4H-pyrrolo[ 1 t2-b]pyrazole,<br>
eeeeeeeeeeeeeee) 4-[2-(2-Meth&gt; l-2H-pyrazol-3-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
fffffffffftlfTTT) 4-(2-Thiazol-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b)pyrazol-3-yI)-<br>
quinoline,<br>
eee&amp;figgggggfiBSe)	4-[2-(l -Methyl- lH-imidazol-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl]-(|uinoline,<br>
hhhhhhhhhhhhhhh)	6,7-Dichloro-4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl]-
iiiiiiiiiiiiiii)	(S)-6-Benzyloxymethyl-3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-<br>
2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazole,<br><br>
jjjjjjjjjjjjjjj)	N,N-Dimethyl-3-{4-[2-(6-melhyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl]- quinolin-7-yl} -acrylamide,<br>
and the pharmaceutically acceptable salts, esters and prodrugs thereof.<br>
The compounds exemplied ;ibove are merely representative of the invention and<br>
are not limiting in any fashion.<br>
The compounds disclosed herein can be made according to the following schemes<br>
and examples. The examples should in no way be understood to be limiting in any way as<br>
to how the compounds may be mads.<br>
The skilled artisan will appreciate that the introduction of certain substituents will<br>
create asymmetry in the compounds of Formula (1). The present invention contemplates<br>
all enantiomers and mixtures of enantiomers, including racemates. It is preferred that the<br>
compounds of the invention containing chiral centers are single enantiomers.<br>
The compounds of the present invention can be prepared by a variety of<br>
procedures, some of which are illustrated in the Schemes below. It will be recognized by<br>
one of skill in the art that the individual steps in the following schemes may be varied to<br>
provide the compounds of Formula (I). The particular order of steps required to produce<br>
the compounds of Formula (I) is dependent upon the particular compound being<br>
synthesized, the starting compound, and the relative lability of the substituted moieties.<br><br><br>
The Compounds of Formula (1) may be prepared from several synthetic methods.<br>
In Scheme I, Methods A and B employ a cyclization of an appropriately substituted<br>
alkylideneamino-pyrrolidin-2-one (1), Method A, or an appropriately substituted<br>
alkanone-alkene-hydrazide (2), Method B. One skilled in the art would also appreciate<br>
Method C, a condensation of an appropriately substituted alkync (3) with a substituted<br>
synthon (4) to afford compounds of Formula (I).<br>
Step a depicts a cyclization of ai compound of formula (I) or a substituted<br>
compound of formula (2), where the R group($) can be any group(s), previously defined<br>
as said for Rl, R2 or R3 of Formula (I) from here on. Typically, the appropriate<br>
compound of formula (1) is contacted to a suitable base that can form the anion of the<br>
hydrazone, such as lithium diisopropylamide, potassium bis(trimethylsilyl)amide, lithium<br>
bis(trimcthylsilyl)amide, sodium bis(trimethylsilyl)amide, sodium hydride, lithium<br>
hydride, potassium hydride, sodium alkoxides (sodium hydoxide, sodium methoxide, or<br>
sodium ethoxide) or potassium alkoxides (potassium hydroxide, potassium methoxide,<br><br>
potassium t-butoxide or potassium ethoxide), with sodium hydride being the preferred<br>
base. The reaction is carried out in a suitable solvent, such as tetrahydrofuran, N,N-<br>
dimethyjformamide, dimethylsulfoxide or toluene, preferably N,N-dimethylformamide at<br>
temperatures of about 0 to 100 °C. The products can be isolated and purified by<br>
techniques well known in the art, such as precipitation, filtration, extraction, evaporation,<br>
trituration, chromatography, and recrystallization. Optionally, a variation of step b of<br>
Scheme I, may be appropriate for trie formation of 4,5,6,7-tetrahydro-pyrazolo[l,5-<br>
a]pyridine derivatives, when n equals to 2, to give the corresponding derivatives of<br>
Formula (I) as shown in Method B.<br>
Another variation a skilled artisan would appreciate is Method C for the formation<br>
of Formula (I), in Scheme I, is step b, which is known and appreciated in the art<br>
(Ranganathan, Darshan; Bamezai, Shakti, Tetrahedron Lett., 1983,1067-1070). For<br>
example, an alkyne of (3) is reacted with a compound of (4) in a suitable solvent, such as<br>
tetrahydrofuran, MN-dimethylformainide, or toluene, xylene, preferably xylene at<br>
temperatures of about 0 to 150 °C. The products can be isolated and purified by<br>
techniques described above.<br><br>
alkoxides (sodium methoxide, or sodium eihoxide) or potassium alkoxides (potassium<br>
methoxide, potassium t-butoxide or potassium ethoxide), with potassium<br>
bis(trimethylsilyl)amide being the preferred base. Generally, the reaction is carried out in<br>
suitable solvents, such as tetrahydrofuran and toluene or a combination of such, at<br>
temperatures of about -78 °C to ambient temperature. The product, formula (7), can be<br>
isolated and purified by techniques well known in the art, such as precipitation, filtration,<br>
extraction, evaporation, trituration, chromatography, and recrystallization. Another<br>
variation of the acylation step c, is to use a nitrile compound of formula (10) in place of<br>
the aromatic- or heteroaromatic-methyl compounds of formula (5). The product, formula<br>
(II), can be transformed to formula (7) by hydrolysis of the nitrile group and then<br>
subsequent decarboxylation. Generally, a compound of formula (I I) is dissolved in a<br>
hydrogen halide acid solution, preferably hydrogen chloride. The reaction is carried out<br>
at temperatures of about ambient to lefluxing for about 24 hours. Tins type of reaction is<br>
well known and appreciated in the art (Larock, R. C, Comprehensive Organic<br>
Transformations, copyright 1989, VCH, pp 993). Compounds of formula (10) can be<br>
acquired by treatment of an appropriate substituted aromatic- or heteroaromatic-methyl<br>
group with a halogenating reagent, such as N-halosuccinimides, preferably N-<br>
bromosuccinimide in carbon tetrachloride and subsequently reacting the aromatic-<br>
halomethyiene intermediate with a nitrile source, such as lithium cyanide, potassium<br>
cyanide, or trimethylsilyl cyanide, preferably sodium cyanide. The reaction is carried out<br>
at ambient temperatures for about 24 hours, as shown in step d, to afford the acetonitrile<br>
compounds of formula (10), (Larock, R. C, Comprehensive Organic Transformations,<br>
copyright 1989, VCH, pp 313; Eur. J. Org. Chem. 1999,2315-2321).<br>
In Scheme 11, step f, compound of formula (7) is contacted to an appropriate<br>
compound of formula (9), this type ol compound is known and appreciated in the art<br>
(Taylor, Edward C; Haley, Neil F.; Clemens, Robert J., J. Amer. Ckem. Soc, 1981, 7743-<br>
7752), to give the compound of formula (1). Typically, the reaction is carried out in an<br>
acidic solvent, such as acetic acid and a suitable acid scavenger such as pyridine, or<br>
triethylamine. The reaction is carried out at temperatures of about 60 °C to ambient for<br>
4-24 hours. The products can be isolated and purified by techniques described above.<br><br><br>
Another variation a skilled artisan would appreciate in the formation of Formula<br>
(I) is shown in Scheme 111.<br>
Scheme 111, step g, depicts n Claisen condensation of two appropriate substituted<br>
carbonyl esters, where X for both compounds of formula (6) and formula (13) is a<br>
suitable leaving group as previously described, preferably a CI-G6 alkoxy group. The<br>
Claisen condensation is well known and appreciated in the art (March, J., Advanced<br>
Organic Chemistry, copyright 1985, John Wiley and Sons, Inc., pp 437-439). The<br>
products of formula (14) can be isolated and purified by techniques described above.<br>
]n Scheme IJJ, step f conditions can be applied to a compound of formula (14)<br>
with the appropriate compound of formula (9), to give the compound of formula (15).<br>
Typically, the reaction is carried out in a suitable solvent such as ethanol, N-<br>
methylpyrrolidinone or pyridine with pyridine being the preferred solvent. The reaction<br>
is carried out at temperatures of about 60 °C to ambient for 4-24 hours. The products can<br>
be isolated and purified by techniques described above.<br>
Step c, as described above, depicts the cyclization of a compound of formula (15)<br>
to give an optionally substituted compound of formula (16). Typically, the appropriate<br>
compound of formula (15) is reacted with to a suitable base that can form the anion of the<br>
hydrazone, sodium hydride being the preferred base in a suitable solvent preferably N,N-<br>
dimethylformamide at temperatures of about 0 to 100 °C. Optionally, a hydrolysis of the<br><br>
carboxyl ester of formula (16) can be performed. The products can be isolated and<br>
purified by techniques described above.<br>
Step h depicts the transformation of a carboxylic acid, formula (16), to a halide of<br>
formula (17). This transformation k well known and appreciated in the art (Larock, R.<br>
C, Comprehensive Organic Transformations, 2"d Ed., copyright 1999, John Wiley &amp;<br>
Sons, pp 741-742). The halide of formula (17) can be used as a leaving group in<br>
combination with a substituted aryf- or heteroarylboronic acid or ester in the presence of a<br>
suitable palladium catalyst, preferably tetrakis(triphenylphosphine)palladium(0), and a<br>
suitable base such as potassium carbonate to further give compounds of Formula (I)<br>
&gt;	(Suzuki reaction see: Miryaura, N.; Yanagi, T.; Suzuki, A. The Palladium-Catalyzed<br>
Cross Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of<br>
Bases. Synth. Commun., 1981, 513-518).<br><br>
Scheme IV, step j, depicts a carbonylation reaction for the formation of<br>
compounds of formula (6) and (20), where X is a suitable leaving group described as<br>
above, preferably a halogen. Compounds of formula (18) and (19) are used in the<br>
i formation of formula (6) and (20), respectively. The carbonyl group of formula (6) and<br>
(20) can further undergo a synthetic i ransformation to incorporate the leaving group X,<br>
where X is previously described. The Y group can be an aromatic or heteroaromatic<br>
halide and the reaction can be carried out in the presence of carbon monoxide, a suitable<br>
nucleophile, such as an amine or an itlcohol, with a palladium (0) or palladium (II)<br>
&gt;	catalyst, such as l,l'-bis(diphenylphc«sphino) ferrocene]dichloropalladium(ll):<br>
dichloromethane, tetrakis(triphenylpi«sphine)-palladium(O),<br>
bis(triphenylphosphine)palladium (II) chloride or palladium(H) acetate,<br><br>
tetrakis(triphenylphosphine)palladium(0), tris-(benzylideneacetone)dipaHa<iium></iium>
palladium dichloride, palladium bis[trifluoroacetate), or preferably 1,1'-<br>
bis(diphenylphosphino) feiTOcene]diehloropaHadium(ll):dichlorornethane. AFI reagents of<br>
the reagents are combined in a suitable solvent, typically terahydrofuran, tohiene or<br>
ethylene glycol dimethyl ether, stirred at temperatures of about 0 to 80 °C. AH products<br>
can be isolated and purified by techniques described above.<br><br>
&gt;<br>
Scheme V depicts the conveision of optionally substituted heteroaryls to<br>
optionally substituted carboxylic acid derivatives. Reaction sequences of this type are<br>
well known and appreciated in the art (Fife, WilmerK., J. Org. Chem., J983,1375-1377).<br>
A representative example of these reactions are as follow. For example, in step k, an<br>
&gt; optionally substituted pyridine compound of formula (21), where R is previously<br>
described as the substitutions for R1 or R2 of Formula (I), is treated with hydrogen<br>
peroxide in acetic acid, at reflux. Formula (23) is produced from the crude intermediate,<br>
formula (22), and results from the removal of the solvent in step k, the addition of a nitrile<br>
source, preferably trimethylsilyl cyanide along with a disubstituted carbamyl halide, such<br><br>
as dimethylcarbamyl chloride. The reaction is carried out at ambient temperatures for<br>
about 24 hours. All products can be isolated and purified by techniques described above.<br>
Scheme V, step e, the nitiile compounds of formula (23) are hydrolized by an acid<br>
to give the carboxylic acid of formula (24). Generally, a compound of formula (23) is<br>
dissolved in a hydrogen halide acid solution, preferably hydrogen chloride, The reaction<br>
is carried out at temperatures of about ambient to reflux for about 24 hours. This type of<br>
reaction is well known and appreciated in the art (Larock, R. C, Comprehensive Organic<br>
Transformations, copyright 1989, VCH, pp 993). Formula (24) can then be converted to<br>
the appropriate carbonyl leaving j;roup, where X is a suitable leaving group described as<br>
above as shown in step m. This conversion is well known and appreciated in the art<br>
(Larock, R. C, Comprehensive Organic Transformations, copyright 1989, VCH, pp 966).<br>
Alternatively, the carboxylic acid of formula (24) can be reduced to the<br>
corresponding alcohol by borane in tetrahydrofuran and then converted to a leaving<br>
group. Theses transformations arts well known and appreciated in the art (Larock, R. C,<br>
Comprehensive Organic Transformations, copyright 1989, VCH, pp 552 reduction; pp<br>
335 conversion to leaving group). The desired products may be isolated and purified by<br>
techniques described above.<br><br><br>
Scheme VI, step o, depict! a hydrazination of formula (7) affording a hydrazone<br>
compound of formula (27). Typically the reaction is carried out with a suitable source of<br>
hydrazine, preferably anhydrous hydrazine in an acidic solution consisting of an alcohol,<br>
such as methanol, ethanol, or projranol, and a hydrogen halo acid, preferably hydrogen<br>
chloride, is used as the solvent. The product can be isolated and purified by techniques<br>
described above. Compounds of formula (28) are commercially available or can be<br>
produced by a ring opening of appropriate substituted cyclic-carbonyl esters. Step p<br>
depicts these ring openings which can be accomplished by an acid hydrolysis using such<br>
as; hydrogen bromide with acetic acid or trimethyl aluminum can give the corresponding<br>
carboxylic acid derivatives to be further transformed to give compound of formula (28).<br>
Scheme VI, step c previously described, transforms the hydrazones of formula<br>
(27) to the hydrazides of formula (2), by acylation with compounds formula (28). The<br>
compound of formula (28) can be an appropriate carboxylic acid derivative, where X can<br>
be a leaving group previously described, preferably a halogen, most preferably a chloride,<br>
and where n and m can equal 1 or 2 carbons. The reaction is carried out in the presence of<br>
an acid scavenger such as pyridinc or triethylamine. The reagents are combined, and<br>
products isolated and purified by techniques described above. The conversion of amines<br>
to an amides by acylation is well known and appreciated in the art (Larock, R. C,<br>
Comprehensive Organic Transformations, copyright 1989, VCH, pp 979).<br><br><br>
One skilled in the art would appreciate the formation of formula (3) by the<br>
palladium-promoted coupling reaction of an alkyne and an aromatic halide. Such a<br>
reaction is known and appreciated in the art (Reisch, Johannes; Gunaherath, G. M. Kamal<br>
B.,J. Heterocycl. Chem., 1993; 1057-1060, Inouye, Masahiko; Miyake, Toshiyuki;<br>
Furusyo, Masaru; Nakazumi, Hiroyiiki, J. Amer. Chem. Soc, 1995; 12416-12425). For<br>
example, in Scheme VII, step q, an appropriate substituted alkyne of formula (29) and a<br>
variably substituted compound of formula (30), where R' and R" are previously<br>
described as substituions for Rl and R2 groups, respectively, for Formula (1) and where Y<br>
can be an appropriate leaving group such as a halide and the R group(s) can be one or<br>
more groups as previously described. Typically, the reaction is carried out by combining<br>
a compound of formula (30) with a palladium (0) or palladium (II) catalyst as described<br>
previously, preferably bis(triphcnylphosphine)palladium (II) chloride with a suitable base,<br>
such as trialkylamine or pyridine, preferably triethylamine along with a copper(l) halide<br>
to facilitate coupling to a compound of formula (29). All reagents are combined in a<br>
suitable solvent, typically terahydrofuran, toluene or ethylene glycol dimethyl ether,<br>
stirred at temperatures of about 0 to 80 °C. All products can be isolated and purified by<br>
techniques described above.<br><br><br>
Scheme VIII, depicts the incorporation of a heteroatom into the acyclic ring<br>
portion of Formula (I). In step r, an appropriate compound of formula (27) is reacted with<br>
an oxalic acid monoalkyl ester derivative, such as ethyl oxalyl chloride to give a<br>
compound of formula (31). Generally, the reaction is carried out in a suitable solvent,<br>
such as pyridine, at temperatures from ambient to reflux. The products can be isolated and<br>
purified by techniques described above.<br>
The reaction of step s, a compound of formula (31) is converted to a lactone of<br>
formula (32), by a sequence of reacti ons. An appropriate compound of formula (31) is<br>
dissolved in a suitable solvent, such as tetrahydrofuran, JV.W-dimethylformamide, or<br>
toluene, preferably W.Af-dimethylfonnamide at temperatures of about 0 to 80 °C. A<br>
suitable base, such as sodium carbonate, sodium bicarbonate, cesium carbonate, cesium<br>
bicarbonate, lithium carbonate, potassium carbonate, preferably cesium carbonate, is used<br>
in 1-3 molar equivalence, along with an appropriate alkylating reagent, such as a halo-<br>
alcohol, preferably 2-bromo-ethanol. The products can be isolated and purified by<br>
techniques described above.<br>
Step t depicts a ring opening and reduction of a compound of formula (32) to give<br>
a di-alcohol compound of formula (33). Typically, the reaction is carried out with a<br>
suitable reducing agent, such as boranes (sodium borohydride, borane-methyl sulfide<br>
complex or potassium borohydride), or aluminum hydrides (lithium aluminum hydride,<br><br>
sodium aluminum hydride or potassium aluminum hydride, preferably lithium aluminum<br>
hydride). All of the reagents are combined in a suitable solvent, typically<br>
dichloromethane, chloroform, tetiahydrorliran, dioxane, or diethyl ether and are stirred<br>
from 1 to 72 hours at a temperature of from ambient to about the refluxing temperature of<br>
the solvent. The desired product may be isolated and purified by techniques described<br>
above.<br>
The reaction »n step u depicts a ring formation of a compound of formula (33) to<br>
give a compound of formula (34), a compound derivative of Formula (I). The di-hydroxy<br>
compound of formula (33) is mixed with a suitable base, such as sodium hydride,<br>
potassium hydride, typically at approximately 2-4 molar equivalents of base per molar<br>
equivalent of the di-alcohol. A suitable sulfonylating agent, such as p-toluenesulfonyl<br>
chloride, p-nitro-benzenesulfonyl chloride, trifluoromethanesulfonic anhydride, or<br>
preferably methanesulfonyl chloride, is added in the reaction for the conversion of the<br>
hydroxy group of formula (33) into a suitable leaving group. The reaction is carried out<br>
in a suitable solvent, such as dichlo omethane, chloroform, tetrahydrofuran, dioxane, or<br>
diethyl ether, preferably tetrahydroluran, and stirred for 1 to 24 hours at a temperature of<br>
about 0 °C to ambient. The desired product may be isolated and purified by techniques<br>
described above.<br><br><br>
Scheme IX, elaborates substitution of the Rl and R2 groups of Formula (I). A<br>
representative transformation is seen m step v, a nucleophilic addition of appropriate<br>
compounds of formula (35) and (36), where Z is an halide, such as chloro, bromo, or<br>
iodo, or a sulfonic ester derivative substituted anywhere upon the aromatic ring, can<br>
undergo a nucleophilic substitution with appropriate nucleophiles, where the R group(s) is<br>
described above, to give compounds of formula (37) and (38), respectively. Typically,<br>
the reaction is carried out in the presence of C1-C6 alkoxide or variably substituted amine<br>
neat or in N.N-dimethylformamide, toluene or xylene, preferably MN-dimethylformamide<br>
at temperatures of about 100 °C to rellux. Alternatively, a metal-nucleophile, such as<br>
trialkylstannyls, or boranes with a suitable base such as, sodium alkoxides (sodium<br>
methoxide, or sodium ethoxide) or potassium alkoxides (potassium methoxide, or<br>
potassium ethoxide) can be used with a palladium catalyst, previously described,<br>
preferably tetrakis(triphenylphosphine) palladium(O). Or a skilled artisan can use as the<br>
metal-nucleophile a magnesium-halogen reagent (Grignard reagent) along with the<br>
palladium catalyst, to further elaborate the aryl-substituents at the C3 and C4 positions of<br>
the pyrazole of Formula (1). All reagents of the reagents are combined in a suitable<br>
solvent, typically tetrahydrofuran, toluene or ethylene glycol dimethyl ether, stirred at<br>
temperatures from room temperature to reflux. All products can be isolated and purified<br>
by techniques described above.<br><br><br>
Scheme X depicts the manipulation of hydroxy-aryi compounds of formula (40)<br>
for further alkylations and transformations to enable the scope of this invention, where the<br>
R group(s) are previously described. Representative conversions are shown in Scheme<br>
X.<br>
Step w, depicts the depiotection of a protected aromatic-hydroxy group of formula<br>
(39) to give a compound of formula (40), where the ~Pg** can be an alkoxide. The<br>
deprotection is well known aitd appreciated in the art (Greene T. W., Wuts, P. G. M.<br>
Protective Groups in Organic Synthesis, copyright 1991, John Wiley and Sons, Inc.,<br><br>
pp 146-149). The product of fonrula (40) can be isolated and purified by techniques<br>
previous described.<br>
Step x, depicts the formation of an aryl ether compound of formula (40) to give<br>
the compounds of Formula (I). The formation of an aryl ether is well known and<br>
appreciated in the art (March, J., Advanced Organic Chemistry, copyright 1985, John<br>
Wiley and Sons, Inc., pp342-343, 5 89. and Mundy, B. P., Ellerd, M. G. Name Reactions<br>
and Reagents in Organic Synthesis, copyright 1988, John Wiley and Sons, Inc., pp 242,<br>
530; Sawyer, J.S., Schmittling, E.A., Palkowiiz, J.A., Smith, 111, WJ., J. Org. Chcm.,<br>
1998, 63, 6338-6343). The products can be isolated and purified by techniques described<br>
above.<br>
Step y depicts an alkyation of a compound of formula (40) to give a variably<br>
substituted compound of formula (4 I), where the leaving group(s) "Lg" and "Lg"* can<br>
include such leaving groups, but are not limited to, halides, oxonium ions, alkyl<br>
perchlorates, ammonioalkanesulfonate esters, alky) fluorosulfonates, nonaflates,<br>
tresylates, triflates, and sulfonic esters, preferably the mesylate or tosylate, given "Lg"<br>
and "Lg'" are not the same group. Typically, the appropriate compound of formula (40)<br>
is reacted with a suitable base that can form the anion of the phenol, such as lithium<br>
carbonate, sodium carbonate, potassi jm carbonate, cesium carbonate, sodium hydride,<br>
lithium hydride, potassium hydride, with cesium carbonate being the preferred base, in<br>
the presence of a compound of formula (42). The reaction is carried out in a suitable<br>
solvent, such as tetrahydrofuran, N.N-dimethylformamide, dimethylsulfoxide, dimethyl<br>
acetamide or toluene, preferably N,N- dimethyl formamide at temperatures of about 0 to<br>
100 °C. The products can be isolated and purified by techniques described above.<br>
Step z depicts the nucleophilic substitution of leaving group "Lg", by a<br>
nucleophile to form a compound of the formula (43). Nucleophilic substitution is well<br>
known and appreciated in the art (March, J., Advanced Organic Chemistry, copyright<br>
1985, John Wiley and Sons, Inc., pp 255-446). Typically, the compound of formula (41)<br>
is reacted with a nucleophile of formula (44), which is typically, but not limited to,<br>
primary amines, secondary amines, alcohols or thiols. The reaction is carried out in a<br>
suitable solvent, such as tetrahydrofurin, N,N~di methyl formamide, dimethylsulfoxide,<br>
dimethyl acetamide or toluene, preferably A'.TV-dimethylformamide at temperatures of<br><br><br>
A skilled artisan would appreciate oxidation reactions on compounds of Formula<br>
(1) to further elaborate the scope of this invention. Representative examples are shown in<br>
Scheme XI. For example, a sulfur- or nitrogen-containing compound can be oxidized to<br>
an oxide (nitrogen or sulfur) or a bis oxide (sulfur) by oxidizing reagents. Typically, a<br>
compound of Formula (1) is contacted to an oxidant which is typically, but not limited to,<br>
hydrogen peroxide, acetoyl peroxide, benzoyl peroxide, tert-butyl peroxide, ozone,<br>
Oxone®, preferably Oxone®, in the presence of an acid which is typically, but not<br>
limited to, hydrochloric, sulfuric, nitric, phosphoric, acetic, trifluoroacetic acids,<br>
preferably acetic acid. The reaction is carried out in a suitable solvent, such as<br>
tetrahydrofuran, water, an alcohol, such as, but not limited to, ethanol, or methanol,<br>
preferably a mixture of water and tetrahydrofuran at temperatures of about 0 to 100 °C.<br>
Oxidations are well known and appreciated in the art (March, J., Advanced Organic<br>
Chemistry, copyright 1985, John Wiley and Sons, Inc., pp J089-1090).<br><br><br>
t<br>
A skilled artisan would appreciate palladium catalyzed couplings to elaborate the<br>
scope of the invention as shown in Scheme XII.<br>
Aryl substitutions of may be accomplished, through the use of a halo or sulfonyl<br>
leaving group, X, in combination with a substituted aryl- or heteroarylboronic acid or<br>
ester in the presence of a suitable palladium catalyst and a suitable base such as potassium<br>
carbonate as previously described in Scheme 111. Another palladium catalyzed reaction,<br>
incorporates alkenyl substitutions may be realized by reacting the corresponding aryl<br>
halide with an alkene in the presence of a suitable base such as triethylamine, a palladium<br>
catalyst, and a suitable ligand, such as triphenylphosphine. The resulting alkene may be<br>
reduced via hydrogenation to provide a substituted alkane-linked derivative (Heck<br>
reaction see: Whitcombe, N. J.; Hii, K. K.; Gibson, S. E. Advances in the Heck<br>
chemistry of aryl bromides and chlorides, Tetrahedron, 2001, 57(35), 7449-7476).<br>
A skilled artisan would also appreciate a carbonylation using an aromatic halide<br>
along with a palladium catalyst and an atmosphere of carbon monoxide in a suitable<br>
solvent such as methanol as previously described in Scheme IV.<br><br><br>
Scheme Xlll also elaborates compounds of Formula (I) to further enable the scope<br>
of this invention. A transformation of a benzylthio-aryl to a sulfonamide formation is<br>
depicted in step aa. A typical reaction is the treatment of a benzylthio-aryl with<br>
molecular chlorine in aqueous acetic acid solution and with the removal of the solvent<br>
then coupling the product to an appropriate substituted amine. One skilled in the art<br>
would also appreciate the conversion of an aryihalide of Formula (1) to the corresponding<br>
amine, shown in step bb. For example, the aryihalide is treated with benzophenone<br>
imine and a suitable base such as sodium methoxide, sodium wo-propoxide or preferably<br>
sodium /e/7-butoxide also using a palladium catalyst as previously described, preferably<br>
bis(dibenzylideneacetone)-palladium with an appropriate ligand such as 2,2*-<br>
bis(diphenylphosphino)-l,r-binaphthyl, this type of amination transformation is well<br>
known and appreciated in the art (Prashad, M.; Hu, B.; Lu, Y.; Draper, R.; Har, D.; Repic,<br>
O.; Blacklock, TJ.,J. Org. Chan., 2JI00,65,2612-1614).<br><br><br>
One skilled in the art would also appreciate other transformations of hetrocyclic<br>
substituions, as shown in Scheme XIV.<br>
Step cc, depicts a cyclizatioi of a hydroxyethyl-carbamic ester, to give an<br>
oxazolidinone. This type of cyclizi tion is well known in the art (Mistunobu, O.,<br>
Synthesis, 1981, 1-28).<br>
Step dd, depicts a transformation of the aryl carboxylic ester, to a 4,5-dihydro-lH-<br>
imidazole by use of a Lewis acid such as trimethylaluminum. This type of transformation<br>
is well known in the an (Neef, G.; Eder, U.; Sauer, G.; J. Org. Chem., 1981,46,2824-<br>
2826).<br>
Many of the compounds of the present invention are not only inhibitors of TGF-<br>
beta receptor kinase, but are also useful intermediates for the preparation of additional<br>
compounds of the present invention. For example, ester moieties may be reduced or<br>
hydrolized to the corresponding alcohols or carboxylic acid (Larock, R. C,<br>
Comprehensive Organic Transformations. Td Ed., copyright 1999, John Wiley &amp; Sons,<br>
pp 1959-1968). These alcohols may then be activated and displaced by a number of<br>
nucleophiles to provide other compounds of the invention (see Larock, Comprehensive<br>
Organic Transformations, 2nd Ed., lohn Wiley &amp; Sons, New York, pg. 779-780 (1999)).<br>
Additionally, in order to substitute alcohol derivatives with a corresponding<br>
amine, the skilled artisan would appreciate that necessary intermediates would<br>
incorporate certain appropriate leaving groups. Such leaving groups include, but are not<br><br>
limited to, halides, oxonium ions, alkyl perchlorates, ammonioalkanesulfonate esters,<br>
alkyl fluorosulfonates, nonaflates, tresylates, triflates, and sulfonic esters, preferably the<br>
mesylate or tosylate. Techniques lor the introduction of these groups are also well known<br>
to the skilled artisan; see, for example, March, Advanced Organic Chemistry, 5th Ed.,<br>
John Wiley and Sons, New York, pg. 445-449 (2001). The skilled artisan will appreciate<br>
the secondary amine moiety can be reacted with an appropriate reagent to introduce a<br>
suitable amino protecting group "Pg", such as a formyl group, acetyl group, or preferably<br>
a tert-butoxycarbonyl moeity. These protecting groups may be removed at any<br>
convenient, point in the synthesis of the compounds of the present invention. Methods of<br>
formation and removal of an amino-protecting group are well known in the art; see, for<br>
example, Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley<br>
and Sons, New York, Chapter 7 (1999).<br>
For example, secondary amines may be acylated, alkylated or coupled with simple<br>
carboxylic acids or amino acids under standard conditions, in the presence of a peptide<br>
coupling reagent, optionally in the presence of a catalyst. Suitable peptide coupling<br>
reagents include N.JV'-carbonyldiiinidazolc (CDI), N,N'-dicyclohexylcarbodiimide<br>
(DCC), l-(3-dimethylarninopropyl)-3-cthylc:arbodiimide hydrochloride (EDC), and l-(3-<br>
(l-pyrrolidinyl)propyl)-3-ethylcarbodiimide (PEPC). Polymer supported forms of EDC<br>
(Tetrahedron Letters, 34(48), 7685 (1993)) and PEPC (U.S. Patent #5,792,763) have been<br>
described, and are very useful for the preparation of the compounds of the present<br>
invention. Suitable catalysts for tine coupling reaction include N,N-dimethy\-4-<br>
aminopyridine (DMAP). Such coupling reactions arc well known and appreciated in the<br>
art (Larock, R. C, Comprehensive. Organic Transformations, 2nd Ed., copyright 1999,<br>
John Wiley &amp; Sons, pp 1941-1949). Also One skilled in the art would appreciate the<br>
treatment of a secondary amine with a phosgene reagent, with a suitable base such as<br>
pyridine and quenching the reaction with an amine or an alcohol to afford the appropriate<br>
ureas and carbamates of Formula (1) (March, J., Advanced Organic Chemistry, copyright<br>
1985, John Wiley and Sons, Inc., pp 370-371).<br>
A skilled artisan would recognize several other transformations that can be<br>
applied to the synthetic process for production of useful and reactive intermediates. Such<br>
transformations include but are not limited to alkylation or acylations of the appropriate<br>
amine, O-alkylation of the hydroxy intermediates, or hydroxy-halogen exchange (Larock,<br><br>
Comprehensive Organic Transformations, 2nd Ed., John Wiley &amp; Sons, New York, pg.<br>
689-697(1999)).<br>
The skilled artisan will also appreciate that not all of the substituents in the<br>
compounds of Formula (I) will tolerate certain reaction conditions employed to<br>
i synthesize the compounds. These moieties may be introduced at a convenient point in the<br>
synthesis, or may be protected and i hen deprotected as necessary or desired.<br>
Furthermore, the skilled artisan wili appreciate that in many circumstances, the order in<br>
which moieties are introduced is not critical.<br>
The skilled artisan will appreciate that the compounds of Formula (1) in Methods<br>
) A, B or C may be formed into acid addition salts using pharmaceutically acceptable acids.<br>
The formation of acid-addition salt!, is well known and appreciated in the art.<br>
The following preparations and examples further illustrate the preparation of<br>
compounds of the present invention and should not be interpreted in any way as to limit<br>
the scope. Those skilled in the art will recognize that various modifications may be made<br>
i while not departing from the spirit ind scope of the invention. All publications<br>
mentioned in the specification are indicative of the level of those skilled in the art to<br>
which this invention pertains.<br>
PREPARATION 1<br>
»	4,5-Dihydroxy-pcntanoic acid ethyl ester<br>
A solution of ethyl pent-4-enoate (11.7 g, 91.3 mmol) in tetrahydrofuran (420 mL)<br>
and water (40 mL) is treated with csmium tetroxide (1.0 g, 4.2 mmol) and 4-<br>
methylmorpholine N-oxide (32.5 mL, 50% in water) at room temperature and stired for 3<br>
&gt; h, at which time no more starting material is detectable by TLC (SK&gt;2, 2%<br>
methanol/dichloromethane, Rr=04Q). The mixture is concentrated in vacuo and the<br>
residue chromatographed on SiC&gt;2 (2% methanol/ethyl acetate) to afford the title<br>
compound 14.37 g (96%) as a colorless oil.<br>
'H NMR (CDCI3): 8 4.10 (q, J = 7 Hz, 2H), 3.60-3.80 (m, 2H), 3.45 (dd, J = 7,11 Hz,<br>
1 1H), 3.00 (bs, 2H), 2.45 (dd, J = 1.3, 7 Hz, 2H), 1.70-1.85 (m, 2H), 1.25 (t, J = 7 Hz, 3H).<br><br>
washed with water and brine, dried over sodium sulfate, and filtered. The filtrate is<br>
concentrated in vacuo to provide ihe title compound, 4.0 g (80%), as a colorless liquid.<br>
'H NMR (CDCb) 8 7.37-7.10 (m, 10H), 4.56 (s, 2H), 3.85-3.72 (m, 1H), 3.5-3.41 (m,<br>
1H), 3.39-3.29 (m, 1H), 2.9-2.6 (m, 2H), 1.8-1.67 (m, 2H).<br>
PREPARATION 5<br>
l-B«'nzyloxy-4-phenyl-butan-2-one<br>
To a solution of 1 -benzylo* y-4-phenyl-butan-2-oI, (8.4 g, 32.8 mmol) in<br>
dichloromethane (400 mL) is added a mixture of pyridinium chlorochromate (14.1 g, 65.6<br>
mmol) with S1O2 (14 g) and stirred for 3 h at room temperature. The mixture is filtered<br>
through a pad of SiO2 and concentrated to provide the title compound 5.7 g (68%) as a<br>
colorless liquid.<br>
lH NMR (CDC13) 8 7.4-7.14 (m, 10H), 4.6 (s, 2H), 4.03 (s, 2H), 2.9- 2.82 (m, 2H), 2.8-<br>
2.72 (m, 2H).<br>
PREPARATION 6<br>
4-Acetoxy-3-phcnyl-bufyric acid methyl ester<br>
A mixture of 4-acetoxy-3-phenyl-but-2-enoic acid methyl ester, (1.0 g, 4.27<br>
mmol), 10 wt. % palladium on activated carbon (1.0 g), acetic acid (10 mL) is shaken<br>
under an atmosphere of hydrogen on a Parr® Shaker. The mixture is filtered through a<br>
pad of Celite® and rinsed with methanol. The solution is concentrated in vacuo to yield<br>
0.93 g (92%) of the title compound.<br>
'H NMR (CDCI3) 8 7.40-7.10 (m, 5H), 4.30-4.05 (m, 2H), 3.60 (s, 3H), 3.55-3.40 (m,<br>
1H), 2.80-2.50 (m, 2H), 2.10 (s, 3H).<br><br>
PREPARATION 7<br>
Acetic acid 2-oxo-2-phenyl-ethyl ester<br>
A solution of 2-hydroxyaceto-phenone (JO g, 73.4 mmol), pyridine (17.4 g, 220.2<br>
mmol), dichloromethane (734 mL), 3 crystals of 4-dimethylaminopyridine is cooled to -<br>
78 °C. To this solution is added acetic anhydride (13.9 mL, 146.9 mmol) then wanned to<br>
room temperature and stirred for 18 h. The mixture is washed with water (200 mL) and<br>
brine (200 mL) then dried over sodium sulfate. The mixture is filtered and concentrated<br>
in vacuo to yield the title compound, 13 g (99%), as a colorless liquid.<br>
'H NMR (CDCb) 5 7.9-7.2 (m, 5H), 5.32 (s, 2H), 2.20 (s, 3H).<br>
PREPARATION 8<br>
4-(3-Methoxy-pheny|)-5//-furan-2-one<br>
3-Methoxy-phenyl-boronic acid (2.16 g, 14.2 ramol) and trifluoromethansulfonic<br>
acid 5-oxo-2,5-dihydro-furan-3-yl ester1 (3 g, 12.92 mmol) in tetrahydrofuran (110 mL) is<br>
dissolved and de-gassed for 15 min. To this solution is added sodium carbonate (3.42 g,<br>
32.3 mmol) in water (10 mL) and tetrakis-triphenylphosphine-palladium(O) (0.75 g, 0.646<br>
mmol). The reaction mixture is refluxed for 45 min, cooled to room temperature, diluted<br>
with ether (50 mL) and filtered through a Celite® pad. The filtrate is washed with water<br>
and brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The<br>
residue is chromatographed on SiO2 (3:7 ethyl acetate/hexanes) to yield the title<br>
compound, 1.9 g (71%), as a white crystalline solid.<br>
'H NMR (CDC13): 8 7.35 (m, 1H), 7.00-7.20 (itn, 3H), 6.30 (s, 1H), 5.2O(s, 2H), 3.80 (s,<br>
3H).<br>
1) Grigg, R.; Kennewell, P.; Savic, V. Tetrahedron, 1994, 5489-5494.<br><br>
PREPARATION 9<br>
4-(4-Fluo«ro-phenyl)-5//-furan-2-one<br>
A method similar to PREPARATION 7, except employing 4-fluoro-phenyl-<br>
boronic acid, is used to yield the title compound as a white crystalline solid.<br>
'H NMR (CDCb): 8 7.50-7.60 (m, 2H), 7.15-7.25 (m, 2H), 6.35 (s, 1H), 5.20 (s, 2H).<br>
PREPARATION 10<br>
4-(3-Melhoxy-phenyl)-dihydro-furan-2-one<br>
To a solution of4-(3-methoxy-phenyl)-5//-furan-2-one, (1.9 g, 10 mmol) is<br>
tetrahydrofuran (100 mL) and is added Raney nickel (7.6 g, 50% suspension in water),<br>
the mixture is stirred under hydrogen (ambient pressure) 18 h at room temperature. The<br>
mixture is filtered through Celite® and concentrated in vacuo to yield the title compound,<br>
1.54 g (80%), as a white crystalline sal id.<br>
'H NMR (CDCh): 8 7.25 (m, 1H), 6.75-6.90 (m, 3H), 4.65 (dd, J = 7.9 Hz, J = 9 Hz, 1H),<br>
4.25 (dd, J = 7.9. Hz, J = 9 Hz, 1H), 3.80 (s, 3H), 3.70-3.85(m, 1H), 2.90 (dd, 3 = 8.7,<br>
17.5 Hz, 1H), 2.65 (dd, 1H, J = 8.7, 17.5 Hz).<br>
PREPARATION 11<br>
4-(4-Fluoro-phenyl)-dihydro-furan-2-one<br>
A method similar lo PREPARATION 9, except employing 4-(4-fluoro-pheayl)-<br>
5//-furan-2-one, (1.4 g, 7.86 mmol), i:s used to yield the title compound, 1.38 g (97.6%),<br>
as a white crystalline solid.<br>
'H NMR (CDCl-i): 8 7.15-7.35 (m, 2H), 7.00-7.10 (m, 2H), 4.65 (dd, J = 7.8, 9 Hi, 1H),<br>
4.20 (dd, J = 7.8, 9 Hz, 1H), 3.70-3.90 (m, IH), 2.90 (dd, J = 9,17.5 Hz, IH), 2.«Mdd, J<br>
= 9, 17.5 Hz, IH).<br><br>
f REPARATION 12<br>
4-Bewyl-dihydio-furan-2-one<br>
A mixture of 3-benzoylpra|«onic acid (18 g, 101 mmol), potassium carbonate (10<br>
g, 75 mmol), water (45 mL) and fitamaldehyde (36% in water, 7.8 mL, 101 mmol) is<br>
stirred at room temperature for 5 days, wanned to 30 °C and stirred for 3 additional days.<br>
To this mixture is added concentrated hydrochloric acid (10 mL) to pH 5.0, heated at 50<br>
°C for 30 min. and copied to room temperature. The mixture is extracted with chloroform<br>
(4 x 200 mL) and the combined organic extracts washed with sodium carbonate (10% in<br>
water, 3 x 100 mL). The solution k dried with anhydrous sodium sulfate and filtered.<br>
The filtrate is concentrated in vacw to yield 4-benzoyl-dihydro-furan-2-one (12 g) as a<br>
colorless liquid.<br>
To a solution of 4-benzoyNlihydro-furan-2-one (5 g) in methanol (250 mL) in a<br>
Parr® reactor is added palladium dJoride (0.25 g). The mixture is shaken under<br>
hydrogen (50 PS1) for 3 h. The mixture is filtered through a pad of Celite® (40 g) and the<br>
filtrate concentrated. The residue is chromatographed on SiO? (10% ethyl<br>
acetate/hexanes, then 30% ethyl ace tate/hexanes) to yield the title compound, (2.5 g, 34%<br>
from 3-benzoylpropionic acid), as a colorless liquid.<br>
'H NMR (CDC13) 57.40-7.05 (ra.5H), 4.38-4.30 (m, 1H), 4.02-3.98 (m, 1H), 2.98-2.70<br>
(m, 2H), 2.68-2.55 (m, 1H), 2.38-2.25 (m, 1H).<br>
PREPARATION 13<br>
4-Phem thyl-dihydro-furan-2-one<br>
A mixture of 3-benzyloxjB*ethyl-5-phenyl-pent-2-enoic acid methyl ester, (3.2 g,<br>
13.5 mmol), 10 wt.% palladium on activated carbon (3.2 g), and acetic acid (40 mL) is<br>
placed in a Parr® Shaker under 1qpdrogen(45 PSI) and shaken 4 h. The mixture is<br>
filtered through a pad of Celite©and concentrated in vacuo. The residue is dissolved in<br>
toluene (30 mL), treated with /Hblunesulfonic acid (0.1 g), refluxed for 2 h and<br>
concentrated in vacuo. The reafce is chromatographed on SiC&gt;2 (10% ethyl<br>
acetate/hexanes then 50% ethyl acetate/hexanes) to yield the title compound 1.2 g (62%)<br>
as a colorless liquid.<br>
'H NMR (CDC13) 6 7.38-7.15 (i* f H), 4.50-4.40 (m, 1H), 4.00-3.92 (m, IH), 2.70-2.50<br>
(m, 4H), 2.25-2.15 (m, 1H), 1 J»-l .80 (m, 2H).<br><br>
PREPARATION 14<br>
4-Metlty|-dihydro-furan-2-one<br>
A method similar to PREPARATION 13, except employing 4-methy|-5H-furan-2-<br>
one (3 g, 30.6 mmol), is used to yield the title compound, 3.06 g (100%,) as a colorless<br>
liquid.<br>
'H NMR (CDC13) 8 4.45-4.37 (m, 1H), 3.93-3.80 (m, 1H), 2.71-2.56 (m, 2H), 2.20-1.99<br>
(m, 1H), 1.21-1.09 (m,3H).<br>
PREPARATION 15<br>
4-Phenyl-dihydro-furan-2-<me></me>
A solution of 4-acetoxy-3-phenyl-butyric acid methyl ester, (4.5 g, 19-2 mmol) in<br>
1,4-dioxane (29 mL) and sulfuric acid (29 mL)is stirred at room temperature for one hour<br>
then heated at 45 °C for 18 h. Volatile solvents are evaporated and the residue is<br>
extracted with toluene. The combined organic extracts are extracted with water and brine,<br>
filterd, and concentrated to yield the title compound, 2.2 g (71%), as a colorless liquid.<br>
'H NMR (CDCI3) 6 7.38-7.1 (m, 5H), 4.73-4.65 (m, 1H), 4.3-4.22 (m,lH), 3,85-3.7 (m,<br>
1H), 3.0-2.9 (m, 1H), 2.75-2.55 (m, IH).<br>
PREPARATION 16<br>
(/?)-5-Benzylo:cymcthyl-dihydro-furan-2-one<br>
To a solution of (/?)-5-hydroxymethyl-dihydro-furan-2-one (5 g, 43.06 mmol) in<br>
tetrahydrofuran (130 mL) is added sodium hydride (2.58 g, 60% oil dispersion, 64.59<br>
mmol) and tetrabutylammonium iodide (spatula) and stirred for 30 min. To the mixture is<br>
added benzyl bromide (6.18 mL, 51.67 mmol) and refluxed for 3 h. The mixture is<br>
cooled and diluted with ethyl acetate (150 mL), washed with a saturated solution of<br>
ammonium chloride (150 mL) and brine. The mixture is dried over magnesium sulfate,<br>
filtered and concentrated in vacuo to yield the title compound, 8.87 g (100%), as a pale<br>
yellow oil.<br>
'H NMR (CDCI3): 8 7.25-7.40 (m, 5H), 4.63-4.72 (m, 1H), 4.56 (s, 2H), 3.68 (dd, J =<br>
10.7, 4.0 Hz, 1H), 3.58 (dd, J = 10.7, 4.0 Hz, 1H), 2.04-2.68 (m, 4H).<br><br>
PREPARATION 17<br>
(5&gt;5-Benzyloxynwfhyl-dihydiro-fiiran-2-one<br>
A method similar to PREPARATION 16, except employing (S)-5-hydroxymethyl-<br>
dihydro-furan-2-one (4.0 g, 34 mtnol), is used to yieMthe title compound, 7.1 g (&gt;98%),<br>
as a colorless oil.<br>
'H NMR (CDCb): 5 7.25-7.40 (m, 5H), 4.63-4.72 (m, 1H), 4.56 (s, 2H), 3.68 (dd, J =<br>
10.7,4.0 Hz, 1H), 3.58 (dd, J= 10-7.4.0 Hz, 1H), 2.04-2.68 (m, 4H).<br>
PREPARATION 18<br>
4-(5-MeJhoxy-«etrahydro-ftiran-3-yl)-benzoic acid ethyl ester<br>
A solution of sodium nitrite (1.67 g, 24.2 mmol) in water (14 mL) is added<br>
dropwise to an ice cold mixture of «;thyl 4-aminobenzoate (4.0 g, 24.2 mmol) and<br>
tetrafluoroboric acid (7.8 mL, 48%, 59.78 mmol) and stirred for 30 min. Methanol (28.5<br>
mL), 2,5-dihydrofuran (3.66 mL, 4K.4 mmol) and palladium(H) acetate (70 mg, 0.31<br>
mmol) are added and the mixture re fluxed for 30 min. The mixture is filtered through<br>
Celite® pad and the filtrate diluted with dichloromethane (100 mL). The organic layer is<br>
separated and concentrated in vacuc. The residue is chromatographed on S1O2 (10%<br>
ethyl acetate/hexanes) to yield the title compound, 2.45 g (42%), as a white solid.<br>
'H NMR (CDCI3): 8 7.98 (d, J = 8.3 Hz, 2H), 7.27-7.39 (m, 2H), 5.18 (m, 1H), 4.27-4.40<br>
(m, 3H), 3.61 -3.87(m, 2H), 3.40(s, 3H),2.28-2.70<m></m>
= 7.1Hz,3H).<br><br>
PREPARATION 19<br>
4-(4-Chloro-ph<:nyl></:nyl>
A method similar to PREPARATION 18, except employing 4-chloroaniline (10.0<br>
g, 78.4 mmol), is used to yield the title compound, 6.7 g (40%), as a pale yellow oil.<br>
'H NMR (CDC13): 8 7.13-7.28 (m,4H), 5.14 (m, 1H), 4.14-4.31 (m, 1H), 3.54-3.82 (m,<br>
2H), 3.32-3.41 (m, 3H), 2.28-2.63 (m, 1H), 1.87-2.08 (m, 1H).<br>
PREPARATION 20<br>
4-(5-Oxo-lctrahydro-furan-3-yl)-benzoic acid ethyl ester<br>
To a solution of 75% 3-chloropcrbenzoic acid (2.7 g, 11.76 mmol) in<br>
dichloromethane (35 mL) is added magnesium sulfate (2.0 g, 16.6 mmol) and the mixture<br>
stirred for 30 min. Solids are removed by filtration and the filtrate treated with<br>
borontrifluoride etherate (0.5 mL, 3.92 mmol) and 4-(5-methoxy-tetrabydro-furan-3-yI)-<br>
benzoic acid ethyl ester (2.45 g, 9.8 mmol) in dkhloromethane (5 mL). The mixture is<br>
stirred at room temperature 18 h, diluted with ether (200 mL) and washed with a 10%<br>
solution of sodium thiosulfite (150 mL), a saturated solution of sodium bicarbonate (150<br>
mL) and brine. The mixture is dried over magnesium sulfate, filtered and concentrated in<br>
vacuo. The residue is chromatogiaphed on SiO2 (elute with 20% ethyl acetate/hexanes)<br>
to yield the title compound, 2.2 g (96%), as an off-white solid.<br>
lH NMR (CDCI3): 8 8.04 (d, J - K.3 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 4.69 (dd, J = 9.0,<br>
7.9 Hz, 1H), 4.26-4.42 (m, 3H), 3.82-3.95 (m, 1H), 2.96 (dd, J = 17.5, 8.7 Hz, 1H), 2.68<br>
(dd, J = 17.5, 8.7 Hz, 1H), 1.39(1, J = 7.1 Hz,3H).<br><br>
PREPARATION 21<br>
4-(4-Chlor»-phenyl) dihydro-furan-2-one<br>
A method similar to PREPARATION 20, except employing 4-(4-chloro-phenyl)-<br>
2-methoxy-tetrahydro-furan (6.78 g, 32 mmol), is used to yield the title compound, 6.2 g<br>
(98%), as an off-white solid.<br>
'H NMR (CDC13): 6 7.34 (d, J = 8 5 Hz, 2H), 7.17 (d, J = 8.5 Hz, 2H), 4.65 (dd, J = 9.1,<br>
7.8 Hz, 1H), 4.23 (dd, J = 9.1, 7.8 Hz, 1H), 3.70-3.84 (m, 1H), 2.92 (dd, J = 17.5, 8.8 Hz,<br>
1H), 2.63 (dd, J = 17.5, 8.8 Hz, 1H).<br>
PREPARATION 22<br>
4-Hydroxy-3-(3-mefhoxy-plienyl)-butyric acid benzhydrylidene-hydrazidc<br>
Trimethylaluminum (12 ml-» 2 M in hcxane, 24 mmol) is added dropwise to a<br>
solution of benzophenone hydrazoiie (1.57 g, 8 mmol) in dichloromethane (20 mL) at<br>
room temperature and under nitrogen. After the mixture is stirred for 30 min, 4-(3-<br>
methoxy-phenyI)-dihydro-furan-2-one, (1.54 g, 8 mmol) in dichloromethane (5 mL) is<br>
added. The mixture is refluxed for 5 h cooled to room temperature and diluted with<br>
dichloromethane (30 mL). The mixture is treated with 4 N sodium hydroxide (30 mL)<br>
and stirred one hour. The organic layer is separated, washed with brine and, dried over<br>
magnesium sulfate. The mixture is filtered, concentrated in vacuo and chromatographed<br>
on SiO2 (2% methanol/dichloromclhane) to yield the title compound, 2.25 g (73%) as a<br>
pale yellow oil.<br>
'H NMR (CDCI3): 5 8.35 (bs, 1H), 7.15-7.60 (m, 11H), 6.75-6.95 (m, 3H), 3.80-3.90 (m,<br>
2H), 3.80 (s, 3H), 3.45-3.6 (m, 1H), 3.15-3.40 (m, 2H), 2.15 (m, 1H).<br><br>
PREPARATION 23<br>
3-(4-Fluoro-phenyl)-4-hydroxy-butyric acid benzhydrylidene-hydrazide<br>
A method similar to PREPARATION 22, except employing 4-(4-fluoro-phenyi)-<br>
dihydro-furan-2-one (1.38 g, 7.67 mmol), is used to yield the title compound, 2.8 g<br>
(90%), as a white crystalline solid.<br>
'H NMR (CDC13): 6 8.30 (bs, 1H), 7.15-7.60 (m, 12H), 6.95-7.15 (m, 2H), 3.75-3.95 (m,<br>
2H), 3.40-3.60 (m, 1H), 3.20-3.35 (m, 3H).<br>
PREPARATION 24<br>
5-(Aerr-Butyl-dimethyl-silylojy)-4-hydroxy-pcntanoic acid benzhydrylidcne-<br>
hydrazide<br>
A method similar to PREPARATION 22, except employing 5-(ie/7-butyl-<br>
dimethyl-silyloxy)-4-hydroxy-penta»noic acid ethyl ester (6.41 g, 23.2 mmol), is used to<br>
yield the title compound, 6.2 g (63%), as a yellow foam.<br>
'H NMR (CDC13): 5 8.30 (bs, 1H), 7.20-7.60 (m, 10H), 3.65-3.85 (m, 2H), 3.50-3.60 (m,<br>
1H), 3.00-3.10 (m, 2H), 2.80 (d, J = 4 Hz, 1H), 1.70-2.00 (m, 2H), 0.90 (s, 9H), 0.10 (s,<br>
6H).<br>
PREPARATION 25<br>
Methansulfonic acid 3-(benzhydrylidene-hydrazinocarbonyl)-2-(3-methoxy-phenyl)-<br>
p ropy I ester<br>
A solution of 4-hydroxy-3-(3-methoxy-phenyl)-butyric acid benzhydrylidene-<br>
hydrazide and (1.7 g, 4.38 mmol) and 4-dimethylaminopyridine (26 mg, 0.22 mmol) in<br>
pyridine (15 mL) is cooled to 0 °C treated with methanesulfonyl chloride (0.4 mL, 5.25<br>
mmol) and stirred 18 h at room temperature. The mixture is diluted with dichloromethane<br>
(30 mL) and washed with 1 N hydrochloric acid (30 mL), a saturated solution of sodium<br>
bicarbonate and brine. The mixture: is dried over magnesium sulfate, filtered,<br>
concentrated in vacuo and chromatographed on SiO2 (2% methanol/dichloromethane) to<br>
yield the title compound, 1.64 g (80%), as yellow foam.<br>
'H NMR (CDC1-0: S 8.35 (bs, 1H), 7.15-7.60 (m, 1 OH), 6.75-6.95 (m, 4H), 4.50 (m, 2H),<br>
3.80 (m, 4H), 3.20-3.40 (m, 2H), 2.85 (s, 3H).<br><br>
PREPARATION 26<br>
Methanesulfonic acid 3-(benzhydrylidenehydra/inurarbonyl)-2-(4-fluoro-phenyl)-<br>
prvpyl ester<br>
A method similar to PREPARATION 25, except employing 3-(4-fluoro-phenyl)-<br>
4-hydroxy-butyric acid benzhydryl dene-fcydrazide (2.78 g, 7.4 mmol), is used to yield<br>
the title compound, 2.1 g (62%), as a yellow foam.<br>
*H NMR (CDC13): 5 8.30 (bs, 1H), 7.20-7.70 (m, J2H), 6.90-7.10 (m, 2H), 4.40-4.50 (m,<br>
2H), 3.75 (m, 1H), 3.25-3.35 (m, 2H), 2.90 (s, 3Hfc<br>
PREPARATION 27<br>
Mcthansulfonic acid 3-(benzhydiylid«ie-hydr«inocarbnyl)-l-(terr-butyl-dirnethyl-<br>
silykxymtfhy l)-pr*pyl ester<br>
A method similar to PREPARATION 25, except employing 5-(/ert-butyl-<br>
dimethyl-silyloxy)-4-hydroxy-pentsinoicacid benihydrylidene-hydrazide (5.55 g, 13<br>
mmol), is used to yield the title compound, 6.08 g(93%), as a yellow foam.<br>
'H NMR (CDCI3): 5 8.30 (bs, 1H), 7.50-7.60 (m,5H), 7.3O-7.40 (m, 5H), 4.80-4.90 (m,<br>
1H), 3.70-3.80 (m, 2H), 3.00-3.15 (m, 5K), 2.00-2.20 (m, 2H), 0.90 (s, 9H), 0.10 (s, 6H).<br>
PREPARATION 28<br>
1 -A mino-4-(3-raelhoKy-pheiiyl)-pyrro}idin-2-onc<br>
Concentrated hydrochloric acid (ft.35 mL) is added to a suspension of 1-<br>
(benzhydrylidene-amino)-4-(3-methoxy-|ihenyl)-pyrrolidiiii-2-one, (0.8 g, 2.16 mmol) in<br>
water (17 mL) and refluxcd for one hour. The mixture is concentrated in vacuo and water<br>
azeotroped away using ethanol and toluene. The residue is dissolved in methanol (5 mL)<br>
and loaded on SCX resin (5 g). The resin is washed with methanol and 2 M solution of<br>
ammonia in methanol. Appropriate fractions are concentrated to yield the title compound,<br>
402 mg (92%), as a white crystalline solid.<br>
'H NMR (CDC1,): 5 7.25 (t, J « 8 Hz, Mfc 6.75-6.85 (m, 3H), 4.20 (bs, 2H), 3.85 (m,<br>
IH), 3.80 (s, 3H), 3.45-3.60 (m, 2H), 2.80 (dd, J = 9,17 H2,1H), 2.50 (dd, J = 9,17 Hz,<br>
1H).<br><br><br><br><br>
PREPARATION 38<br>
J -Aminopyi rolidin-2- one hydrochloridc<br>
4-Chlorobutyryl chloride(57 mL, 510 mmol)is added to a solution of<br>
benzophenone hydrazone (100 g, 510 mmol) and pyridine (41 mL, 510 mmol) in<br>
anhydrous dichloromethanc (520 mL) under nitrogen at a rate that maintains a gentle<br>
reflux throughout the addition. The mixture is stirred for 0.5 h and poured into water (1<br>
L). The layers are separated and the organic layer washed with brine, dried (sodium<br>
sulfate), filtered, and concentrated in vacuo to yield 4-chloro-butyric acid<br>
benzhydrylidene-hydrazide as a residue.<br>
MS ES+m/e 303.1 (M+l).<br>
The residue is dissolved in tet rahydrofuran (1.5 L), cooled in an ice-water bath,<br>
treated with portions 60% sodium hydride suspended in mineral oil (20 g, 498 mmol) and<br>
stirred for 1 h. To the mixture is added saturated aqueous ammonium chloride solution (1<br>
L) and ethyl acetate (1 L). The layers are separated and the organic solution washed with<br>
brine, dried (sodium sulfate), filtered ;ind concentrated in vacuo to yield 1-<br>
(benzhydrylideneamino)pyrrolidin-2-one as a residue.<br>
'H NMR (CDCb): 8 7.58-7.62 (m, 2H), 7.39-7.46 (m, 4H), 7.29-7.36 (m, 4H) 3.31 (t, J =<br>
7 Hz, 2H), 2.32 (t, J = 7 Hz, 2H), 1.91 (quintet, J = 7 Hz, 2H); MS ES+ m/e 267.1 (M+l).<br>
The residue is suspended in water (3 L), treated with concentrated hydrochloric<br>
acid (80 mL), and heated to reflux for 1.5 h. The solution is cooled to room temperature<br>
and extracted twice with dichloromethane. The aqueous portion is concentrated in vacuo<br>
followed by azeotropic removal of water with three portions of absolute ethanol and three<br>
portions of toluene to yield the title compound, 56 g (81%), as a white solid.<br><br>
'H NMR (DMSO-d6): 8 3.58 (t, J = 7 Hz, 2H), 2.33 (t, J = 7Hz, 2H), 2.04 (quintet, J = 7<br>
Hz, 2H), TOF MS ES+ exact mass calculated for C4H8N2 (p+1): m/z = 100.0637. Found:<br>
100.0641.<br>
PREPARATION 39<br>
(L)-N-Nitr
A solution of 30 g L-prolinc, in in 100 mL water and 20 mL concentrated<br>
hydrochloric acid is cooled in ice bath and treated with 25 g sodium nitrite over 10 min.<br>
The mixture is stirred I h and concentrated in vacuo with minimal heat. The mixture is<br>
diluted with 1 N hydrochloric acid (100 mL) and extracted with chloroform (150 mL)<br>
and dichloromethane (2 x 200 mL). Organic portions are combined, dried (magnesium<br>
sulfate) and concentrated in vacuo. The residue was crystallized from dichloromethane-<br>
hexane to yield 5.58 g (L)-N-nitrsoproline.<br>
MS ES+ m/e 145 (M+l), MS ESm/e 143 (M-l).<br>
PREPARATION 40<br>
3a JJ-pyrrolidino(],2-C] l,2,3-oxadiazolin-3-one<br>
(L)-N-Nitrsoproline (1.08 g, 7 mmol) is dissolved in ether (180 mL). This solution<br>
is added to trifluoroacetic anhydride (1.5 mL) cooled in an ice bath. The mixture is stirred<br>
6 h in ice bath, evaporated with minimum heat, and chromatographed on SiC&gt;2 (0 to 100<br>
% ethyl acetate in hexane) to yield (0.75 g, 85%) of the title compound as an oil.<br>
MS ES+m/e 127 (M+l).<br>
PREPARATION 41<br>
l-(Bcnzylidcnc-at«iino)-3-methyl-pyrrolidin-2-one<br>
To an ice-cooled solution of water (48 mL) and concentrated hydrochloric acid<br>
(20.4 mL) added, with stirring, a solution of sodium nitrite (16.5 g, 240 mmol) dissolved<br>
in water (48 mL) over 20 min. The sodium nitrite solution is added to a solution of 3-<br>
methypyrrolidinone (10.11 g, 102 mmol) in waiter (60 mL) over 30 min while cooling the<br>
reaction mixture in an ice-salt bath. The reaction mixture is stirred 3 h in an ice-salt bath<br>
and extracted with methylene chloride (2 x 300 mL). The organic layers are combined,<br>
dried (magnesium sulfate), and evaporated to yield 9.22 g, (71%) of the intermediate N-<br>
nitroso compound as an oil. Product formation is confirmed by TLC (5% methanol in<br><br>
PREPARATION 44<br>
3-Benzyloxy-4-methoxy-phenylamine<br>
To a solution of 2-(benzyloxy&gt;-]-methoxy-4-nitrobenzene (35.35 g, 136 mmol) in<br>
1:1 ethyl acetate: ethanol (640 mL) at 80 °C is added tin(H) chloride hydrate in portions<br>
over 25 minutes. The mixture is heated at this temperature for 5 h. The mixture is<br>
allowed to cool to room temperature und stirred for 2 days. The mixture is poured into<br>
water (1 L) and neutralized with solid sodium bicarbonate. The mixture is extracted three<br>
times with ethyl acetate. The combined organic extracts are washed with water and brine,<br>
dried (sodium sulfate), filtered and evaporated to yield the title compound as a dark<br>
brown oil.<br>
MSES+m/e230(M+1).<br>
PREPARATION 45<br>
2-Broifno-5-fluoropyridine<br>
This preparation is conducted in a manner similar to that described for the<br>
preparation of 2-bromopyridine from 2-aminopyridine in Org. Syn. Coll. Vol. 3, p. 136,<br>
except that 2-amino-5-fluoropyridine if used to yield the title compound, 47.5 g (55%), as a<br>
red oil.<br>
'H NMR (CDC13) 5 7.3 (ddd, 1H), 7.5 (dd, 1H), 8.3 (d, 1H).<br>
PREPARATION 46<br>
Elhyl 5-fluoropyridine-2-carboxylate<br>
A mixture of 2-bromo-5-fluoropyridine (5.00 g, 28.4 mmol), sodium acetate (9.33 g,<br>
114 mmol), and 1-1 'bis(diphenylphospliino)ferrocene]dichloropalIadium(II):CH2Cl2 (0.464<br>
g, 0.57 mmol) in ethanol (80 mL) in a F'arr® high pressure stainless steel reactor vessel is<br>
placed under an atmosphere of 50 psi carbon monoxide and heated at 80-100 °C for 4 h.<br>
The vessel is cooled, volatiles removed in vacuo, and the residue partitioned between ethyl<br>
acetate and water. The ethyl acetate exiract is washed with water and brine, dried over<br>
sodium sulfate, filtered, and evaporated to give a dark solid. The residue is<br>
chromatographed on SiO2 (10% ethyl acetate / hexanes) to yield the title compound 2.8 g<br>
(58%) as a white solid that is recrystallked from hexanes to give white crystals: mp 61-63<br>
°C.<br><br>
PREPARATION 47<br>
6-Methyl-pvridine-2-carboxylic acid methyl ester<br>
To a suspension of 6-metliyl-pvridine-2-carboxylic acid (10 g, 72.9 mmol) in<br>
methylene chloride (200 mL) cooled to 0 °C is added methano! (10 mL), 4-<br>
dimethylaminopyridine (11.6 g, 94.8 mmol), and EDC (18.2 g, 94.8 mmol). The mixture<br>
is stirred at room terr/perature for 6 h, washed with water and brine, and dried over<br>
sodium sulfate. The mixture is filtered and concentrated in vacuo. The residue is<br>
chromatographed on SiC&gt;2 (50% ethyl acetatc/hexanes) to yield the title compound, 9.66 g<br>
(92%), as a colorless liquid.<br>
'H NMR (CDCU) 6 7.93-7.88 (m, 1H), 7.75-7.7 (m, 1H), 7.35-7.3 (m, 1H), 4.00 (s, 3H),<br>
2.60 (s, 3H).<br>
PREPARATION 48<br>
6-Propy lpyridine-2-carboxylic acid<br>
A solution of 6-propyl-pyridine-2-carbonitrile (9.1 g, 61.9 mmol) in 6 N<br>
hydrochloric acid is heated at reflux for 18 h. The mixture is cooled to room temperature<br>
and concentrated in vacuo. The residue is partitioned between dichloromethaneand<br>
water. The aqueous portion is adjusted to pH 6 with saturated aqueous sodium<br>
bicarbonate solution and extracted five times with dichloromethane. The organic extracts<br>
are combined, dried (sodium sulfate), filtered, and concentrated in vacuo to yield the title<br>
compound, 8.32 g (81 %), as a white solid.<br>
TOF MS ES+ exact mass calculated for C9H12NO2 (p+l): m/z = 166.0868. Found:<br>
166.0874.<br><br>
PREPARATION 49<br>
6-]sopropylpyridinc-2-carboxylic acid<br>
A method similar to PREPARATION 48, except employing 6-isopropyl-pyridine-<br>
2-carbonitrile (6.35 g, 43.4 mmol), is used to yield the title compound, 6.62 g (92%), as a<br>
white solid.<br>
TOF MS ES+ exact mass calculated for C9H)2NO2 (p+1): m/z • 166.0868. Found:<br>
166.0867.<br>
PREPARATION SO<br>
6-Ethylpyridine-2-carboxylic acid hydrochloride<br>
A method similar to PREPARATION 48 is used except employing 6-ethyl-<br>
pyridine-2-carbonitrile (7.94 g, 60.1 mmol) in 6 N hydrochloric acid (150 mL), heating at<br>
reflux for 18 h, cooling to room temperature, concentrating the mixture in vacuo, and co-<br>
evaporating with toluene four times to yield the title compound, 12.5 g (72%), as a white<br>
solid.<br>
TOF MS ES* exact mass calculated for C8Hl0NO2 (p+1): m/z = 152.0712. Found:<br>
152.0701.<br>
PREPARATION 51<br>
Methyl 3-fluorobenzoate<br>
A solution of 3-fluorobenzoic acid (3.0 g, 21.4 mmol) in methanol (71 mL) at 0<br>
°C is treated drop wise with thionyl chloride (3.1 mL,42.8 mmol). The solution is stirred<br>
for 15 min at 0 °C, 2.5 h at room temperature, and 2 h at 50 °C. The reaction is<br>
concentrated in vacuo and the residue dissolved in ethyl acetate (150 mL). The organic<br>
solution is washed with saturated aqueous sodium bicarbonate (2 x 100 mL), brine (100<br>
mL), and dried over sodium sulfate. The solution is decanted and concentrated to yield<br>
the title compound, 2.61 g (79%), a&gt; a clear, colorless oil.<br>
'H NMR (CDCI3): 5 7.85 (m, 1H), 7.75 (m, IH), 7.32 (m, 1H), 7.21 (m, 1H), 3.85<br>
(s,3H).<br><br><br><br><br>
PREPARATION 66<br>
Pyrazinc-2-cari)o«ylic acid methoxy-mcthyl-amidc<br>
To a solution of pyrazine-2-orboxylic acid (2.0 g, 16.1 mmol) in methylene<br>
chloride (54 mL) at 0 °C is added oxalyl chloride (7.1 mL, 80.6 mmol) and N,N~<br>
dimethylformamide (0.12 mL, 1.6 mmol). The cooling bath is removed after 10 min and<br>
the reaction mixture stirred 18 h at room temperature. The reaction mixture is<br>
concentrated in vacua The residual oil is dissolved in methylene chloride (54 mL) and<br>
treated with iV,O-dimethylhydroxylar»iine hydrochloride (2.36 g, 24.15 mmol) and<br>
triethylamine (1J .2 mL, 80.6 mmol). The reaction mixture is stirred for 3 h at room<br>
temperature and diluted with methylene chloride. The resulting mixture is washed with<br>
water (50 mL), saturated aqueous bicarbonate (50 mL), and brine (100 mL), and<br>
concentrated in vacuo to yield the title compound, 2.35 g (88%), as a brown oil.<br>
'H NMR (CDC13): 88.92 (s, 1H),8;.63 (s, 1H), 8.52 (s, 1H), 3.72 (s, 3H), 3.51 (s, 3H).<br>
MS (Cl, methane) m/e 168 (M+l).<br><br><br>
PREPARATION 69<br>
3-Benzyloxymclhyl-5-phenyl-pont-2-enoic acid methyl ester<br>
Methyl (triphenylphosphoranylidiene)-acetate (1 eq)and 1-benzyloxy-4-phenyl-<br>
butan-2-one (I eq) are combined in toluene and refluxed for 18 h. Additional methyl<br>
(triphenylphosphoranylidiene)-acetate is added and refluxed for another 18 h. The<br>
solvent is removed in vacuo, and the residue suspended in hexanes and filtered. The<br>
filtrate is concentrated in vacuo to yield the title compound.<br>
'H NMR (CDCb) 5 7.4-7.1 (m, 10H), 6.08 (s, 1H), 4.5 (s, 2H), 3.9 (s, 2H), 3.65 (s, 3H),<br>
2.9-2.55 (m, 4H)<br><br><br>
PKEPARATION 71<br>
(4-Fluoronaphlhalen-l-yl)acetonitriIc<br>
A solution of ]-chloromethyl-4-fluoronaphthalene (5.45 g, 5.66 mmol), sodium<br>
cyanide (333 mg, 6.79 mmol), and water (2 mL) in MN-dimethylformamide (30 mL) is<br>
stirred for 8 h, then heated at 70 °C for 15 h. The mixture is cooled to room temperature<br>
and partitioned between saturated sodium bicarbonate solution and ethyl acetate. The<br>
organic portion is washed with three portions of water, one portion of brine, dried<br>
(sodium sulfate), filtered and evaporated. The residue is chromatographed on S1O2 (30%<br>
ethyl acetate/ hexane) to yield the title compound, 4.67 g (90%), as a light brown solid.<br>
'H NMR (CDCI3): 8 8.19 (d, J = 8 H;:, 1H), 787 (d, J = 8 Hz, 1H), 7.68 (ddd, J = 8, 7, 1<br>
Hz, IH), 7.63 (ddd, J = 8, 7, 1 Hz, Ifcl), 7.51 (dd, J = 8, 5 Hz, 1H), 7.14 (dd, J = 10,8 Hz,<br>
lH),4.09(s, 2H).<br><br><br>
PREPARATION 73<br>
Quinolin-6-yl-acctonirrile<br>
A solution of 6-meihyl-quinoline (3.00 g, 20.6 mmol), N-bromosuccinimide (3.96<br>
g, 22.0 mmol), and benzoyl peroxide (0.51 g, 2.10 mmol) in carbon tctrachioride (100<br>
mL) is stirred at reflux for 2 h. The reaction is cooled lo room temperature then washed<br>
with saturated aqueous sodium bisulfite (50 mL). The organic phase is passed through 30<br>
g SiO2 (2 x) eluting with dichloromethane then diethyl ether. MW-Dimethylformamide<br>
(83 mL) is added to the combined organic fractions and solvent removed under reduced<br>
pressure leaving only the reaction mixture in WN-dimethylformamide. To the reaction<br>
mixture in A/.N-dimethylformamide is added sodium cyanide (1.22 g, 24.9 mmol) and<br>
potassium bicarbonate (2.51 g, 24.9 mmol). The reaction mixture is allowed to stir at 50<br>
°C for 2 h. The cooled reaction mixture is poured into pH 7 buffer (75 mL) and extracted<br>
with ethyl acetate (2 x 100 mL). The organic layers are combined, washed with saturated<br>
aqueous sodium chloride (100 mL), dried over solid sodium chloride, and concentrated<br>
under reduced pressure to afford an oil that is purified by normal phase flash<br>
chromatography (120 g Biotage KP-Sil 40L: 10% ethyl acetate in hexanes for 5 min, 20%<br>
ethyl acetate in hexanes for 20 min, 40% ethyl acetate in hexanes for 20 min, 60% ethyl<br>
acetate in hexanes for 20 min, then 60-100% ethyl acetate in hexanes ramp over 20 min)<br>
to provids 645 mg (18%) of the title compound. MS ES+ m/e 169 (M+l).<br><br><br>
PREPARATION 77<br>
2-Ethynyl-6-methyl-pyridine<br>
A solution of 2-bromo-6-methy1pyridine (0.5 g, 2.9 mmol) and<br>
(trimethylsilyi)acetylene (0.29 g, 2.9 mmol) in triethylamine (15 mL) is purged with<br>
argon. Copper(l) iodide (11 mg, 0.06 mmol) and (PPh^PdCh (42 mg, 0.06 mmol) are<br>
added and the reaction is stirred under argon at room temperature for 2 h. The solvent is<br>
removed in vacuo and the residue is diluted in ethyl acetate (50 mL) and water (50 mL).<br>
The organic is separated and washed with brine. The solvent is removed to afford a dark<br>
oil. This oil is diluted in methanol (50 mL) and treated with a 1 N sodium hydroxide<br>
solution (10 mL) and stirred for 3 h 3t room temperature. The aqueous is neutralized with<br>
1 N hydrochloric acid and extracted with ethyl acetate. The solvent is removed in vacuo<br>
to afford a dark oil that is purified by SiOi column chromaiography to yield 1.16 g (24%)<br>
of the title compound as a light yellow oil.<br>
MSES+m/e 1I8(M+1).<br><br>
PREPARATION 78<br>
(6-Methyl-pyi idin-2-yl)-propinoic acid ethyl ester<br>
A solution of 2-ethynyl-6rnethyl-pyridine (0.5 g, 4.3 mmol) in tetrahydrofuran<br>
(20 mL) is cooled to -78 °C and treated with 1.6 M N-butyllithium in hexanes (2.9 mL,<br>
4.7 mmol) and stirred for 0.5 h. This solution is then treated with ethyl chloroformate<br>
(2.85 mL, 30 mmol) and stirred lor 3 h while the solution warms to room temperature.<br>
The reaction is quenched with saturated ammonium chloride solution and extracted with<br>
ethyl acetate. The solvent is removed to yield 0.67 g (83%) of desired product as a light<br>
yellow oil.<br>
MSES+m/e 190 (M+l).<br>
PREPARATION 79<br>
4-(2 (2-Pyridyl)ethynyl)quinoHne<br>
A mixture of triphenyphosphine oxide (5.56 g, 10 mmol) in 1,2-dichloroethane<br>
(30 mL) is cooled in an ice bath. Trifluoromcthanesulfonic anhydride (1.57 mL, 10<br>
mmol) is added dropwise over 5 min. To this mixture is added a solution of l-(2-<br>
pyridyl)-2-(4-quinolyl)ethan-l-one(2.5 g, 10mmol)in 1,2-dichloroethane (lOmL) and<br>
triethylamine (2.84 mL, 20 mmol). The ice bath is removed and the mixture heated at<br>
reflux for 16 h. The mixture is diluted with dichloromethane (100 mL) and washed with<br>
water (3 x 100 mL), dried (magjiesium sulfate), filtered, concentrated in vacuo, and<br>
chromatographcd on SiO2 (0 to 100 % hexane in ethyl acetate) to yield 1 g of title<br>
compound as an oil.<br>
MSES+m/e231 (M+l).<br><br>
PREPARATION 80<br>
4-Pyri(lin-2-ylethynyl~quinoline-2-carboxyIic acid «*hyl ester<br>
A mixture of ethyl 4-bromoquinoline-2-carboxylate (2.80 g, 10.0 mmol, J.Org.<br>
Chem. 1947,12, 456), triethylaminc (1.7 mL, 12 mmol), bis(triphenylphosphine)-<br>
palladium(Il)chloride (0.561 g, 0.80 mmol), Cul (0.114 g, 0.60 mmol), and 2-<br>
ethynylpyridine (1.11 g, 10.8 mmol) in CH3CN (80 mL) is heated at 75-80 °C for 18 h in<br>
a sealed tube. Additional triethylanwme (0.85 ml, 6.1 mmol),<br>
bis(triphenylphosphine)palladium (II) chloride (0.23 g, 0.40 mmol), and Cul (0.055 g,<br>
0.29 mmol) is added and the mixture heated for an additional 18 h. The mixture is<br>
concentrated in vacuo and partitioned between water and chloroform. The chloroform<br>
extracts are washed with brine and evaporated. The residue is chromatographed on SiOj<br>
(50% ethyl acetate / hexanes) to yidid 1.52 g (50%) of a yellow soKd. Precipitation from<br>
ethyl acetate gave the title compound as yellow crystals: mp 129-131° C; MS ES+ m/e<br>
303 (M+l).<br>
PREPARATION 81<br>
3-Bcnifl-4-bromo-butyric acid<br>
A mixture of 4-benzyl-di!»ydrofuran-2-one (1.0 g, 5.6 mmol), acetic acid (1.7<br>
mL), HBr (33% in acetic acid, 2.0 mL) is heated at 80 °C for 4 h. The mixture is cooled<br>
to room temperature, poured into kit-water (20 mL), and extracted with chloroform (2 x<br>
30 mL). The combined organic exnacts are washed with water and brine, dried with<br>
anhydrous sodium sulfatc, filtered, Jaid concentrated in vacuo to yield 3-benzyl-4-bromo<br>
butyric acid, 1.5 g (99%), as a colorless liquid.<br>
'H NMR (CDCI3) 5 7.30-7.12 (m, 50), 3.58-3.35 (m, 2H), 2.80-2.38 (m, 5H).<br><br><br>
PREPARATION 85<br>
3-Benzyl-4-bromo-butyric acid (1 pyridin-2-yl-2-quinolin-4-yl-ethylidene)-hydrazide<br>
A mixture of 3-benzyl-4-bromo-butyric acid (2.0 g, 7.78 mmol) andthionyl<br>
chloride (6.0 mmol) is heated lo 80 "C for 2 h. The thionyl chloride is evaporated to yield<br>
3-benzyI-4-bromo-butyryl chloride 2A g (99%), as a colorless liquid.<br>
'H NMR (CDClj) 5 7.25-7.11 (m, 5H), 3.55-3.48 (m, 1H), 3.40-3.35 (m, 1H), 3.20-3.10<br>
(m, 1H), 3.00-2.90 (m, IH), 2.80-2.70 (m, 2H), 2.60-2.57 (m, 1H).<br>
A solution of (l-pyridin-2-yl-2-quinolin-4-yl-ethylidene)-hydrazine{2.25 g, 8.40<br>
mmol) in anhydrous dichlorometham; (100 mL) and pyridine (1.81 mL, 22.4 mmol) is<br>
cooled to -78 °C, treated with a solution of 3-benzyl-4-bromo-butyryl chloride (2.1 g, 7.8<br>
mmol) in dichloromethane (10 mL), and stirred for 2 h. The mixture is treated with<br>
methanol (3 mL), stirred for 10 min, and diluted with saturated ammonium chloride<br>
solution (30 mL). The mixture is dik ted with dichloromethane (300 mL), washed with<br>
water (2 x 50 mL) and brine (50 mL), dried with anhydrous sodium sulfate, filtered, and<br>
concentrated in vacuo. The residue is precipitated from ether to yield the title compound,<br>
2.3 g (60%), as a pale yellowish solid<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
PREPARATION 130<br>
7-Mt*hyl-4-methyl-quinoline<br>
A solution of 3-meihyl-phenylamine (1 eq), in 1,4-dioxane is stirred and cooled to<br>
S approximately 12 °C. Sulfuric acid (2 eq.) is slowly added and heated at reflux.<br>
Methylvinyl ketone (l.S eq) is added dropwise into the refluxing solution. The solution is<br>
heated for 1 h after addition is complete. The reaction solution is evaporated to dryness<br>
and dissolved in methylene chloride. The solution is adjusted to pH 8 with 1 M sodium<br><br>
carbonate and extracted with three times with water. The residue is chromatographed on<br>
SiC&gt;2 (70/30 hexane/ethylacetate) to yield the title compound.<br>
MS ES+m/e= 158.2 (M+l).<br><br><br><br>
PREPARATION 148<br>
] -(2-Pyridyl)-2-(4-quinolyl)elhan-l -one<br>
In a 3-neck 3-liter round bottom flask equipped with two addition funnels is<br>
dissolved lepidine (10.0 mL, 75.63 inmol) in tetrahydrofuran (200 mL). One addition<br>
funnel is charged with ethyl picolinute (20.43 mL, 151.26 mmol) and the other with 0.5<br>
M potassium bis(trimethylsilyl)amide (166.4 mL, 83.19 mmol) in toluene. The solution is<br>
cooled to -78 °C and the base added to the reaction mixture dropwise over 40 min. The<br><br>
reaction mixture is stirred an additional 1.5 h and ethyl picolinate is added rapidly. The<br>
ice bath is removed and the reaction mixture stirred at ambient temperature for 3 h. The<br>
reaction is quenched with water (20 mL) and after 5 min formic acid added until the pH is<br>
slightly less than 7. The mixture is concentrated in vacuo and partitioned between ethyl<br>
acetate (300 mL) and brine-sodium bicarbonate (300 mL) mixture. The organic layer is<br>
washed with brine and sodium bicarbonate, dried over sodium sulfate, and concentrated.<br>
The product is chromttographed on SiO2 (27-30 % acetone in hexane) to yield 15.31 g<br>
(82%) of a yellow-brown sol id.<br>
MSES+m/e249(M+l).<br><br><br><br><br><br><br><br><br><br><br><br><br><br>
PREPARATION 205<br>
2-(4-Fluoro-phcnyl)-3-oxo-3-t6-lrinu«romethyl-pyridin-2-yl)-propionilrile<br>
A solution of4-fluorophenylitcetonitril«: (0.12 mL, 1.0 mmol) in dry<br>
tetrahydrofuran (2 mL) is treated dropwise with potassium bis(trimethylsilyl)amide (0.5<br>
M toluene, 3.0 mL, 1.5 mmol) at 0° 0 under an atmosphere of nitrogen. The mixture is<br>
stirred 10 min then 6-trifluoromethyl-pyridine-2-carbothioic acid S-(4-chloro-phenyl)<br>
ester is added all at once. The mixture is allowed to warm to room temperature then<br>
warmed to reflux for 10 min, at which time the reaction is complete by TLC (methylcne<br>
chloride). The mixture is allowed to cool then poured into 10% citric acid and extracted<br>
into methylene chloride. The methylene chloride solution is dried over magnesium<br>
sulfate and concentrated in vacuo. T ie residue is purified on a silica gel cartridge<br>
prepared with hexane then eluted witlti methylene chloride to yield 204 mg (66 %) 2-(4-<br>
fluoro-phenyl)-3-oxo-3-(6-trifluoromethyl-pyridin-2-yl)-propionitrile. MS ES' m/z 307<br>
(M-l).<br><br>
PREPARATION 206<br>
2-(3-Chloro-4-fluoro-phenyl)-J-(6-methyl-pyridin-2-yl)-ethanone<br>
A dispersion of sodium hydride, (60% in mineral oil, 0.7 g, 17.7 mmol) is added<br>
to ethanol (25 mL). When gas evolution ceases, 3-chloro-4-fluorophenylacetonitrile<br>
(Fluorochemicals, 2.0 g, 11.8 mmol) and 6-methyl-pyridine-2-carboxylic acid methyl<br>
ester (1.8 g, 11.8 mmol), are added. The mixture is refluxed for 2.5 h and adjusted to pH<br>
7 with 1 N hydrochloric acid. The mixture is concentrated in vacuo. Concentrated<br>
hydrochloric acid (50 mL) is added to the mixture after which it is refluxed for 1.5 h. The<br>
mixture is poured over ice and adjusted to pH 8 with 5 N sodium hydroxide. The<br>
mixture is extracted with rnethylene chloride and the organic portions dried over<br>
anhydrous sodium sulfate. The mixture is filtered and concentrated in vacuo to yield the<br>
title compound, 2.1 g (68%), as i, yellowish solid.<br>
'H NMR (CDClj) 8 7.86-7.83 (m, 1H), 7.73-7.71 (m, 1H), 7.42-7.33 (m, 2H), 7.26-7.04<br>
(m, 2H), 4.49 (s, 2H), 2.65 (s, 311).<br><br><br><br>
PREPARATION 231<br>
l-(6-Methylpyridia-2-yl)-2-p-tolyl-ethanone<br>
To a slurry of magnesium turnings (406 mg, 16.7 mmol) in toluene (10 mL) is<br>
added 4-methylbenzylchloride (10 mg, 0.06 mmol) dropwise in tetrahydrofuran (0.2 mL).<br>
Two drops of 1,2-dibromoethane are added, the mixture heated to 50 °C, and allowed to<br>
cool to room temperature. This process is repeated until reaction initiates. 4-<br>
Methylbenzylchloride (1.5 g, 10 mmol) in tetrahydrofuran (7 mL) is added slowly while<br>
keeping the internal temperaturr below 32 °C. After the addition is complete the reaction<br>
is stirred at room temperature fcr I h. The reaction mixture is added dropwise over 5<br>
minutes to a solution of 6-methyl-pyridine-2-carboxylic acid methoxy-methyl-amide<br>
(Prep 250,1 g, 5.6 mmol) in toluene (5 mL). The reaction is stirred for an additional 45<br>
minutes. The reaction is quenclied with I N hydrochloric acid and stirred for 30 minutes.<br>
The aqueous layer is neutralized with saturated sodium bicarbonate and extracted twice<br>
with ethyl acetate. The combined organic extracts are washed with brine, dried (sodium<br>
sulfate), filtered and concentrate in vacuo. The crude residue is chromatographed on<br>
S1O2 (50% ethyl acetate/hexane to 75% ethyl acetate/hexane) to yield the title compound,<br>
633 mg (25%), as a brown oil.<br>
MSES+m/e226(M+l)<br><br><br>
PREPARATION 213<br>
2-(4-Fluoro-phenyl)-1^6-trifluoromethyl-pyridin-2-yl)-ethanoiic<br>
A slurry of 2-(4-fluoro-pl»enyl)-3-oxo-3-(6-trifluoromethyl-pyridin-2-yl)-<br>
propionitrile (1.4 g, 4.4 mmol) in 48% HBr is warmed to reflux for 8 h, allowed to stand<br>
at ambient temperature 16 h, then warmed at reflux for 8 h. The mixture is extracted with<br>
ether, treated with a small amount of sodium bicarbonate, extracted with ether, made<br>
basic with solid sodium hydroxide, and extracted again with ether. Ethereal extracts are<br>
combined, dried over magnesium sulfate, and concentrated in vacuo to a dark oil. The<br>
residual oil is purified on a silica gel cartridge prepared with hexane then eluted with<br>
methyl ene chloride to yield 816 ing (65%) of the title compound as a dark oil.<br>
MSESrn/z282(M-l).<br><br><br><br><br>
PREPARATION 229<br>
|2-QuinuIin-4-yl-]-(3-fri(lluoromcilhyl-phenyl)-elhylidene]-hydrazine<br>
A solution of 2-quinolin-4-&gt;l-l-(3-trifluoromeihyI-phenyl)-ethanone (1.0 g, 3.2<br>
mmol) in ethanol (13 mL) is cooled to 0 °C and treated with hydrazine (0.6 g, 19 mmol)<br>
and concentrated hydrochloric acid (0.13 mL, 1.6 mmol). The mixture is refluxed for 2 h<br>
and concentrated in vacuo. The residue is taken up in dichloromethane and washed with<br>
saturated sodium bica/bonate (30 mL), water (2 x 30 mL), and brine (30 mL). The<br>
solution is dried over anhydrous sodium suliate and filtered. The filtrate is concentrated<br>
to yield the title compound, 1.0 g (97%), as a pale yellow foam.<br>
'H NMR (CDC13) 6 8.80 (m, 1H), 8.28-8.05 (m, 3H), 7.90-7.40 (m, 4H), 7.20-7.05 (m,<br>
2H), 5.50 (s, 2H), 4.45 (m, 2H).<br><br><br><br><br><br><br><br>
PREPARATION 2S2<br>
4-BcnzyJ-)-(]-pyridin-2-yl-2-quinolin-'l-yJ-ethylidcncamino)-pyrroHdin-2-one<br>
A mixture of 3-benzyl-4-bromo-butyric acid (l-pyridin-2-yl-2-quinolin-4-yl-<br>
cthylidene)-hydrazide (PREP. 70, 0.8 g, 1.6 mmol) in leirahydrofuran (26 mL) at 0 °C is<br>
treated with NaH (60% in mineral oil, 0.086 g, 2.2 mmol). The mixture is wanned to<br>
room temperature and stirred for 2 h. Saturated ammonium chloride (2 mL) is added and<br>
volatiles removed in vacuo. The residue is chromatographed on SiC&gt;2 (90% ethyl<br>
acetate/hexanes followed bydichlotomethane:methanol:ammonium hydroxide/94:5:1)<br>
to yield the title compound, 0.4 g (45%), as &amp; yellowish foam.<br>
'H NMR (CDCh) 6 8.86-8.82 (m, 1.H), 8.70-8.60 (m, 1H), 8.30-8.05 (m, 3H), 7.80-7.30<br>
(m, 4H), 7.30-7.20 (m, 5H), 6.85-6.H0 (m, 1H), 5.20-4.85 (m, 2H), 3.05-2.95 (m, 2H),<br>
2.30-2.15 (m, 3H), 2.00-1.90 (m, 2h).<br><br><br><br><br><br><br><br><br><br><br><br><br><br>
PREPARATION 286<br>
4-(3-Mcihoxy-phcnyl)-l-(] pyridin-2-yl-2-quinolin-4-yl-ethylideneainino)-<br>
pyrroUdin-2-one<br>
A solution ofl-pyridin-2-yl-2-quinolin-4-yl-ethanone, (0.25 g, 1 mmol) and<br>
pyridine (0.242 mL, 3 mmol) in acetic acid (2 mL) is added to 1-amino-4-(3-methoxy-<br>
phenyl)-pynrolidin-2-one, (0.2 g, I mmol) at room temperature under nitrogen. The<br>
mixture is stirred 18 h and concentrated in vacuo. The residue is chromatographed on<br>
SiOj (2% methanoi/dichloromethane) to yield the title compound, 0.25 g (57%), as a<br>
yellow foam.<br>
'H NMR (CDC13): S 8.75 (d, J - 4.5 Hz, 1H), 8.65 (d, J = 4.5 Hz, 1H), 7.70-8.20 (m, 3H),<br>
7.20-7.60 (m, 3H), 6.70-6.85 (m 3H), 6.40-6.55 (m, 3H), 5.25 (d, J = 16.7 Hz, 1H), 4.70<br>
(d, J = 16.7 Hz, 1H), 3.70 (s, 3H&gt;, 3.45-3.60 (m, 1H), 3.10 (dd, J = 8,9.3 Hz, 1H), 2.25-<br>
2.80 (m,3H).<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
PREPARATION 358<br>
t<br>
(y?)-5-Bcn2yloxymethy)-l-|2-(4-fluoro-phcnyl)-l-(6-mcthyl-pyridin-2-yl)-<br>
eth)tideneamino]-pyrrnlidin-2-one<br>
Boron trifluoride etherate (0.25 mL, 1 -98 mmol) is added to a solution of 2-(4-<br>
fluoro-phenyl)-l-(6-methyl-pyridin-2-yl)-ethanone (0.45 g, 1.98 mmol) in<br>
tetrahydrofuran (6.6 mL) under nitrogen and stirred for 30 min. A solution of (•/?)-!-<br>
amino-5-benzyloxymethy]-pyrrolidin-2-one (0.43 g, 1.98 mmol) in tetrahydrofuran (1.0<br>
mL) is added and the resulting mixture is stirred for 1 h. The mixture is concentrated in<br>
vacuo and the residue chromatographed on a SiC&gt;2 column (30% ethyl acetate/hexanes) to<br>
yield the title compound, 380 nig (45%)., as a yellow foam.<br>
'H NMR (CDCI3): 5 7.81 (d, J = 7.8 Hz, ]H), 7.55 (t, J = 7.8 Hz, 1H), 7.11-7.32 (m, 8H),<br>
6.81 (td, J = 8.7, 2.0 Hz, 2H), 4.45 (s, 2H), 4.30-4.43 (m, 2H), 3.80 (m, 1H), 3.39-3.51<br>
(m, 2H), 2.51-2.63 (m, 4H), 2.23-2.41 (m, 1H), 1.86-2.04 (m, 2H).<br>
PREPARATION 359<br>
4-(4-Chloro-phenyl)-l-|2-(4-fluoro-phenyl)-l-(6-methyl-<br>
pyridin-2-)l)-cthylideneaminoj-pyrrolidin-2-one<br>
A method similar to PREPARATION 358, except employing 1-amino-4-(4-<br>
chloro-phenyl)-pyrrolidin-2-one (1.47 g, 7.0 mmol), is used to yield the title compound,<br>
1.56 g (53%), as a yellow foam.<br>
'H NMR (CDCI3): 5 7.55-7.66 (m, IH), 7.15-7.45 (m, 7H), 6.89-7.07 (m, 3H), 4.61 (d, J<br>
- 15.4 Hz, IH), 4.28 (d, J = 15.4 Hz, IH), 3.54-3.71 (m, 2H), 3.26-3.42 (m, IH), 2.75-<br>
2.89 (m, IH), 2.58 (s, 3H), 2.46-2.56 (m, IH).<br><br><br><br>
PREPARATION 368<br>
2-(6-Melhyl-pyridin-2-yl)-5,6-dthydro-4H-pyrrolo| 1,2-b]pyrazole-3-carboxylic acid<br>
ethyl ester<br>
A solution of (6-methyl-pyridin-2-yI}-propynoic acid ethyl ester (3 g, 15.9 mmol)<br>
and 3a H-pyrrolidino[l,2-C] 1,2,3-oxadiazolin-3-one (2 g, 15.9 mmol) is heated in xylcne<br>
(50 mL) at 150 °C for 48 h. The mixture is cooled and concentrated in vacuo. The crude<br>
residue is chromatographed on SiO»(ethyl acetate) to give the title compound, 1.6 g<br>
(37%), as a brown solid.<br>
MSES+m/e272(M+l).<br>
PREPARATION 369<br>
2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo|l,2-b]pyrazolc-3-carboxylicacJd<br>
A solution of 2-(6-methyl-p)'ridin-2-yl)-5,6-dihydro-4H-pyrrolo[l ,2-b]pyrazole-3-<br>
carboxylic acid ethyl ester (1.6 g, 5. &gt; mmol) and 2 N sodium hydroxide (6 mL, 29 mmol)<br>
in absolute ethanol (50 mL) is reflu&gt; cd for 5 h. The mixture is cooled to room<br>
temperature and concentrated in vacuo. The residue is suspended in water and acidified<br>
to pH 5 with 1 N hydrochloric acid. The aqueous solution is extracted three times with<br>
dichloromethane. The organic extracts are combined, dried (sodium sulfate), filtered, and<br>
concentrated in vacuo to yield the title compound, 1.4 g (97%), as a white solid.<br>
MSESm/e242(M-l).<br>
PREPARATION 370<br>
3-Br«mo-2-(6-mclhyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo|l,2-bJpyrazole<br>
A solution of 2-(6-methyJ-pyiidin-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole-3-<br>
carboxylic acid (1.4 g, 5.8 mmol) in iV.A^dimethylformamide (20 mL) is treated with N-<br>
bromosuccinamide (1 g, 5.6 mmol) and stirred at room temperature for 16 h. The mixture<br>
is diluted with ethyl acetate and washed three times with water, once with brine, dried<br>
(sodium sulfate), filtered, and concentrated in vacuo to yield the title compound, 1.5 g<br>
(94%), as light yellow solid.<br>
MSES+m/e278(M+l).<br><br>
PREPARATION 371<br>
4-(2-Pyridin-2-yl-5,6-dihydro-4H pyrrolofl,2-b)pyrazol-3-yl)-quinoline-7-carboxylic<br>
acid<br>
Lithium hydroxide monohydratc (0.65 g, 15.6 mmol) is added to a solution of 4-<br>
(2-pyridin-2-yl-5,6-dihydro-4H-pynolo[ 1,2-b]pyrazol-3-yl)-quinoline-7-carboxylic acid<br>
methyl ester (1.44 g, 3.89 mmol) in 2:1 tetrahydrofuran/water (30 mL), stirred at room<br>
t<br>
temperature for 18 h, and concentrated in vacuo. The residue is purified by SCX resin, (2<br>
N ammonia in methanol), to yield the title compound, 1.22 g (88%), as a tan solid.<br>
'H NMR (DMSO-rf6): 8 8.91 (m, 1H), 8.55 (rn, 1H), 7.48-7.85 (m, 7H), 7.41 (m, 1H),<br>
7.09 (m, 1H), 4.22 (m, 2H), 2.81 (m 2H), 2.60 (m, 2H).<br><br><br>
PREPARATION 374<br>
(5&gt;6-Ben2yloxymelhyl-3-(4-nu«»ro-phcnyl)-2-(6-mclhyl-pyridin-2-yl)-5,6-dihydro-<br>
4Hpyrrolo|]l,2-b]pyn»zole<br>
A method similar to PREPARATION 360, except employing (5)-5-<br>
benzyloxymethyJ-]-[2-(4-fluoro-pJienyl&gt;]-(6-methyl-pyTidin-2-yl&gt;ethylideneamino3-<br>
pyrrolidin-2-one (0.5 g, 1. J 6 mmol), is used lo yield the title compound, 325 mg (68%),<br>
as pale brown oil.<br>
'H NMR (CDCh): 6 7.50 (t, J « 8.8 Hz, 1H), 7.17-7.47 (m, 8H), 6.96-7.06 (m, 3H), 4.61<br>
(m, 1H), 4.50 (s, 2H), 3.98 (dd, J = 9.8, 3.2 Hz, 1H), 3.87 (dd, J = 9.8,5.6 Hz, 1H), 2.68-<br>
3.05 (m, 4H), 2.54 (s, 3H).<br>
MSAPCI+m/c414(M+l).<br>
PKEPARATION 375<br>
5-Chloromethyl-2,2-difluoro-benzo|l,3]dioxolc<br>
A solution of (2,2-difhioro-benzo[l,3]dioxol-5-yl)-methanol (1.0 g, 5.32 mmol) in<br>
carbon tetrachloride (10.6 mL) is added to polymer-supported triphenylphospine (3.5 g, 3<br>
mmol/g, 10.6 mmol) at room temperature. The reaction is heated for 3 h at 80 °C, cooled<br>
to room temperature, filtered, and the solids washed with dichloromethane. The filtrate is<br>
concentrated in vacuo to yield the title compound, 0.79 g (72%), as a clear, orange oil.<br>
MSCI+m/e207(M+l).<br><br><br>
PREPARATION 378<br>
Methanesulfonic acid 2-pyridii»-2-yl-3-quinolin-4-yl-5,6-dihydro-4H-pyrrolo|l,2-<br>
b]pyrazol-6-ylmcthyl ester<br>
A solution of [2-(6-methyl-pyridin-2-yl)-3-quinolin-4-yl-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-6-yl]-methanol (30mg, 0.07 mmol) and 4-dimethylaminopyidine<br>
(catalytic) in pyridine (0.2 mL) is cooled to 0 °C and treated with methanesulfonyl<br>
chloride (8 mL, 0.105 mmol) and stirred for 30 min. The mixture is stirred at room<br>
temperature for 30 min, diluted with ethyl acetate (20 mL), washed with water and brine,<br>
dried over magnesium sulfate, filtered, and concentrated in vacuo to yield the title<br>
compound, 30 mg (86%,) as a yellow oil.<br>
'H NMR (CDC13): 5 8.90 (d, J = 4.0 Hz, IH), 8.45 (d, J = 4.0 Hz, 1H), 8.15 (d, J = 8.5<br>
Hz, 1H), 7.55-7.70 (m, 2H), 7.36-'.48 (m, 2H), 7.05-7.30 (m, 3H), 4.80-4.90 (m, 2H),<br>
4.65-4.75 (m, 1H), 2.65-3.05 (m, 7H).<br><br><br><br><br>
PREPARATION 387<br>
4-j4-(2-Pyridin-:!-yl-S,6-dihydro-4H-pyrrolo|l,2-bJ<br>
py razol-3-yl)- q u inolin-7-y loxy]-piperidine-l -<br>
carboy lie acid lert-buty) ester<br>
To a suspension of 4-(2-pyridm-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b)pyra2oI-3-yl)-<br>
quinolin-7-ol (0.27 g, 0.84 mmol) irii WN-dimethylformamide (15 mL) is added 4-bromo-<br>
piperidine-1-carboxylic acid tert-buiyl esier (0.29 mL, 2.28 mmol) and cesium carbonate<br>
(1.5 g, 4.57 mmol. The mixture is heated at 80 °C for 48 h and concentrated in vacuo.<br>
The residue is taken up in dichlororr ethane, washed with water and brine, dried over<br>
sodium sulfate, and concentrated in vacuo. Purification by flash chromatography (S1O2,<br>
7% methanol in dichloromethane) yields the title compound, 262 mg (61 %,) as a yellow<br>
oil.<br>
MSES+m/e512(M+l).<br><br><br><br><br>
Regioisomer ]:<br>
'H NMR (CDC13) 5: 8.26 (d, 2h), 8.04 (s, 1H), 7.69 (d, 1H), 7.63 (t, 1H), 7.39 (t,<br>
1H), 7.35 (t, 1H), 7.25 (d, 1H), 6.79 (t, 1H), 4.47 (quartet, 2H), 4.31 (t, 2H), 2.82 (m, 2H),<br>
2.65 (quintet, 2H), J .40 (t, 3H); MS ES* m/c 385 (M+l).<br>
Regioisomer 2:<br>
'H NMR (CDCIj) 8: 8.39 (d, JH), 3.27 (d, 1H), 8.20 (s, 1H), 7.90 (d, 1H), 7.65 (t, 1H),<br>
7.37 (t, 1H), 7.18 (t, \U), 6.57 (d, 1H), 4.26 (t. 2H), 3.26 (t, 2H), 2.70 (quintet, 2H), 1.38<br>
(t, 3H); MS ES+ m/e 385 (M+l).<br>
PREPARATION 395<br>
2-(2-Hydroxyelhyl)-3-hydro&gt;ymelhyl-.'&gt;-pyridin-2-yl-4-quinolin-4-yl-pyrazole<br>
To a solution of 2-pyridin-2-yl-3-quiinolin-4-yl-pyrazolo[5,l-c]morpholin-4-one<br>
(0.50 g, 1.46 mmol) in tetrahydrofuran (20 mL) is added L1AIH4 (0.50 g, 13.1 rnrnol) at<br>
room temperature. The mixture is stirred for 2 h quenched with 1 N sodium hydroxide<br>
solution, and partitioned between dichloromethane and water. The organic portion is<br>
dried (sodium sulfate), filtered, anc concentrated in vacuo. The residue is<br>
chromatographed on SiO2 (10% mcthanol/dichloromethane) to yield the title compound,<br>
0.35 g (70%), as an off-white solid<br>
TOF MS ES+ exact mass calculated for C20H19N4O2 (p+1): m/z = 347.1508. Found:<br>
347.1496.<br><br><br>
PREPARATION 397<br>
3-Elhoxycarbonfl-5-pyridiii-2-yl-4-quinolin-4-yl-pyra2ole<br>
A solution of 2-quinolin-4-yl-l-pyiridin-2-yl elhanone (1.00 g, 4.0 mmol) and<br>
hydrazine monohydrate (1.0 ml.) in ethanol (200 mL) is heated at reflux for 2 h. The<br>
mixture is concentrated in vacua to dryness, the residue dissolved in pyridine (SO mL),<br>
cooled to 0 °C, and treated with ethyl oxalyl chloride (0.60 mL, 5.4 mmol) dropwise over<br>
20 min. The mixture is warmed to room temperature, stirred for 2 h, and heated at reflux<br>
for 3 h. The mixture is concentrated in vacuo and the residue partitioned between<br>
dichloromethane and water. The organic portion is dried (sodium sulfate), filtered, and<br>
concentrated in vacuo to yield tine title compound, 0.6 g (44%,) as a white solid which is<br>
crystallized from ether.<br>
'H NMR (CDC13): 6 12.43 (br s, 1H), 9.02 (d, J = 5 Hz, 1H), 8.56 (br s, 1H), 8.32 (d, J =<br>
7 Hz, 1H), 7.76 (t, J = 7 Hz, 1H), 7.65 (d, J = 8 Hz, 1H), 7.46 (m, 2H), 7.33 (br s, 1H),<br>
7.17 (t, J = 7 Hz, 1H), 4.11 (m, 1H), 0.90 (t, J = 7 Hz, 1H).<br>
MS ES+m/e 345.0 (M+l).<br>
PREPARATION 398<br>
5-Pyridin-2-yl-4-quinolin-4-yl-2H-pyrazol-3-ol<br>
To a solution of (l-pyridin-2-yl-2-quinolin-4-yl-ethylidene)-hydrazine (2.0 g, 7.6<br>
mmol) in pyridine (20 mL) at 0 °C is added ethyl chloroformate (2 mL) dropwise. The<br>
mixture is warmed to room temperature and stirred for 2 h. The solution is refluxed for<br>
12 h and concentrated in vacuo The residue is treated with dichloromethane/methanol<br>
and the precipitate collected by vacuum filtration. The precipitate is triturated with<br>
ethanol to yield the title compound, 300 mg (13%), as a white solid.<br>
MS ES+m/e 288.9 (M+l).<br><br>
PREPARATION 401<br>
4-|4-(2-Pyridiii-:!-yl-5,6-dihydro-4H-pyrrolo|l,2-b|<br>
pyrazol-3-yl&gt;quinolin-7-yloxy)-piperidine-]-<br>
carbo) ylic acid ilcrt-butyl ester<br>
To a suspension of 4-(2-pyridin-2-yl-5,6-dihydro-4H-pym&gt;lo[l,2-b]pyrazoI-3-yl)-<br>
quinolin-7-ol ( 0.27 g, 0.84 mmol) in 7V,JV-dimethylformamide (15 mL) is added 4-bromo-<br>
piperidine-1-carboxylic acid tert-bulyl ester (G.29 mL, 2.28 mmol) and cesium carbonate<br>
(1.5 g, 4.57 mmol). The mixture is heated at 80 °C for 48 h and concentrated in vacuo.<br>
The residue is taken up in dichloromethane, washed with water and saturated aqueous<br>
sodium chloride, dried over sodium sulfate, and concentrated in vacuo. The residue is<br>
chromatographed on SiO2 (7% methanol in dichloromethane) to yield the title compound,<br>
262 mg (61%), as a yellow oil.<br>
MSES+m/e512(M+l).<br><br>
PREPARATION 403<br>
|4-(2-Pyridin-2-yl-5,6-dihydr(»-4H-pyrrolo|l,2-b]pyrazol-3-yl)-quinolin-7-yloxyJ-<br>
acctic acid<br>
To a solution of [4-(2-pyridiri-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazoI-3-yl)-<br>
quinolin-7-yloxy]-acetic acid ethyl ester (250 ring, 0.6 mmol) in methanol (4 mL) at room<br>
temperature is added 1 N lithium hydroxide (1.2 mL, 1.2 mmol). The mixture is heated at<br>
60 °C for 4 h. The mixture is cooled to room temperature and concentrated in vacuo. The<br>
residue is taken up in water and acidified to pH = 6 with 1 N hydrochloric acid. The<br>
aqueous solution is extracted with dichloromethane 5 times. The combined organic<br><br>
PWF.PARAIIUIN iyy<br>
|2.Methyl-2-({4-|2-(6-nielhyl-pyridin-2-yt)-5,6-dihydro-4H-pyrroIofM-bJpyra2oJ-3.<br>
yl]-quinoline-7carbonyl}-»roino)-propylj-carbamic acid ten-butyl ester<br>
To a solution of 4.[2-(6-mcthyl-pyriclin-2-y1)-5,6'dihydro-4H-pyiTolon,2-<br>
b]pyrazol-3-yl]~quinoline-7-carboxylic acid (0.16 g, 0.43 mmol), (2-amino-2-methyl-<br>
propyJ)-carbamic acid /<?r /-buty! ester (0.09 g, 0.47 mmol), EDC (0.09 g, 0.47 mmol), 1-<br/>
hydroxybenzotriazole (0.06 g, 0.47 mmol)in .iichloromethane (8.6 mL)is added N.N-<br>
diisopropylethylamine (0.25 mL, 1.29 mmol) The mixture is stirred at room temperature<br>
for 18 hand concentrated in vacuo. The residue is taken up in ethyl acetate, washed with<br>
water and saturated aqueous sodium chloride, dried over sodium sulfate and concentrated<br>
in vacuo. The residue is chromatographed on !&gt;iO2 (methanol/dichloromethane / 2:98) to<br>
yield the title compound 0.21 g (91%) as a wh te solid.<br>
'H NMR (CDCI.0 6 8.93-8.86 (m, 1H), 8.51 (s 1H), 7.79 (s, 2H), 7.39-7.23 (m, 2H),<br>
7.08-7.00 (m, 1H), 6.93-6.85 (m, 1HX 5.32-5.20 (m, 1H), 4.42-4.31 (m, 2H), 3.41-3.32<br>
(m, 2H), 2.89-2.78 (m, 2H), 2.75-2.61 (m, 2H), 2.26 (s, 3H), 1.54-1.41 (m, 15H).<br><br><br>
extracts are dried (sodium sulfate), filtered, and concentrated in vacuo to yield the title<br>
compound, 150 mg (65%), as an off white solid.<br>
MSESm/e385(M-l).<br>
PREPARATION 404<br>
4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo|J,2-b]pyrazol-3-yl)-7-(tetrahydro-furan-2-<br>
ylmethoxy)-quino)ine<br>
A mixture of methanesulftmic acid tetrahydro-furan-2-ylmethyl ester (0.70 g, 3.66<br>
mmol), 4-(2-pyridin-2-yl-5,6-dih&gt;dro-4H-pyuolo[l,2-b]pyrazol-3-yl)-quinolin-7-ol (400<br>
mg, 1.22 mmol), and cesium carbonate (2.38 g, 7.32 mmol) in WAf-dimethylformamide<br>
(2.5 mL) is heated at 60 °C for 42 h. The mixture is concentrated in vacuo and the residue<br>
chromatographed to yield the title compound, 79 mg (15%), as a tan solid.<br>
MSAPC+m/e413(M+I).<br><br><br><br>
To a suspension of hexane-washed sodium hydride (60 % dispersion in mineral<br>
oil, 347 mg, 50 mmol) in 7V,W-diineiby)formaniide (20 mL) is added l-[2-(6-bromo-<br>
quinolin-4-yl)-l -pyridin-2-yl-ethylkfeneamino)-pyrrolidin-2-one (2.2 g, 5.37 mmol). The<br>
resulting mixture is heated at 80-85 "C under nitrogen atmosphere for 18 h. The reaction<br>
is adjusted to pH 2 and neutralized with solid sodium carbonate. The product is extracted<br>
with ethyl acetate, dried over sodium sulfate, and concentrated in vacuo. The residue is<br>
chromatographed on SiO2 (dichloronethane to 2% methanol/dichloromethane) to yield a<br>
colorless solid, 1.145 g (54 %).<br>
MS ES+m/e 391.2 &amp; 393.2 (M+I).<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
A mixture of 3-bromo-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l ,2-<br>
b]pyrazolc (99 mg, 0.36 mmol), 3,4-methylcnedioxyphenylboronic acid (65 mg, 0.39<br>
mmol), (PPhj^Pd (20 mg, 0.02 mmol), I N aqueous sodium carbonate solution (500 ^iL,<br>
0.5 mmol) in toluene (5 mL) and methanol (1 mL) is purged with argon for 10 min and<br>
heated at 80 °C under nitrogen for 30 h. The mixture is cooled and partitioned between<br><br>
water and ethyl acetate, and the organic portion washed with water and brine, dried<br>
(sodium sulfate), filtered, and concentrated in vacuo. The crude residue is<br>
chromatographed on SiO2 (ethyl ncetate) to yield the title compound, 10 mg (9%), as a<br>
yellow solid.<br>
MSES+m/e320(M+l).<br><br><br><br>
To a mixture of sodium acetate (0.84 g, 10.2 mmol) and [1,1 '-<br>
bis(diphenylphosphino)ferrocene]dichloropalladium (11):CH2C]2 (42 mg, 0.05 mmol) in<br>
methanol (40 mL) is added 6-bromo-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrololl,2-<br>
b]pyrazol-3-yl)-quinoline (1.0 g, 2.56 mmol). The mixture is heated at 90 °C under 68 psi<br>
carbon monoxide for 24 h. The mixture is cooled, filtered, and concentrated in vacuo.<br>
The product is partitioned between ethyl acetate and water. The organic layer is dried<br>
over sodium sulfate and concentrated n vacuo. The residue is chromatographed on SiO2<br>
(dichloromethane to 2% methanol/dichloromethane) to yield a solid, 918 mg (97%).<br>
MS ES+m/e 371.2 (M+l).<br><br><br><br>
To a solution of 2-(2-hydroxyeihyl)-3-hydroxyrnethyl-5-pyridin-2-yM-
4-yl-pyrazole, (0.10 g, 0.29 mmol) in tetrahydrofuran (10 mL) cooled at 0 °C is added<br>
NaH (0.04 g, 50% in mineral oil). The mixture is stirred for 2 h at room temperature and<br>
methanesulfonyl chloride (0.065 g, 0.57 mmol) is added dropwise over 30 min. The<br>
reaction is quenched with water and extracted into ethyl acetate. The organic layer is<br>
washed with water,.dried (sodium sulfate), filtered, and concentrated in vacuo. The<br>
residue is chromatographed on S1O2 [10% methanol/dichloromethane) to yield the title<br>
compound, 31 mg (33%), as a white solid.<br>
TOF MS ES+ exact mass calculated ior C20H,6N4O (p+1): m/z = 329.1402. Found:<br>
329.1409.<br><br>
A mixture of3-ethoxycarbonyi-5-pyndin-2-yl-4-quiriolin-4-yi-pyra2OJe (\).55 g,<br>
1.00 mmol), 2-bromoethanol (0.15 g, 1.12 mmoll), and cesium carbonate (0.50 g, 1.5<br>
mmol) in W.yV-dimethylformamide (20 mL) is heated at 60 °C for 2 h. The mixture is<br>
cooled to room temperature and poured into ethyl acetate (60 mL). The organic portion is<br>
washed with water, dried (sodium sulfate), filtered, and concentrated in vacuo. The<br>
residue is chromatographed on SiO2 (ithyl acetafe/hexane) to yield the title compound,<br>
110 nig (32%).<br><br><br>
A solution of 7-(3-chloio-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-3-yl)-quiiioline (54 mg, 0.13 mmol), sodium iodide (5 mg, 0.03<br>
mmol), and 2 N dimethylamine in tetrahydrofuran (3 mL, 6 mmol) in N.N-<br>
dimethylformamide (5 mL) is heated at 100 °C for 48 h. The mixture is cooled and<br>
concentrated in vacuo. The residue is chromatographed on S1O2 (100% ethyl acetate to<br>
10% methanol in ethyl acetate) to yield the title compound, 41 mg (74%), as a brown<br>
solid.<br>
TOF MS ES+ exact mass calculated for C25H28N5O (p+1): m/z = 414.2294 Found:<br>
414.2313<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinohn-7-ol<br>
(0.100 g, 0.305 mmol), N-(3-bromoprof.yl)-phthalimide (0.163 g, 0.609 mmol, 2.0 equiv)<br>
and cesium carbonate (0.248 g, 0.761 mmol, 2.50 equiv) are combined in N.N-<br>
dimethylformamidc (1.0 mL) and the reaction is heated at 60 °C for 48 hours. The<br>
reaction is diluted with water (1 mL) ami the reaction mixture is partitioned between ethyl<br>
acetate (6 mL) and water (5 mL). The organic layer is removed and placed on alO g SCX<br>
resin column. The resin is washed sequentially with dichloromethane (20 mL) and 4:1<br>
dichloromethane/2 N ammonia in melhacK)! (125 mL). The latter fractions are evaporated<br>
to dryness and the residue is subjected to chromatography on silica gel (20 g) (9:1 ethyl<br><br><br><br><br><br><br><br><br>
A solution of (R)-(-)-5-<hyi mg mmol in></hyi>
JV.W-dimethylformamide (3 mL) is treated with methansulfonyl chloride (320 mg, 2.74<br>
mmol) and heated at 60 °C for 5 h. The reaction mixture is diluted with N,N-<br>
dimethylformamide (1 mL) and4H;2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo[l,2-b]pyra2ol-<br>
3-yl)-quinolin-7-ol (200 mg, 0.91 mmol) added. The mixture is stirred at 60 °C for<br>
additional 16 h, cooled to room temperature, and partitioned between ethyl acetate and<br>
water. The organic portion is washed three times with water, once with brine, dried<br>
(sodium sulfate), filtered and concentrated in vacuo. The crude residue is<br>
chromatographed on SiO2 (89% dichloromethane 10% methanol 1 % concentrated<br>
ammonium hydroxide) to yield the title compound, 32 mg (8%), as a light red solid.<br>
MSES+m/e426(M+l).<br><br><br><br>
To a solution of 4-[2-(6-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl]-quinoline (133 ing, 0.41 mmol) in dichloromethane is added m-<br>
chloroperoxybenzoic acid (248 mg, 1.44 mmol) and the resulting mixture stirred for 3 h.<br>
The mixture is diluted with dicMoromethane and washed twice with saturated aqueous<br>
sodium bicarbonate solution, once with brine, dried (sodium sulfate), filtered and<br>
concentrated in vacuo to yield the title compound, 140 mg (96%), as white foam.<br>
TOF MS ES+ exact mass calculated for C2,H,9N4O2 (p+1): m/z = 359.1508. Found:<br>
359.1516.<br><br><br><br><br><br><br>
Nitrogen is bubbled through a solution of 7-bromo-4-[2-(6-methyl-pyridin-2-yl)-<br>
5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl|-quinoline (0.050 g, 0.12 mmol),<br>
tributylamine (0.032 mL, 0.17 mraiol), methyl acrylaie (0.027 mL, 0.24 mmol), and N.N-<br>
dimethylformamide (0.5 mL) in toluene (1.0 mL) for 20 min. Pd(OAc)2 (0.002 g, 0.006<br>
mmol) and tri(o-toly])phosphine (0.007 g, 0.021 mmol) are added and nitrogen bubbled<br>
through the reaction mixture for 0 min. The mixture is heated to 80 °C for 24 h. An<br>
additional portion of Pd(OAc)2 (0.002 g, 0.006 mmol) and tri(o-tolyl)phosphine (0.007 g,<br>
0.021 mmol) is added and heating continues for another 24 h. The reaction is cooled and<br>
concentrated in vacuo and the residue chromatographed on SiO2 (2% methanol in<br>
methylene choloride) to yield the title compound, 0.49 g (97%), as a yellowish solid.<br>
MS APC1+ m/e 411 (M+l).<br><br><br><br>
Nitrogen is bubbled through a solution of 7-bromo-4-[2-(6-methyl-pyridin-2-yl)-<br>
5,6-dihydro-4H-pyrrolo[1,2-b]pyra2.ol-3-yl]-quinoline (0.050 g, 0.14 mmol) and<br>
tributylvinyltin (0.079 mL, 0.22 mmol) in toluene (2.0 mL) for 20 min. Pd(PPh3)2Cl2 is<br>
added and nitrogen bubbled througli the reaction mixture for another 10 min. The<br>
mixture is heated to 90 °C for 24 h, concentrated in vacuo, and the residue<br>
chromatographed on SiC&gt;2 (elute with 2% methanol in methylene choloride) to yield the<br>
title compound, 0.030 g (61%), as a yellowish solid.<br>
MSAPa+m/e353(M+l).<br><br><br>
Zinc(II) chloride (0.34 mL, 1.0 M solution, 0.34 mmol) is added, at room<br>
temperature with stirring, to a solution of benzyl magnesium chloride (0.15 mL, 2.0 M<br>
solution, 0.31 mmol) in tetrahydrofuran (1 ml.). After 15 min, Pd(PPh3)2Cl2 (5.4 mg,<br>
0.0076 mmol) is added followed by a solution of 4-[2-(6-bromo-pyridin-2-yl)-5,6-<br>
dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl]-quinoline (60 mg 0.153 mmol) in tetrahydrofuran<br>
(1 mL). The reaction mixture is stirred for 18 h at room temperature and quenched with<br>
saturated aqueous ammonium chloride (1 mL). The reaction mixture is concentrated in<br>
vacuo, filtered, and the residue chromatographed on SiC&gt;2 (20-50% acetone/hexanes) to<br>
yield the title compound, 33.4 mg (54%), as a white solid.<br>
MS (CI, methane) m/e 403 (M+l).<br><br><br><br>
To a solution of 4-[2-(6-methyl-pyridin-2-yl&gt;5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl]-quinoline-7-carboxy*ic acid ethyl ester (250 mg, 0.6 mmol) in methanol<br>
(4 mL) at room temperature is added 1 N lithium hydroxide (1.2 mL, 1.2 mmol). The<br>
mixture is heated at 60 °C for 4 h. The mixture is cooled to room temperature and<br>
concentrated in vacuo. The mixture is diluted with water and acidified to pH 6 with 1 N<br>
hydrochloric acid. The aqueous solution is extracted with dichloromethane 5 times. The<br>
combined organic extracts are dried sodium sulfate), filtered, and concentrated in vacuo<br>
to yield the title compound, 150 mg (65%), as an off white solid.<br>
MSESm/e369(M-l).<br><br><br><br>
A mixture of l-(3-dimetltylaminopropyI)-3-ethylcarbodiimide hydrochloride, (53<br>
mg, 0.30 mmol), HOBT, (24 mg, 0.28 mmol), cyclopentylamine (0.03 mL, 0.30 mmol),<br>
and 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline-7-carboxylic<br>
acid (90 mg, 0.25 mmol) in dichloromethane (1 mL) is stirred room temperature for 18 h.<br>
The mixture is concentrated in vacuo and the residue chromatographed on S1O2 to yield<br>
the title compound, 31 mg (31 %,) as a white solid.<br>
MSAPC+m/e424(M+l).<br><br><br><br><br><br><br>
To a solution of [4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-acetic acid (150 mg, 0.39 mmol) in dichloromethane (3 mL) is added<br>
oxalyl chloride (490 mg, 3.9 mmol) and 1 drop of N.JV-dimethylformamide. The mixture<br>
is stirred at room temperature for 5 h, concentrated in vacuo, and residual solvents<br>
removed by co-evaporation three times with chloroform to yield [4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[l,2-b]pyrazos-3-yl)-quinolin-7-yloxy]-acetyl chloride as a yellow<br>
solid. To a solution of [4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo(l,2-b]pyrazol-3-yl&gt;-<br>
quinolin-7-yloxy]-acetyl chloride (50 mg, 0.12 mmol) in dichloromethane at room<br>
temperature is added 1-methyl-piperazine (62 mg, 62 mmol) and the mixture stirred for<br>
2.5 h. The mixture is partitioned between dichloromethane and water, the organic portion<br>
dried (sodium sulfate), filtered, and concentrated in vacuo. The crude residue is<br>
chromatographed on SiO2 (89% dichloromethane 10% methanol 1% concentrated<br>
ammonium hydroxide) to yield the title compound, 28 mg (48%), as a light brown solid.<br>
MSES+m/e469(M+l).<br><br><br><br><br>
A solution of 4-[2-(6-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-yl]-quinoline-6-carboxylic acid methyl ester (0.055 g, 0.14 mmol) in 2-N.N-<br>
dimethylaminoelhylamine (1.5 iwL) is healed at 100 °C for 24 h. The mixture is<br>
concentrated in vacuo and the residue chrornatographed on SiO^ (100% ethyl acetate) to<br>
yield the title compound, 0.045 g (74%), as a yellowish solid.<br>
MS APCI+ m/e 441 (M+l).<br><br><br><br><br><br><br><br>
Molecular chlorine is bubbled through a solution of 7-benzylsulfanyI-4-(2-<br>
P)Tidin-2-yl-5,6H^ihydro-4H-pyl^olo[I,2-b]pyrazoJO-yl)-quino^ine (190.2 mg, 0.44<br>
mmol) in water (0.3 mL) and glacial acetic acid (1.8 mL) for 10 min. The resultant<br>
solution is divided into six 4 mL vials and each is concentrated. One vial is treated with 7<br>
M ammonia in methanol for 10 min. The mixture is concentrated in vacuo and the<br>
residue chromatographed on SiO? (dichloromethane, 2%, and 5%<br>
methanol/dichloromethane) to yield the desired product, (17 mg), as colorless oil.<br>
MS ES*m/e 392.3 (M+l).<br><br><br><br>
A solution of 7-bromo-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-<br>
yl)-quinoline (135.0 mg, 0.34 mmoi), sodium /er/-butoxide (64.0 mg, 0.62 mmol), and<br>
benzophonone imine (91.0 mg, 0.51 mmol) in toluene (3 mL) is degassed with nitrogen<br>
for 20 min. To this solution is added tri(dibenzyldeneacetone)-dipa11adium(0) (1.0 mg,<br>
0.0011 mmol) and 2,2'-bis(dipheny«phosphine)-l,l'-binaphthyl (J.5 mg, 0.0024 mmol)<br>
and the mixture degassed with nitrogen for another 10 min. The mixture is heated at 80<br>
°C for 24 h, cooled to room temperature, quenched with saturated ammonium chloride,<br>
and extracted with chloroform. The combined organic portions are washed with water<br>
and brine, dried (sodium sulfate), and concentrated in vacuo. The residue is dissolved in<br>
1 M hydrochloric acid (5 mL )and heated at reflux for 2.5 h. The mixture is concentrated<br>
in vacuo and the residue neutralized with saturated sodium bicarbonate. The resultant<br>
mixture is extract with chloroform and the organic extracts concentrated in vacuo to yield<br>
the desired product as a yellow solid, 96.5 mg (85%).<br>
MS ES+m/e 327.9 (M+l).<br><br><br>
A mixture of dimethylamimo-acetyl chloride (620.0 mg, 13.33 mmol), 4-(2-<br>
pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolin-7-ylamine (75 mg,<br>
0.23 mmol), and 4-N, TV-dimethylaminopyridine (10.2 mg, 0.09 mmol) in drypyridine (1<br>
mL) is refluxed for 72 h. The mixture is treated with saturated sodium bicarbonate<br>
solution and extracted with ethyl acetate. The organic layer is washed with brine, dried<br>
(sodium sulfate), concentrated in vacuo, and the residue chromatographed on S1O2 ((5%<br>
to 20% methanol in dichloromethane) to yield a yellow oil, 62.3 mg (67%).<br>
MS ES'm/e 413.1 (M+l).<br><br><br><br>
To a mixture of 4-(2-pyridin-2-yl-5,6-dihydro-4H pyrrolo[ 1,2-b]pyrazol-3-yl&gt;<br>
quinolin-7-ylamine (38.1 mg, 0.11 mmol) and 4-N, JV-dimethylaminopyridine (4.2 mg,<br>
0.034 mmol) in dry pyridine (1 mL) is added 20% phosgene in toluene (80 nL, 0.76<br>
mmol). The resulting mixture is stirred at 50 °C for 18 h, treated with N, N-<br>
dimethylethylendiame (0.5 mL), and stirred for 4 h. The mixture is concentrated in vacuo<br>
and the residue partitioned between eihyl acetate and brine. The organic layer is dried<br><br><br><br><br>
A 2 M solution of isopropyi magnesium chloride in tetrahydrofuran (65 uX, 0.13<br>
mmol) is added lo solution of 7-biomo-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrroIo[l,2-<br>
b]pyrazol-3-yl)-quinoline (50.0 mg, 0.13 mmol) in tetrahydrofuran (1 mL) at room<br>
temperature with stirring for 2 h. The mixture is cooled to -78 °C and triethylamine (21.4<br>
U.L, 0.154 mmol) and methanesuHonyl chloride (11 nL, 0.14 mmol) added. The mixture<br>
is warmed to room temperature and allowed to stand 18 h. The mixture is treated with<br>
water, extracted with ethyl acetatt:, dried (sodium sulfate), filtered, and concentrated in<br>
vacuo. The residue is chromatog&gt;raphed on S1O2 (dichloromethane to 75% ethyl<br>
acetate/dichloromethane) to yield the title compound as a solid, 4.5 mg (9%).<br>
MS ES+m/e 433.1 &amp; 435.1 (M+1)-<br><br>
A solution of 4-[2-(6-rnethyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l ,2-<br>
b]pyrazol-3-yl]-quinoline-6-carboxylic acid methyl ester (0.06 g, 0.16 mmol) in<br>
tetrahydrofuran (1 mL) is cooled to -78 °C and degassed with nitrogen for 20 min. To<br>
this solution is added 3 M methylmagnesium chloride in tetrahydrofuran (0.17 mmol,<br>
0.06 mL) and the resulting mixture stirred at 0 °C for 2 h. The mixture is treated with<br><br>
aqueous saturated ammonium chloride and extracted with ethyl acetate. The combined<br>
organic extracts are washed with brine, dried (anhydrous sodium sulfate), filtered, and<br>
concentrated, in vacuo. The residue is chromatographed on S1O2 (100% ethyl acetate)<br>
to yield the title compound, 17 mg (28%), as an off-white foam.<br>
MSAPCi+in/e385(M+l).<br><br>
To a solution of Preparation #21, 3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-7-ylsulfanyl)-propan-l-ol (25.0 mg, 0.062 mmol) in<br>
dry pyridine (0.1 mL) is added toluene sulfonyl chloride (60.0 mg, 0.31 mmol) and the<br>
resulting mixture stirred at room temperature for 72 h. Saturated sodium bicarbonate<br>
solution is added and the resulting solution extracted with ethyl acetate. The organic<br>
layer is washed with brine, dried (sodium sulfate), filtered, and concentrated in vacuo.<br>
Purification of the residue on S1O2 (5% to 10% methanol in dichloromethane) gives the<br>
desired product, 11.2 mg (43%). MS ES+m/e 421.1 (M+l).<br><br><br>
A solution of 1 M sulfuryl chloride in dichloromethane (20 mL, 20 mmol) is<br>
added to a solution of 7-bromo-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolop^b]pyrazol-<br>
3-yl)-quinoline (2.2 g, 5.62 mmol) in dry pyridine (50 mL). The mixture is stirred for 18<br>
h and concentrated in vacuo. The residue is partitioned between chloroform and saturated<br>
sodium chloride. The organic layer is dried (sodium suJfate), filtered, concentrated in<br>
vacuo, and the residue chromatographed on S1O2 (dichloromethane to 20% methanol in<br>
dichloromethane) to yield the title compound as a red solid, 1.8 g (75%).<br>
MS ES+ m/e 424.7 &amp; 426.7 (M+l).<br><br><br><br>
A solution of 7-bromo-4-(4 chIoro-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yI)-quinoline (765.0 mg, 1.80 mmol) in 15% (v/v) aqueous Af-methyl<br>
pyrrolidinonc (IS mL) is heated at 120 °C for 18 h. The mixture is concentrated in vacuo<br>
and the residue chromatographed on SiO2 (dichloromethane to 20% methanol in<br>
dichloromethane) to yield a yellow solid, 408.0 mg (60%).<br>
MS ES+m/e 406.8 and 408.8 (M+l&gt;.<br><br><br><br>
To a solution of 3-(7-bromo-quinolin-4-yl)-2-pyridin-2-yl-5,6-dihydro-4H-<br>
pynolo[ 1,2-b]pyrazol-4-ol (89.0 nig, 0.22 mrnol) in dry dichloromethane (2 mL) is added<br>
Dess-Martin periodinane (301.0 mg, 0.7] mmol) and the resulting mixture stirred for 18<br>
h. The reaction mixture is chromatographed on SiO2 (dichloromethane to 20% methanol<br>
in dichloromethane) to yield a yellow solid, 78 mg (88%).<br>
MS ES+m/e 404.7 and 406.7 (M+1).<br><br>
A mixture of 4-(2-pyridin-:2-yl-5,6-dihydro-4H-pyiTolo[ 1,2-b)pyrazol-3-yl)-<br>
quinolin-7-ol (1.42 g, 4.30 mmol), 3-fluorobenzontrile (550.0 mg, 4.5 mmol), 18-crown-6<br>
(80.0 mg, 0.37 mmol), and 37%(w/w) potassium fluoride on alumina (3.5 g) in dimethyl<br><br>
sulfoxide (12 mL) are heated at 140 °C for 18 h. The reaction mixture is cooled to room<br>
temperature, filtered, and the solics are washed with chloroform. The organic filtrate is<br>
washed with brine, dried (sodium sulfate), filtered, and concentrated in vacuo. The<br>
residue is chromatographed on S1O2 (dichloromethane to 20% methanol in<br>
dichloromethane) to yield a yellow oil.<br>
3-[4-(2-Pyridin-2-yl-5,6-dihydro--tH-pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-<br>
r<br>
benzonitrile;<br>
MS ES+m/e 430.1 (M+l).<br>
3-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-<br>
benzamide;<br>
MS ES+m/e447.8 (M+l).<br><br><br><br>
Lawasson's Reagent (1.01 g, 2.49 mmol) is added to a solution of Ar,A'-dimethyl-<br>
3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-<br>
benzamide (0.72 g, 1.51 mmol) in toluene (lOmL). The resulting mixture is heated at<br>
120 °C for 45 min. The mixture is concentrated in vacuo and the residue<br>
chromalographed on SiO2 (dichlorc<mcthane to methanol in dichloromethane></mcthane>
yield a red solid, 556 mg (75%).<br>
MS ES+m/e 491.8 (M+l).<br><br>
To a refluxing mixture of Raney-nickcl and hydrazine-monohydrate (0.5 mL,<br>
10.17 mmol) in methanol (5 mL) is added MAf-dimethyl-3-[4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyrazol-:l-yl)-quinolin-7-yloxy]-thiobenzamide (311.0 mg,<br>
0.63 mmol) in methanol (20 mL). The mixture is stirred 10 min and cooled to room<br>
temperature, filtered, and concentrated in vacuo. The residue is chromatographed by<br>
HPLC (Cig column) to yield the title compound, 60.2 mg (20%).<br>
MS ES+m/e 462.0 (M+l).<br><br><br>
To a solution of 4-[2-(6-methyI-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l ,2-<br>
b]pyrazol-3-yl]-quinoline-l -oxide (103 mg, 0.30 mmol) in TV.jV-dimethylformamide (3<br>
mL) is added trifluoroacetic anhydride (425 ^iL,3.0 mmol). The mixture is stirred for 40<br>
h, poured into water, and the pH adjusted to 8 with saturated aqueous sodium bicarbonate<br>
solution. The mixture is extracted three times with ethyl acetate, the combined organic<br>
extracts washed three times with water and once with brine, dried (sodium sulfate),<br>
filtered, and concentrated in vacuo. The residue is triturated with 10% acetone/90%<br>
dichloromethane and filtered. The solid is dried under vacuum to yield the title<br>
compound, 11.6 mg (10%), as a yellow solid.<br>
TOF MS ES+ exact mass calculated for C23H22CIN4O2 (p+1): m/z = 343.1559. Found:<br>
343.1550.<br><br>
To a solution of 7-methoxy~4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l ,2-<br>
b]pyrazol-3-yl)-quinoline (53 mg, 0 16 mmol) in JV.JV-dimethylformamide (3 mL) at room<br>
temperature is added sodium ethanthiolate (133 mg, 1.6 mmol). The solution is refluxed<br>
for 4 h, cooled, and concentrated in vacuo. The residue is dissolved in methanol and<br>
loaded onto an SCX column. The column is washed with water, methanol, and 7 N<br><br>
ammonia in methanol. The appropriate fraction is concentrated in vacuo to yield the title<br>
compound, 28 mg (56%), as a yellow solid.<br>
TOF MS ES+ exact mass calculated for C2oH|7N40 (p+l): m/z = 329.1402 Found:<br>
329.1413.<br>
By the above method the following compounds are prepared (unless otherwise<br><br>
To a mixture of 7-benzyloxy-6-methoxy-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline (17 mg, 0.04 mmol) and 10% palladium on<br>
activated carbon (3 mg) in absolute ethanol (2 mL) is added 1,4-cyclohexadkne (100 mg,<br>
1.2 mmol). The mixture is stirred at room temperature for 3 h, treated with methanol<br>
(500 |lL), and heated at 60 °C for 3 li. The mixture is cooled, filtered, and loaded onto an<br>
SCX column. The column is washed with water, methanol, and 7 N ammonia in<br>
methanol. The appropriate fraction is concentrated in vacuo to yield the title compound,<br>
10 mg (77%), as a yellow solid.<br>
TOF MS ES* exact mass calculated for C2iH,9N4O2 (p+l): m/z = 359.1508Found:<br>
359. J 520.<br><br><br>
To a solution of 3-{4-[2-{6-methyl-jjyridJn-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazoI-3-yl]-quinolin-7-yl}-acrylic acid methyl ester (0.041 g, 0.1 mmol)in<br>
methanol (1 mL) is added 10% Pd/C (0.1 g). The resulting mixture is placed under<br>
one atmosphere of hydrogen and stirred for 18h. The mixture is filtered and<br>
concentrated in vacuo. The residue is chromatographed on SiC&gt;2 (2% methanol in<br>
dichloromethane) to yield the desired product as a pale yellow solid, 0.035 g (85%).<br>
MSAPCf m/e413(M+1).<br><br><br><br>
A mixture of 7-bromo-4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrro)o(l,2-b]pyrazol-3-yl]-quinoline(1.35 g,, 3.34 mmol), sodium i-butoxide(0.64 g,<br>
6.68 mmol), benzophcnone imine (0.91 g, 5.01 mmol) in toluene (30 mL) is de-gassed<br>
with nitrogen for 20 min. To the mixture is added Pd2(dba)3 (0.008 g, 0.008 mmol)<br>
and BfNAP (0.012 g, 0.019 mmol), and further de-gassed with nitrogen for 10 min.<br>
The mixture is heated at 80 °C for 24 h. Saturated ammonium chloride (30 mL) is<br>
added and the mixture extracted with chloroform. The combined organic portions are<br>
washed with water and brine, dried (sodium sulfate), and concentrated in vacuo. The<br>
residue is taken up in 1:1 methanol/1 N hydrochloric acid (50 mL) and heated at reflux<br>
for 2 h. The mixture is concentrated in vacuo and the residue partitioned between<br>
saturated sodium bicarbonate and chloroform. The combined organic layers are<br>
washed with water and brine, dried (i;odium sulfate), filtered, and concentrated in<br>
vacuo. The residue is precipitated from dichloromethane with hexanes (100 mL) and<br>
collected by filtration to yield the tith: compound, 1.10 g (96%), as a yellow solid.<br>
MSAPCI+m/e342(M+l).<br><br><br>
To a solution of 3-{4-[2-(6~methyl-pyridin-2-yl)-5,6-dihydro^H-pyjTolo[l,2-<br>
b]pyrazol-3-yl]-quinolin-7-yl}-propionic acid methyl ester (0.30 g, 0.73 mmol) and 2M<br>
dimethylamine in methanol (1.05 mL, 2.1 mmol) in dichloromethane (1 mL) is added 2<br>
M trimcihylaluminum in hexane (1.64 mL, 3.25 mmol). The solution is healed at 40 °C<br>
for 48 h. The mixture is diluted with dichloromethane (150 mL), treated with saturated<br>
potassium sodium lartrate (30 mL) and stirred 1S h. The organic portion is separated and<br>
washed with water and brine, dried (sodium sulfate), filtered, and concentrated in vacuo.<br>
The residue is chromatographed on SiC&gt;2 (10% methanol in dichloromethane) to yield the<br>
title compound, 0.29 g (89%), as a yellow foam.<br>
MSAPCrm/e426(M+l).<br><br>
To a solution of 3-(4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrro)o[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-propylamine (25 mg, 0.06 mmol) in pyridine (1 mL) at room<br>
temperature is added acetic anhydridt (500 |iL, 5.3 mmol). The mixture is stirred for 2 h,<br>
concentrated in vacuo, and the residue chromatographed on S1O2 (89% dichloromethane<br><br>
10% methanol 1 % concentrated ammonium hydroxide) to yield the title compound ,12<br>
mg (47%), as a light brown solid<br>
TOF MS ES+ exact mass calculated for C25H26N5O2 (p+1): m/z = 428.2086. Found:<br>
428.2095.<br><br>
Neat 1 -(1 -aza-2-pyridin-2-yl-3-quiiiolin-4-yl-prop-1 -enyl)piperidine-2,6-dione (0.64<br>
g, 1.8 mmol) is heated at 180 °C for 2 h. After cooling, the residue is allowed to cool,<br>
dissolved in dichloromethane (15 mL), cooled to -70 °C, and treated with a 1.0 M<br>
solution of D1BAL-H in toluene (1.9 mL, 1.9 mmol) dropwise. The mixture is stirred for<br>
0.S h, the cold bath removed, and stirred for an additional 18 h. The reaction is diluted<br>
with saturated aqueous ammoniom chloride solution. The mixture is partitioned between<br>
ethyl acetate and water. The organic portion is washed with water and brine, dried<br>
(sodium sulfate), filtered, and concentrated in vacuo. The residue is precipitated from<br>
ethyl acetate with hexane to yidd title compound, 0.S8 g (62%), as a white solid.<br>
TOF MS ES+ exact mass calculated for C2|H|8N4O (p+1): m/z = 343.1559. Found:<br>
343.1570.<br><br><br>
A solution of 2-pyridin-2-yl-3-quinolin-4-yl-pyrazolo[l,5-a]piperidin-7-ol (0.04 g,<br>
0. ] 2 mmol) and acetic anhydride (0.2 mL) in pyridine (2 mL) at room temperature is<br>
stirred for 24 h. The mixture is partitioned between ethyl acetate and water. The organic<br>
portion is washed with water and brine, dried (sodium sulfate), filtered, and concentrated<br>
in vacuo. The residue is chromatographed on S1O2 (5% methanol/dichloromethane) to<br>
yield the title compound, 0.41 g (91%), as a white solid.<br>
TOF MS ES+ exact mass calculated for C23H21N4O2 (p+1): m/z = 385.1665. Found:<br>
385.1668.<br><br>
A solution of methyl-{3-(4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo{l,2-b]pyrazol-<br>
3-yl)-quinolin-7-yloxy]-propyl}-carbamic acid tert-butyl ester (100 mg, 0.2 mmol) in<br>
trifluoracetic acid (3 mL) is stirred at room temperature for 6 h. The mixture is<br>
concentrated in vacuo and traces of trifluoroacetic acid removed by repeated evaporation<br>
with chloroform. The residue is placed on an SCX column and washed with water,<br>
methanol, and 7 N ammonia in methanol. Concentration of the appropriate fraction<br>
yields the title compound, 40 mg (50%), as yellow oil.<br>
MSES+m/e400(M+l).<br><br><br>
A solution of 3-(4-fluoro-phenyl)-2-«&gt;-methyl-1 -oxy-pyridin-2-yl)-5,6-dihydro-<br>
4H-pyrrolo[l,2-b]pyrazole (82 rag, 0.27 mmol) in chloroform (2 mL) is treated with<br>
excess trifluoroacetic anhydride aind warmed at reflux for 2 h then concentrated in vacuo.<br>
The residue is treated with excess; solid potassium carbonate in methano! at reflux for 30<br>
min. The mixture is concentrated, then partitioned between ethyl acetate and water. The<br>
ethyl acetate portion is concentrated and the residue purified on a silica cartridge (10%<br>
pyridine ethyl acetate) to yield 24 mg (29%) of the title compound as a yellow foam.<br>
MS,Erm/e310(M+l).<br><br><br>
To a solution of 6-(3-quinolin-4-yl-5,6-dihydro-4H-pyrrolo(l,2-b]pyrazol-2-<br>
yl)pyridine-2-carboxylic acid meithyl ester (0.550 g, 1.48 mmol) in methanol (20 mL) is<br>
added lithium borohydride (35.5 img, 1.63 mmol). The mixture is stirred lh, additional<br>
lithium borohydride (35.5 mg, 1.63 mmol) added, and the resulting mixture stirred at<br>
room temperature for 16 h. 4 N Hydrochloric acid (3 mL) is added slowly and the<br>
resulting mixture concentrated in vacuo. The residue is taken up in methanol (10 mL)<br>
and partitioned between ethyl acetate (150 mL) and saturated potassium carbonate (150<br>
mL). The organic portion is washed with brine (150 mL), dried (magnesium sulfate), and<br>
concentrated in vacuo. The residue is precipitated from ethyl acetate with hexanes to yield<br>
296 mg (58%) of the title compound.<br>
MSES+m/e342(M+l).<br><br>
To a solution of 3-(4-roethoxy-phenyl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-bJpyrazole (72 mg, 0.24 mmol) in methylene chloride (1 mL) is added boron<br>
tribromide (0.3 mL). The solution is stirred at ambient temperature for 3 h, then<br>
quenched with methanol. The mixture is concentrated in vacuo to a reddish solid. The<br>
solid is passed through a silica gel cartridge (methylene chloride, ethyl acetate, then<br><br>
acetone). The appropriate methylene chloride fractions are concentrated in vacuo to yield<br>
4 mg (5.8%) of the title compound. The more polar fractions are concentrated in vacuo<br>
then treated with aqueous ammonium chloride and methanol. The mixture is<br>
concentrated in vacuo and the residue purified on a silica cartridge eluting as above.<br>
Appropriate fractions are combined and concentrated in vacuo to yield an additional 49<br>
mg (71%) of the title compound.<br>
MSES+m/z292(M+l).<br><br>
To a 1 M solution of lithium aluminum hydride in letrahydrofuran (0.60 mL, 0.59<br>
mmol) is added a solution of 3-[4H2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-yl)-quinolin-7-yloxymethyl]-pyrrolidine-l -carboxylic acid benzyl ester (215 mg, 0.39<br>
mmol) in tetrahydrofuran (2 mL). The mixture is heated at 65 °C for 2 h, cooled to 0 °C,<br>
and diluted with saturated aqueous sodium potassium tartrate solution. The mixture is<br>
extracted with chloroform and the organic portion chromatographed on SiOj to yield the<br>
title compound, 112 mg (67%), as a yellow foam.<br>
MS APC+m/e426(M+l).<br><br><br>
A mixture of 4-[2-(6-niethyl-pyridin-2-yl)-5,6-dihydro-4H-pyrroIo[l,2-b]pyrazoI-<br>
3-yI]-quinoline-7-carboxy1ic acid (2-amino-l,l-dimethyl-ethyl)-amide (0.12 g, 0.27<br>
mmol), sodium cyanoborohydridt: (0.038 gv 0-6 mmol), and acetic acid (0.077 ml, 1.3<br>
mmol) in methanol (5 mL) is cooled to 0 °C and stirred for 10 min. A solution of 37%<br>
aqueous formaldehyde (0.086 ml., 3.1 mmol) in methanol (2 mL) is added dropwise. The<br>
mixture is allowed to warm to room temperature and stirred for 1 h. The reaction is<br>
quenched with saturated aqueous potassium carbonate solution and concentrated in<br>
vacuo. The residue is taken up in chloroform, washed with water and brine, dried<br>
(sodium sulfate) and concentrated in vacuo. The residue is chromatographcd on SiOz<br>
(8% methanoI/92% dichloromethane) to yield the title compound, 33 mg (27%), as a<br>
white foam.<br>
MS APC* m/e 504 (M+l).<br><br><br>
To a solution of (S)-6-ben2yloxymclhyl-3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-<br>
2-yl)-5,6-dihydro-4H-pyiToJo[l,2-b]pyra2ole (0.3 g, 0.73 mmol) in chloroform (1.0 mL)<br>
is added trimethylsilyl iodide (0.173 mL, 1.21 mmol). The mixture is stirred 2 h, diluted<br>
with methanol (10 mL), stirred 10 rain, and concentrated in vacuo. The residue is taken<br>
up in ethyl acetate (50 mL), washed with aqueous sodium thiosulfate (2 X 50 mL),<br>
saturated sodium bicarbonate solution, and brine. The resulting solution is dried<br>
(magnesium sulfate), filtered, and concentrated in vacuo. The residue is<br>
chromatographed on S1O2 (3% methanol/ethyl acetate) to yield the title compound, 149<br>
mg (64%), as a pale yellow solid.<br>
MS APC1* m/e324 (M+l); melting range: 142-144°C.<br><br><br><br>
A mixture of potassium cyanide (44 mg, 0.67 mmol), tetrabutylammonium iodide<br>
(catalytic), and (S)-methanesulfonic acid 3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-<br>
5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-6-ylmethyl ester (54 mg, 0.135 mmol) in N,N-<br>
dimethylformamidc (0.35 mL) and water (0.13 mL) is heated at 70 °C for 4 h. The<br>
mixture is cooled, taken up in ethyl acetate (20 mL), washed with water and brine, dried<br>
(magnesium sulfate), filtered, and concentrated in vacuo. The residue is<br>
chromatographed on SiO2 (2% methanol/chloroform) to yield the title compound, 25 mg<br>
(56%).<br>
MS APCI+ m/e 333 (M+1).<br><br><br><br><br>
To a solution of (0.230 g, 1 nimol) of 4-(2-(2-pyridy))ethynyl)quinoline in xylene<br>
(2mL) is added 3a H-pyrrolidino[l,2-C] l,2,3-oxadiazolin-3-one (0.252 g, 2 mmol) and<br>
the resulting solution heated in an oil bath at reflux under argon for 48 h, concentrated in<br>
vacuo, and the residue chromatographed on SiO2 (0 to 1 % methanol in chloroform with 3<br>
drops ammonium hydroxide per 150 mL solvent) to yield 18 mg of title compound as an<br>
oil.<br>
MSES+m/e3l3(M+l).<br><br>
To a solution of 5-pyridin-2-yl-4-quinolin-4-yl 2H-pyrazol-3-ol (50 mg, 0.17<br>
mmol), ethylene glycol (15 mg, 0.24 mmol) and tri-n-butylphosphine (100 mg, 0.50<br>
mmol) in tetrahydrofuran (15 mL) is added 1,1 *-(azodicarbonyl)dipiperidine (120 mg,<br>
0.48 mmol). The solution is heated at reflux for 5 h, cooled, and filtered through an SCX<br>
cartridge. The residue is chromatographed on SiO2(15:l dichloromethane:methanol).<br>
The product residue is converted to the disoxylate salt to give the title compound 40 mg<br>
(46%).<br><br>
'H NMR (CDCb): 6 8.81 (d, J - 4 Hz, 1H), 8.42 (m, 1H), 8.11 (d, J = 8 Hz, 1H), 7.83 (d,<br>
J = 8 Hz, 1H), 7.65 (ddd, J = 8,7, Hz, 1H), 7.46 (ddd, J = 8,7, J Hz, 1H), 7.38 (ddd, J =<br>
8, 7,1 Hz, IH) 7.24-7.29 (m, 2H), 7.O6-7.IO(m, 1H); MS ES+ m/e 315.0 (M+l).<br>
TOF MS ES+ exact mass calculated for CH,jN40 (p+1): m/z= 315.1246. Found:<br>
315.1248.<br><br>
To a solution of [4-(2-py)idin-2-yl-5,6-dihydro-4H-pyrTolo[l,2-b]pyrazol-3-yl)-<br>
quinolin-7-yl]-carbamic acid 2-hydroxy-ethyI ester (40.2 mg, 0.097 mmol) and<br>
triphcnylphosphine (35.0 mg, 0.14 mmol) in tetrahydrofuran (1 mL) at room temperature<br>
is added diethyl 40% azodicartmylate in toluene (50 uL, 0.11 mmol). The mixture is<br>
stirred 18 h, filtered, and the filtrate concentrated in vacuo. The residue is<br>
chromatographed on SiO2 (2% to 15% methanol in dichloromethane) to yield the desired<br>
product, 15.2 mg (40%).<br>
MS ES+m/e 398.0 (M+l).<br><br><br>
4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazoI-3-yl)-quinolin-7-ol<br>
(0.100 g, 0.305 mmol), triphenylphosphine (0.080 g, 0.305 mmol), and 4-pyridylcarbinoJ<br>
(0.033 g, 0.305 mmol) are combined in toluene (1.0 mL) and treated with<br>
diisopropylazodicarboxylate (0.062 g, 0.305 mmol). The resulting mixture is heated at 75<br>
°C for 18 hours. The mixture is diluted with tetrahydrofuran and heated at 75 °C for 24 h.<br>
The mixture is placed on a 10 g SiCX resin column which is washed sequentially with<br>
dichtoromethane (120 mL), methanol (60 mL), and 4:1 dichloromethane/2 N ammonia in<br>
methanol (125 mL). The latter fraction is concentrated in vacuo and the residue<br>
chromatographed on SiC&gt;2 (9:1 ethyl acetate:2N ammonia in melhanol) to yield the<br>
desired product as a tan solid, 0.035 g (27%).<br>
MSES' m/e 420 (M+l).<br><br><br>
Ethylenediame (45 mL, 0.67 mmol) is added dropwise to a stirred solution of 2.0<br>
M trimethylaluminum in toluene (0.5 mL, 1.0 mmol) and 4-(2-pyridin-2-yl-5,6-dihydro-<br>
4//-pyTTolo[l,2-b]pyrazol-3-yl)-quinoline-6-carboxylic acid methyl ester (250.0 mg,<br>
0.675 mmol) at 0 °C. The mixture is warmed to room temperature, then refluxed for 3 h.<br>
The solution is cooled and diluted with water (0.5 mL) and methanol (1 mL). The mixture<br>
is refluxed for 10 min, cooled, filtered, extracted into chloroform, and the organic portion<br>
washed with brine. The organic layer is concentrated in vacuo and the residue is<br>
chromatographed on SiO2 (10% to 30% methanol in dichloromethane) to yield the title<br>
compound, 46 mg (18%), as an yellow oil.<br>
MS ES'm/e 381.0 (M+l).<br><br><br>
Racemic4-[5-(4-nuoro-plicnyl)-2-(6-methyl-pyridin-2-yl)-5,6-dihychro-4H-<br>
pyrrolo[l,2-b]pyrazoI-3-yl]-quinoline (1 JO mg, 0.26 mmol) is separated into pure<br>
enantiomers by preparative HPLC with a Chiralcel OD (50X500mm) column (25:75<br>
isopropanol/heptane and detector at 220 nm). Fractions containing the first eluting<br>
compound are combined and concentrated to yield the title compound, 44 mg (40%), as<br>
an off-white foam.<br>
'H NMR (CDC13): 5 8.85 (d, J = 4.5 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 8.4<br>
Hz, 1H), 7.65 (td, J = 1.5, 8 Hz, IH), 7.35 (td, J = 1.5, 8 Hz, 1H), 7.20-7.30 (m, 4H),<br>
6.85-7.10(m,4H), 4.80 (dd,J = 8.4,11 Hz, IH), 4.35 (dd, J = 7, 11 Hz, 1H), 4.15-4.25<br>
(m, IH), 3.30 (dd, J = 8.4, 16 Hi, IH), 2.85 (dd, J = 6, 16 Hz, IH), 2.30 (s, 3H).<br>
MS APC1+ m/e421 (M+l).<br><br><br>
Racemic4-[5-(4-fluoro-pbmyl&gt;2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yI]-quinolime (110 ing, 0.26 mmol) is separated into pure<br>
enantiomers by preparative HPLC with a Chiralcel OD (50X500mm) column (25:75<br>
isopropanol/hepiane and detector al 220 nm). Fractions containing the second eluting<br>
compound are combined and concentrated to give the title compound, 59 mg(54%), as an<br>
off-white foam.<br>
'H NMR (CDC1,): 5 8.85 (d, J = 4.5 Hz, 1H), 8. JO (d, J = 8.4 Hz, 1H), 7.80 (d, J - 8.4<br>
Hz, 1H), 7.65 (td, J = 1.5, 8 Hz, 1H), 7.35 (td, J=1.5,8 Hz, 1H), 7.20-7.30 (m, 4H), 6.85-<br>
7.10 (m, 4H), 4.80 (dd, J = 8.4, 11 Hz, 1H), 4.35 (dd, J - 7,11 Hz, 1H), 4.15-4.25 (m,<br>
1H), 3.30 (dd, 3 - 8.4,16 Hz, 1H), 2.85 (dd, J = 6,16 Hz, 1H), 2.30 (s, 3H).<br>
MSAPCl+m/e421 (M+l).<br><br>
Add tributylvinyltin (0.0S9mL, 0.19mmol) to a solution of 4-[2-(6-chioro-pynain-<br>
2-yl)-5,6-dihydro-4H-pyrrolo[U-bi&gt;yrazol-3-yl)-quinoline, EXAMPLE 101, (59 mg,<br>
0.17mmol) in toluene (0.7mL) atRT. Bubble nitrogen into the reaction mixture for 5min<br>
and add tetrakis-(triphenylphospi«te) palladium (0) (10 mg, 0.0085mmol). Bubble<br><br>
nitrogen into the solution for an additional 2min and heat the reaction to 1 lOoC for 18h.<br>
Concentrate the reaction in vacuo and purify by flash column chromatography (SiO2,20-<br>
40% acetone/hexanes) to provide the title compound (35 mg, 62%) as a white solid.<br>
MS Calcd. 338; MS (APC1) (M-^l) 339.<br><br>
Dissolve 3-{4-{2-(6-methyl-pyridin-2-y1)-5'6-dinydro"4H'pyrrolo[ '<br>
b]pyrazol-3-ylJ-quinolin-6-yl}-aciyIic acid methyl ester (0.040 g, 0.1 mmol) in<br>
methanol/water (3:1,2 mL). Acid lithium hydroxide (0.010 g, 0.25 mmol) and stir the<br>
mixture 18 h. Remove the solvait then load the residue on a SCX resin column with<br>
methanol. Elute the column with methanol (50 mL) then with 2 N ammonia/methanol<br>
to give the desired product as a pale yellow solid 0.036 g (92%)<br>
MS APCI" m/e 397 (M+l).<br><br>
The compounds disclosed herein were tested by the following protocols for TGF-<br>
P inhibition, as described below in the protocol description. The data collected thereby is<br>
shown below.<br>
TGF-B RECEPTOR I AiND 11 PURIFICATION AND IN VITRO K1NASE<br>
REACTIONS<br>
For TGF-p" Type I (RIT204D) and Type II (RI1 WT) Receptors:<br>
The 6X-H1S tagged cytoplasmic kimase domain of each receptor was expressed and<br>
purified from Sf9 insect cell lysates as briefly described below:<br>
Cell pellets after 48-72 hrs of infection were lysed in lysis buffer (LB: 50 mM Tris<br>
pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5% NP40 with freshly added 20 mM p1-<br>
mercaptoethanol, 10 mM imidazole, 1 mM PMSF, IX EDTA-frce Complete Protease<br>
lnhibitor(Boehringer Mannheim).<br>
Cell lysates were clarified by centrifugation and 045 uM filtered prior to<br>
purification by Ni/NTA affinity chromatography (Qiagen).<br>
Chromatography Protocol:<br>
Equilibrate with 10 CV of LB, load sample, wash with 10 CV RIPA buffer (50<br>
mM Tris pH 7.5, 150 mM NaCl, 1% NP40, lmM EDTA, 0.25% sodium deoxycholate,<br>
added fresh 20 mM p-mercaptoethanol, 1 mM PMSF), wash with 10 CV LB, wash with<br>
10 CV IX KB (50 mM Tris pH 7.5, 150 mM NaCl, 4 mM MgCI2, 1 mM NaF, 2 mM p*-<br>
mercaptoethanol), eiute with a linear gradient of IX KB containing 200 mM lmidazole.<br>
Both enzymes were approximately 90% pure and had autophosphorylation<br>
activity.<br>
Reactions: 170-200 nM enzyme in IX KB, compound dilution series in IX<br>
KB/16% DMSO (20 uM to 1 nM final concentration with 4% OMSO final<br>
concentration), reactions started by adding ATP mix (4 uM ATP/I uCi 33P-D-ATP final<br>
concentrations) in IX KB.<br>
Reactions were incubated at SO °C for 1 hr RIT204D or 40 min for R1I WT.<br>
Reactions were stopped and quantitated using standard TCA/BSA precipitation onto<br><br>
Millipore FB glass fiber filter plates and by liquid scintillation counting on a MicroBeta<br>
JET.<br>
Representative data for compounds of the current invention with the RIT204D<br>
1C50 
 <br><br><br><br><br><br><br>
MV1LU P3TP-LUX ASSAY<br>
A stable MvlLu clone (Ci) containing the p3TP-Lux reporter was created by<br>
standard transfection and puromycin selection protocols. This stable clone was used to<br>
screen the example compounds for their ability to inhibit TGF-p dependent luciferase<br>
production as briefly described below:<br>
1.	Plated Mv 1 Lu C1 cells in Wallac™ Black Isoplates<br>
2.	Allowed cells to adhere overnight.<br>
3.	Removed media and replaced with 0.5% FBS DMEM<br>
media<br>
4.	Added the compound dilution series in 0.5%<br>
FBS/DMEM containing 1% DMSO such that the final compound concentration<br>
ranged from 20 uM to 0.1 nM and the final DMSO concentration was 0.2%.<br>
5.	Incubated at 37°C/5% CO2 for 2 hrs.<br>
6.	Added 0.5% FBS/DMEM as control or TGF-pl diluted<br>
- in 0.5% FBS/DMEM (final concentration of 10 pM) to the -/+ TGF-{3 wells<br>
respectively<br>
7.	Incubated for 16-20 hrs. at 37°C/5% CO2<br>
8.	Removed media and rinsed IX with PBS.<br>
9.	Removed PBS and lysed the cells with IX Passive<br>
Lysis Buffer (Promega) at room temperature.<br>
10.	Counted relative luciferase activity on the<br>
MicroBeta JET by injecting Luciferase Assay Reagent 11 (PROMEGA).<br>
The use of the above assay in measuring TGF-ji responsive activity is described in<br>
Wrana.etal. CeH71: 1003-1014(1992).<br>
Representative data for compounds of the current invention with the p3TP-LUX<br>
1C50 
 <br><br><br><br>
p38otlN VITRO KINASE ASSAY<br>
Active p38a/SAPK2a w»s purchased from Upstate Biotechnology (cat#l4-251).<br>
A known p38oc substrate from EGFR was used in the assay (Young, et al. (1997) JBC<br>
272:12116-12121).<br>
Reactions were performed in IX kinase buffer (25 mM Tris-HCl pH 7.5, 5 mM p-<br>
glycerophosphate, 2 mM DTT,0.1 mM Na3VO4, 10 mM MgCl2, 1 uM Microcystin) with<br>
5 nM p38a, 62.5 uM substrate, 40 uM to 0.2 nM compound dilution series in IX<br>
KB/16% DMSO (final 4% DMSO concentration). Reactions were started by addition of<br>
100 uM ATP (final concentration) with 1 uCi "P-y-ATP in IX KB and incubated at 30°C<br>
for 40 min. Reactions were stopped with HjPO4 and quantitated on Millipore PH<br>
phosphocellulose filter plates by liquid scintillation counting on a MicroBeta JET.<br>
Representative data for compounds of the current invention with the p38a IC50<br><br><br><br><br>
KDR fVEGFR2) PURIFICATION AND IN VITRO K1NASE ASSAY<br>
The 6X-H1S tagged cytopJasmic kinase domain of KDR was expressed and<br>
purified from Sf9 insect cell lysates as described above with the following modification:<br>
IX kinase buffer for chroraiatography washes and elution was changed to 100 mM<br>
HEPES pH 7.5, ] 0 mM MnCl2 and 5 mM P-mercaptoethanol. The resulting material was<br>
approximately 40% pure and had tyrosine autophosphorylation activity.<br>
Reactions: 1 ug enzyme in IX KB, compound dilution series in IX KB/16%<br>
DMSO (20 uM to I nM final concentration with 4% DMSO final concentration),<br>
reactions were started by adding ATP mix (1 uM ATP/1 uCi 33P-D-ATP final<br>
concentrations) in IX KB.<br>
Reactions were incubated at 30°C for 20 min. The reactions were stopped and<br>
quantitated using standard TCA/BSA precipitation onto Millipore FC glass fiber filter<br>
plates and by liquid scintillation counting on a MicroBeta JET.<br>
Representative data for compounds of the current invention with the KDR ICS0<br><br><br><br><br>
Conditions "characterized by enhanced TGF-P activity" include those wherein<br>
TGF-P synthesis is stimulated so that TGF-P is present at increased levels or wherein<br>
TGF-P latent protein is undesirably activated or converted to active TGF-P protein or<br>
wherein TGF-P receptors are uprcgulated or wherein the TGF-P protein shows enhanced<br>
binding to cells or extracellular matrix in the location of the disease. Thus, in either case<br>
"enhanced activity" refers to any condition wherein the biological activity of TGF-p is<br>
undesirably high, regardless of the cause.<br>
A number of diseases haw been associated with TGF-p 1 over production.<br>
Inhibitors of TGF-B intracellular signaling pathway are useful treatments for<br>
fibroproliferative diseases. Specifically, fibroproliferative diseases include kidney<br>
disorders associated with unregulated TGF- 0 activity and excessive fibrosis including<br>
glomerulonephritis (GN), such as nesangial proliferative GN, immune GN, and<br>
crescentic GN. Other renal conditions include diabetic nephropathy, renal interstitial<br>
fibrosis, renal fibrosis in transplant patients receiving cyclosporin, and HIV-associated<br>
nephropathy. Collagen vascular disorders include progressive systemic sclerosis,<br>
polymyositis, scleroderma, dermatomyositis, eosinophilic fascitis, morphea, or those<br>
associated with the occurrence of Raynaud's syndrome. Lung fibroses resulting from<br>
excessive TGF- B activity include adult respiratory distress syndrome, idiopathic<br>
pulmonary fibrosis, and interstitial pulmonary fibrosis often associated with autoimmune<br>
disorders, such as systemic lupus erythematosus and scleroderma, chemical contact, or<br>
allergies. Another autoimmune disorder associated with fibroproliferative characteristics<br>
is rheumatoid arthritis.<br>
Eye diseases associated with a fibroproliferative condition include retinal<br>
reattachment surgery accompanying proliferative vitreoretinopathy, cataract extraction<br>
with intraocular lens implantation, and post glaucoma drainage surgery are associated<br>
with TGF-P 1 overproduction.<br><br>
Fibrotic diseases associated with TGF-|3l overproduction can be divided into<br>
chronic conditions such as fibrosis of the kidney, lung and liver and more acute<br>
conditions such as dermal scarring and restenosis (Chamberlain, J. Cardiovascular Drug<br>
Reviews, J9(4):329-344). Synthesis and secretion of TGF-pi by tumor cells can also<br>
lead to immune suppression such as seen in patients with aggressive brain or breast<br>
tumors (Arteaga, et al. (1993) J. Oin. Invest. 92:2569-2576). The course of Leishmanial<br>
infection in mice is drastically altered by TGF-pl (Barral-Netto, et al. (1992) Science<br>
257:545-547). TGF-pl exacerbated the disease, whereas TGF-pM antibodies halted the<br>
progression of the disease in genetically susceptible mice. Genetically resistant mice<br>
became susceptible to Leishmanial infection upon administration of TGF-pM.<br>
The profound effects of TGF-fJl on extracellular matrix deposition have been<br>
reviewed (Rocco and Ziyadeh (1991) in Contemporary Issues in Nephrology v.23,<br>
Hormones, autocoids and the kidney, ed. Jay Stein, Churchill Livingston, New York<br>
pp.391-410; Roberts, et al. (1988) Rec. Prog. Hormone Res. 44:157-197) and include the<br>
stimulation of the synthesis and the inhibition of degradation of extracellular matrix<br>
components. Since the structure and filtration properties of the glomerulus are largely<br>
determined by the extracellular matrix composition of the mesangium and glomerular<br>
membrane, it is not surprising that TGF-Pl has profound effects on the kidney. The<br>
accumulation of mesangial matrix in proliferative glomerulonephritis (Border, et al.<br>
(1990) Kidney Int. 37:689-695) and diabetic nephropathy (Mauer, et al. (1984) J. Clin.<br>
Invest. 74:1143-1155) are clear and dominant pathological features of the diseases. TGF-<br>
PI levels are elevated in human diabetic glomerulosclerosis (advanced neuropathy)<br>
(Yamamoto, et al. (1993) Proc.Nati.Acad. Sci. 90:1814-1818). TGF-pl is an important<br>
mediator in the genesis of renal fibrosis in a number of animal models (Phan, et al. (1990)<br>
Kidney Int. 37:426; Okuda, et al. (1990) J. Clin. Invest. 86:453). Suppression of<br>
experimentally induced glomerulonephritis in rats has been demonstrated by antiserum<br>
against TGF-fJl (Border, et al. (1990) Nature 346:371) and by an extracellular matrix<br>
protein, decorin, which can bindTGF-|Jl (Border, et al. (1992) Nature 360:361-363).<br>
Too much TGF-p*l leads to dermal scar-tissue formation. Neutralizing TGF-pl<br>
antibodies injected into the margins of healing wounds in rats have been shown to inhibit<br>
scarring without interfering with the rate of wound healing or the tensile strength of the<br><br>
wound (Shah, et al. (1992) Lancet 339:213-214). At the same time there was reduced<br>
angiogenesis, reduced number of macrophages and monocytes in the wound, and a<br>
reduced amount of disorganized collagen fiber deposition in the scar tissue.<br>
TGF-pl may be a factor in he progressive thickening of the arterial wall which<br>
results from the proliferation of smooth muscle cells and deposition of extracellular<br>
matrix in the artery after balloon angioplasty. The diameter of the restenosed artery may<br>
be reduced 90% by this thickening, and since most of the reduction in diameter is due to<br>
extracellular matrix rather than smooth muscle cell bodies, it may be possible to open<br>
these vessels to 50% simply by reducing extensive extracellular matrix deposition. In<br>
uninjured pig arteries transfected in vivo with a TGF-01 gene, TGF-p*l gene expression<br>
was associated with both extracellular matrix synthesis and hyperplasia (Nabel, et al.<br>
(1993) Proc. Natl. Acad. Sci. USA «&gt;0:10759-10763). The TGF-J31 induced hyperplasia<br>
was not as extensive as that induced with PDGF-BB, but the extracellular matrix was<br>
more extensive with TGF-Pl transfectants. No extracellular matrix deposition was<br>
associated with FGF-1 (a secreted form of FGF) induced hyperplasia in this gene transfer<br>
pig model (Nabel (1993) Nature 362:844-846).<br>
There are several types of cancer where TGF-pi produced by the tumor may be<br>
deleterious. MATLyLu rat prostate cancer cells (Steiner and Barrack (1992) Mol.<br>
Endocrinol 6:15-25) and MCF-7 human breast cancer cells (Arteaga, et al. (1993) Cell<br>
Growth and Differ. 4:193-201) became more tumorigenic and metastatic after<br>
transfection with a vector expressing the mouse TGF-pi. TGF-p* 1 has been associated<br>
» with angiogenesis, metastasis and poor prognosis in human prostate and advanced gastric<br>
cancer (Wikstrom, P., et al. (1998) Prostate 37: 19-29; Saito, H. et al. (1999) Cancer 86:<br>
1455-1462). Jn breast cancer, poor prognosis is associated with elevated TGF-p*<br>
(Diclcson, et al. (1987) Proc. Natl. Acad. Sci. USA 84:837-841; Kasid, et al. (1987)<br>
Cancer Res. 47:5733-5738; Daly, et al. (1990) J. Cell Biochem. 43:199-211; Barrett-Lee,<br>
et al. (1990) Br. J Cancer 61:612-617; King, et al. (1989) J. Steroid Biochem. 34:133-138;<br>
Welch, et al. (1990) Proc. Natl. Acad. Sci. USA 87:7678-7682; Walker, et al. (1992) Eur.<br>
J. Cancer 238:641-644) and induction of TGF-p*l by tamoxifen treatment (Butta, et al.<br>
(1992) Cancer Res. 52:4261-4264) has been associated with failure of tamoxifen<br>
treatment for breast cancer (Thompson, et al. (1991) Br. J. Cancer 63:609-614). Ami<br><br>
TGF-P 1 antibodies inhibit the growth of MDA-231 human breast cancer cells in athymic<br>
mice (Arteaga, et al. (1993) J. Clin. Invest. 92:2569-2576), a treatment which is<br>
correlated with an increase in spleen natural killer cell activity. CHO cells transfected<br>
with latent TGF-P 1 also showed decreased NK activity and increased tumor growth in<br>
nude mice (Wallick, et al. (1990) J. Exp. Mcd. 172:1777-1784). Thus, TGF-P secreted by<br>
breast tumors may cause an endocrine immune suppression. High plasma concentrations<br>
of TGF-P 1 have been shown to indicate poor prognosis for advanced breast cancer<br>
patients (Anscher, et al. (1993) N. Engl. J. Med. 328:1592-1598). Patients with high<br>
circulating TGF-P before high dose chemotherapy and autologous bone marrow<br>
transplantation are at high risk for hepatic veno-occlusive disease (15-50% of all patients<br>
with a mortality rate up to 50%) and idiopathic interstitial pneumonitis (40-60% of all<br>
patients). The implication of these findings is 1) that elevated plasma levels of TGF-p*1<br>
can be used to identify at risk patients and 2) that reduction of TGF-P 1 could decrease the<br>
morbidity and mortality of these common treatments for breast cancer patients.<br>
Many malignant cells secrete transforming growth factor-P (TGF-p), a potent<br>
immunosuppressant, suggesting than TGF-P production may represent a significant tumor<br>
escape mechanism from host immunosurvcillance. Establishment of a leukocyte sub-<br>
population with disrupted TGF-P signaling in the tumor-bearing host offers a potential<br>
means for immunotherapy of cancel. A transgenic animal model with disrupted TGF-P<br>
signaling in T cells is capable of eradicating a normally lethal TGF-P overexpressing<br>
lymphoma tumor, EL4 (Gorelik and Flavell, (2001) Nature Medicine 7(10): 1118-1122).<br>
Down regulation of TGF-P secretion in tumor cells results in restoration of<br>
immunogenicity in the host, while 1 -cell insensitivity to TGF-P results in accelerated<br>
differentiation and autoimmunity, elements of which may be required in order to combat<br>
self-antigen-expressing tumors in a (olerized host. The immunosuppressive effects of<br>
TGF-p have also been implicated in a subpopulation of HIV patients with lower than<br>
predicted immune response based on their CD4/CD8 T cell counts (Garba, et al. J.<br>
Immunology (2002) 168: 2247-2254). A TGF-p neutralizing antibody was capable of<br>
reversing the effect in culture, indicating that TGF-P signaling inhibitors may have utility<br>
in reversing the immune suppression present in this subset of HIV patients.<br><br>
During the earliest stages ofcarcinogenesis, TGF-pi can act as a potent tumor<br>
suppressor and may mediate the actions of some chemopreventive agents. However, at<br>
some point during the development and progression of malignant neoplasms, tumor cells<br>
appear to escape from TGF-P-depeifident growth inhibition in parallel with the appearance<br>
of bioactive TGF-P in the microenvironment. The dual tumor suppression/tumor<br>
promotion roles of TGF-p have been most clearly elucidated in a transgenic system<br>
overexpressing TGF-P in keratinocytes. While the transgenics were more resisitant to<br>
formation of benign skin lesions, the rate of metastatic conversion in the transgenics was<br>
dramatically increased (Cui, et al (1996) Cell 86(4):531 -42). The production of TGF-p 1<br>
by malignant cells in primary tumors appears to increase with advancing stages of tumor<br>
progression. Studies in many of the major epithelial cancers suggest that the increased<br>
production of TGF-P by human cancers occurs as a relatively late event during tumor<br>
progression. Further, this tumor-associated TGF-P provides the tumor cells with a<br>
selective advantage and promotes tumor progression. The effects of TGF-P on cell/cell<br>
and cell/stroma interactions result in a greater propensity for invasion and metastasis.<br>
Tumor-associated TGF-p may allow tumor cells to escape from immune surveillance<br>
since it is a potent inhibitor of the clonal expansion of activated lymphocytes. TGF-P has<br>
also been shown to inhibit the production of angiostatin. Cancer therapeutic modalities<br>
such as radiation therapy and chemotherapy induce the production of activated TGF-P in<br>
the tumor, thereby selecting outgrowth of malignant cells that are resistant to TGF-p<br>
growth inhibitory effects. Thus, these anticancer treatments increase the risk and hasten<br>
the development of tumors with enhanced growth and invasiveness. In this situation,<br>
agents targeting TGF-p-mediated signal transduction might be a very effective<br>
therapeutic strategy. The resistance of tumor cells to TGF-P has been shown to negate<br>
much of the cytotoxic effects of radiation therapy and chemotherapy and the treatment-<br>
dependent activation of TGF-P in the stroma may even be detrimental as it can make the<br>
microenvironment more conducive to tumor progression and contributes to tissue damage<br>
leading to fibrosis. The development of a TGF-P signal transduction inhibitors is likely<br>
to benefit the treatment of progressed cancer alone and in combination with other<br>
therapies.<br><br>
be administered and the choice of route of administration and therefore the above<br>
preferred dosage range is not intended to limit the scope of the present invention in any<br>
way.<br>
The formulations useful for separate administration of the TGF-p* antagonists will<br>
normally consist of at least one compound selected from the compounds specified herein<br>
mixed with a carrier, or diluted by a carrier, or enclosed or encapsulated by an ingestible<br>
carrier in the form of a capsule, sachet, cachet, paper or other container or by a disposable<br>
container such as an ampoule. A carrier or diluent may be a solid, semi-solid or liquid<br>
material which serves as a vehicle, excipient or medium for the active therapeutic<br>
substance. Some examples of the diluents or carrier which may be employed in the<br>
pharmaceutical compositions of the present invention are lactose, dextrose, sucrose,<br>
sorbitol, mannitol, propylene glycol, liquid paraffin, white soft paraffin, kaolin, fumed<br>
silicon dioxide, microcrystalline cellulose, calcium silicate, silica, polyvinylpyrrolidone,<br>
cetostearyl alcohol, starch, modified starches, gun acacia, calcium phosphate, cocoa<br>
butter, ethoxylated esters, oil of theobroma, arachis oil, alginates, tragacanth, gelatin,<br>
syrup, methyl cellulose, polyoxyethylene sorbitan monolaurate, ethyl lactate, methyl and<br>
propyl hydroxybenzoate, sorbitan trioleate, sorbitan sesquioleate and oleyl alcohol and<br>
propel Ian ts such as trichloromonofluoromethane, dichlorodifluoromethane and<br>
dichlorotetrafluoroethane. In the case of tablets, a lubricant may be incorporated to<br>
prevent sticking and binding of the powdered ingredients in the dies and on the punch of<br>
the tableting machine. For such purpose there may be employed for instance aluminum,<br>
magnesium or calcium stearates,tele or mineral oil.<br>
Preferred pharmaceutical forms of the present invention are capsules, tablets,<br>
suppositories, injectable solutions, creams and ointments. Especially preferred are<br>
formulations for inhalation application, such as an aerosol, for injection, and for oral<br>
ingestion.<br><br><br><br>
trifluoromethyl, halo, trifluoromethoxy, hydroxymethyl, N-pyrrolidino, N-morpholino,<br>
phenylthio, (Cl-C4)dialkylaminomelhyl, methoxyphenyl, amino, hydroxy, carboxyl,<br>
phenyl, arylalky;<br>
R2 is unsubstituted or substituted quinolinc; unsbustitutcd OR.substituted quinoline<br>
N-oxide; unsbustituted or substituted phenyl; unsubstituted or substituted naphthalene;<br>
r<br>
unsubstituted or substituted pyridine; unsubstituted or substituted pyridine N-oxide;<br>
unsbustituted or substituted quinazoline; unsubstituted or substituted cinholine;<br>
unsubstituted or substituted benzodioxole; unsbustituted or substituted benzodioxane;<br>
unsubstituted or substituted pyrimid ne; unsubstituted or substituted benzothiophene; or<br>
unsubstituted or substituted phenantforolene; wherein the substitution may independently<br>
be one or more of the following: hydrogen, (Cl-C6)alkyl, (C2-C6)alkenyl, (C2-<br>
C6)alkynyl, (C1-C6) alkylhalide, (C 1-C6)alkoxy, (C2-C6)alkenyloxy, (C2-<br>
C6)alkynyloxy, (Cl-C6)alkylthio, (Cl-C6)alkylsulphinyl, (Cl-C6)alkylsulphonyl, (Cl-<br>
C6&gt;lkylamino, di-((Cl -C6)alkyl)ainino, (C! -C6)alkoxycarbonyl, N-(C 1 -<br>
C6)alkylcarbamoyl, N,N-di-((Cl-C5)aIkyl]carbamoyl, aminooxy, N-(C 1 -C6)alkyl<br>
aminooxy, N,N-di-((Cl-C6)alkyl]aminooxy, (C2-C6)alkanoyl, (C2-C6)alkanoyloxy,<br>
(C2-C6)alkanoylamino,N-(Cl-C6)alkyl-(C2-C6)alkanoylamino, (C3.C6)alkenoylamino,<br>
N-(C1-C6)alkyl-(C3-C6)alkenoylarnino, (C3-C6)alkynoylamino, N-(C1 -C6)alkyl-(C3-<br>
C6)alkynoylamino, sulphamoyl,N.(Cl-C6)alkylsulphamoyl, N,N-di-((Cl-<br>
C6)alkyl}sulphamoyl,(Cl-C6)a1kanesulphonylaniino,N-(Cl-C6)alkyl.(Cl-<br>
C6)alkanesulphonylamino, carboxumide, ethylene, phenyl, thiophenyl, aminophenyl,<br>
phenylthio, halo, cyano, pyridinyl, arylalkyl, hydroxy, N-pyrrolidino, N-morpholino,<br>
carboxyl, (5&gt;phenyM,2,4-oxadiazole-3-yl]methoxy, 6-methyl-pyridazin-3-yloxy, (5-oxo-<br>
2-pyrrolidinyl)methoxy, 2-(4,5-dihydro-lH-imidazolyl),N, N-dialkylcarbamoyloxy, 1-<br>
hydroxy-1-methylethyl, 4-fluorophenyl, 3,4-rnethylenedioxyphenyl, trifluoromethyl,<br>
trifluoromethoxy,<br><br><br>
wherein: X| is 0, N, S, SO^NRu, 0(0), or bond; Q( is hydrogen, phenyl, 5-
difluoro-1,3-benzodioxolyl), C(OXJs&gt; or pyridyl when, except when one is 0 the other<br>
cannot be 0 are independently 0-2; Qi is ORn, NR11R12, halo, N-morpholino, N-<br>
pipcrazino-N'R, j, N-imidazolyl, N pyrazolyl, N-triazolyi, N-(4-pipcridinylpiperidine),<br>
SO2R14, SORM, NHSO2R15, acetamido, N-phthalimido, N-oxazolidino, N-imidazolino, N-<br>
benzoxazolidino, N-pyrolidinonyl, N(N'-mcthylbenzimidazolino), N,N-di(CI-<br>
C4)alkylamino(Cl-C4)alkoxy, N-benzimidazolino; when m and n are independently 0-2,<br>
but one or the other of m or n is not 0; Q} is hydroxy, methoxy, amino, diethylamino,<br>
dimcthylamino; Rt0 is hydrogen, halo, (Cl-C6)alkyl; Ru and R12 are independently<br>
hydrogen, (Cl-C6)alkyl, (Cl-C6)alkoxy, arylalkyl, (C3-C8)cycloalkyl, (C3-<br>
C8)cycloalkylmethyl, 4-(N-methylpipcridinyi), pyndyl, or Rn and R,o can be taken<br>
together to form a 4,5,6, or 7 mernbered ring, or Rn and R12 can be taken together to<br>
form a 3,4, 5,6, or 7 membered ring; Ru is hydrogen, (Cl-C6)alkyl, 2-melhoxyphenyl,<br>
2-pyridimidinyl; Ru is 2-pyrimidinyl, N-methyl-2-imidazolyt, 4-chlorophenyl, 2-<br>
pyridylmethyl; R,$ is (Cl-C6)alkyl, N-methyl-4-imidazolyl; R|6 is hydrogen, halo,<br>
arylalkyl, aryl,<br><br><br>
wherein: Q2 is hydrogen, 4-imidai:o)yl, or C(O)NR24R25 when o and p are independently<br>
0-2; Q2 is OR23, NR24R25, or N-roorpholino, when o and p are independently 0-2, but one<br>
or the other of o or p is not 0; Rjo is hydrogen, or (C1 -C6)alkyl; R2| is hydrogen, (Cl -<br>
C6)alkyl, or R2| and R2o can be taken together 10 form a 4, 5,6, or 7 membered ring; R22<br>
is hydrogen, (Cl-C6)alkyl, arylalkyl, aryl, or RJI and R22 can be taken together to be a 3,<br>
4, 5,6, 7 membered ring; R23 is hydrogen or (CJ-C6)alkyl; R24 is hydrogen, (Cl-<br>
C6)alkyl, or R2A and R2$ can be taken together to form a 3, 4, 5, 6, or 7 membered ring, or<br>
R24 and Rj0 can be taken together to form a 6 or 7 membered ring; R» is hydrogen, (C1 -<br>
C6)alkyl, or acetyl,<br><br><br><br>
wherein: R32 and R33 are each independently hydrogen, (Cl-C6)alkyl, acetyl, (Cl-<br>
C4)alkylsulphonyl, or R32 and R33 can be taken together to form a 4, 5, 6, or 7 membercd<br>
ring,<br>
or a group of the formula<br><br>
wherein: X2 is CH2, O, or N; q is 2-3 except when Qj is a bond, q is 0-3; Q3 is NR3«,R37l<br>
or OR.™, and RM is hydrogen, or Rj? and Q3 can be taken together to form a 5 membercd<br>
ring; R36, R37, and R3» are each independently hydrogen, or (Cl-C6)aJkyl,<br>
or a group of the formula<br><br>
wherein: X3 \$ cyano, carboxamide, N,N-dimethylcarboxamide, N,N-<br>
dimethylthiocarboxamide, N.N-dimethylaminomethyl, 4-methylpiperazin-lyl-methyl or<br>
carboxylate,<br><br><br>
wherein: Q6 is NR^R*,; r is 2-3; F4o is hydrogen, or (Cl-
hydrogen, (Cl-C6)alkyl, or R*, and R40 can be taken together to form a 6 or 7 membered<br>
ring,<br><br>
wherein: Ch is hydroxy, methoxy, dimethylamino, or N-piperidiny);<br>
with the proviso that when one of Rl or R2 is unsubtituted or substituted phenyl, then<br>
the other cannot be unsubstituted or substituted phenyl or thiophen-2-yl; and with the<br>
proviso that when R2 is quinolin-4-yl, substitution at the quinoline 7-position cannot<br>
include an aryl, heieroaryl, fused aryl, or fused heteroaryl;<br>
k is 1-8; R3 is one or more of the following: hydrogen; (Cl-C4&gt;lkyl; (Cl-<br>
C4)aJkylhydroxy;hydroxy;N,N-di(Cl-C4)alkylamino(C1-C4)alkoxv;benryloxvmethyl;<br>
phenyloxymethyl; oxo; carboxyi; [C\-C4) alkylaryl; benzyloxy; acetaxy; amino(CI-<br>
C4)alkyl; (C2-C4&gt;lkenyl; halo; -O-(C1-C4)alkyl; chlorophenethyl; acetonitrile;<br>
unsubsituted or substituted phenyl; wherein the substitution may be one or more of the<br>
following: (Cl -C6)alkoxy, halo, carboxy, or (C1 -C6)alkoxycarbonyl; and the<br>
pharmaceutically acceptable salts esters and prodrugs thereof.<br><br><br>
is a five or six membered saturated ring;<br>
R1 is defined as in Claim I;<br>
R21 is hydrogen; (C1-C6)dkyl; (Cl-C6)alkylthio; (Cl-C6)alkoxy; halo;<br>
thiophenyl; aminophenyl; N-pynolidino; N-morpholino;<br>
R6' and R7' are independently one or more of the following: hydrogen, (Cl-<br>
C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (CI-C6) alkylhalide, (Cl-C6)alkoxy, (C2-<br>
C6)alkenyloxy, (C2-C6)alkynykiKy»(Cl-C6)alkylthio, (Cl-C6)alkylsulphinyl, (Cl-<br>
C6)alkylsulphonyt, (C)-C6)alkyi«nino, di-[(Cl-C6)alkyl]amino, (Cl -<br>
C6)alkoxycarbonyl, N-(C1 -C6&gt;*ylcarbamoyJ, N,N-di-[(C1 -C6)alkyl]carbamoyl,<br>
aminooxy, N-(C1-C6)alkyl ammooxy, N,N-di-[(Cl-C6)alkyl]aminooxy, (C2-<br>
C6)alkanoyt, (C2-C6)alkanoyl
C6)alkanoy1amino, (C3-C6)alkeMoylamino, N-(C1-C6)alkyl-(C3-C6)alkenoylamino, (C3-<br>
C6)alkvnoylamino, N-(C1-C6)alkyl-(C3-C6)alkynoylamino, sulphamoyl, N-(CI-<br><br>
C6&gt;lkylsulphamoyl, N,N-di-[(Cl-C6)a!ky)]su]priamoyl, (Cl -C6)alkanesulphonylamim<br>
N-(C1-C6)alkyl-(CI-C6)alkanesulphonylamino, carboxamidc, ethylene, phcnyl,<br>
ihiophcnyl, aminophenyl, phenylthio, halo, cyano, pyridinyl, arylalkyl, hydroxy, N-<br>
pynrolidino, N-morpholino, carboxyl, [5-phenyl-l,2,4-oxadiazolc-3-yl]methoxy, 6-<br>
methyl-pyridazin-3-yloxy, (5-oxo-:i-pyrrolidinyl)methoxy, 2-(4,5-dihydro-l H-<br>
imidazolyl), N, N-dialkykarbamoyloxy, 1 -hydroxy- l-mcihylethyl, 4-fluorophenyi, 3,4-<br>
methylenedioxyphenyt, trifluoromcthyl, trifluoromethoxy,<br>
or a group of the formula<br><br>
wherein: X| is O, N, S, SO^NRu, 0(0), or bond; Qi is hydrogen, phenyl, 5-(2,2-<br>
dif1uoro-l,3-benzodioxolyl), C(OX!s, or pyridyl when m and n are independently 0-2,<br>
except when one is 0 the other cannot be 0; Qi is ORn, NRnR,j, halo, N-morpholino,<br>
N-pipera2ino-N'Ru, N-imidazolyl, N-pyrazolyl, N-triazolyl, N-(4-piperidinylpiperidine),<br>
SO^Ru, SOR|4, NHSO]R|}, acetamido, N-phthalimido, N-oxazolidino, N-imidazolino, N-<br>
benzoxazolidino, N-pyrolidinonyl, N(N'-methylbenzimidazolino), N,N-di(Cl-<br>
C4)alkylamino(CI-C4)alkoxy, N-benzimidazolino; when m and n are independently 0-2,<br>
but one or the other of m or n is not 0; Qi is hydroxy, methoxy, amino, diethylamino,<br>
dimethylamino; Rio is hydrogen, halo, (Cl-C6)alkyl; Ru and R12 are independently<br>
hydrogen, (Cl-C6&gt;lkyl, (Cl-C6)alkoxy, arylalkyl, cycloalkyl, cycloalkylmethyl, 4-(N-<br>
methylpiperidinyl), pyridyl, or Ru and Rio can be taken together to form a 4, 5,6, or 7<br>
membered ring, or Ru and Ru can be taken together to form a 3,4, 5,6, or 7 membered<br>
ring; Ru is hydrogen, (Cl-C6)alkyl 1, 2-methoxyphenyl; Rl4 is 2-pyrimidtnyl, N-mcthyl-2-<br>
imidazolyl, 4-chlorophenyl, 2-pyriclylmethyl; RtJ is (Cl-C6)alkyl, N-methyl-4-<br>
imidazolyl; Rl6 is hydrogen, halo, *rylalkyl, aryl,<br><br><br>
wherein: Q2 is hydrogen, 4-imidazoJyl, or C(O)NR24R25 when o and p are independently<br>
0-2; Q2 is ORj3, NR24R25, or N-moipholino, when o and p are independently 0-2, but one<br>
or the other of o or p is not 0; R20 i«i hydrogen, or (Cl -C6)alkyl; Rj( is hydrogen, (CI-<br>
C6)a!kyl, or R2) and R20 can be taken together to form a 4, 5,6, or 7 membered ring; R22<br>
is hydrogen, (Cl«C6)alkyl, arylalkyl, aryl, or R21 and R22 can be taken together to be a 3,<br>
4, 5,6, 7 membered ring; R2J is hydrogen or (Cl-C6)alkyl; R*» is hydrogen, (Cl-<br>
C6)alkyl, or R24 and R2S can be taken together to form a 3,4,5,6, or 7 membered ring, or<br>
RM and R» can be taken together to form a 6 or 7 membered ring; R2$ is hydrogen, (Cl-<br>
C6)alky], or acetyl,<br><br><br><br>
wherein: Rw and R33 are each independently hydrogen, (Cl-C6)alkyl, acetyl,<br>
alkylsulphonyl, or R32 and R33 can be token together to form a 4,5,6, or 7 membered<br>
ring,<br><br>
wherein: X2 is CH2,0, or N; q is 2-3 except when Qj is a bond, q is 0-3; Q3 is NR^^,<br>
OR3», or a bond; R3S is hydrogen, or R3J and Q3 (when Q3 is a bond) can be taken<br>
together to form a 5 membered ring; Rw, R3?, and RM are each independently hydrogen,<br>
or (Cl-C6)alkyl,<br>
or a group of the formula<br><br>
wherein: X3 is cyano, carboxamide, N,N-dimeihylcarboxamide, N,N-<br>
dimethylthiocarboxamide, N,N-dimcthylaminomethyl, 4-mcthylpiperazin-lyl-methyl or<br>
carboxylate,<br><br><br>
wherein: Q6 is NR«,R«; r is 2-3; R* is hydrogen, or (Cl-C6)alkyl; R41 and R42are<br>
hydrogen, (Cl-C6)alkyl, or R41 and R40 can be taken together to form a 6 or 7 membered<br>
ring,<br><br>
wherein: Q7 is hydroxy, methoxy, or N-piperidinyl;<br>
k is I -8; R3 is one or mott of the following: hydrogen; (C1-C4) alkyl; (C1-C4)<br>
alkylhydroxy; hydroxy; N,N-di(Cl-C4)alkylamino(Cl-C4)alkoxy; benzyl oxymcthyl;<br>
phcnyloxymethyl; oxo; carboxyl;(Cl-C4) alkylaryl; benzyloxy; acetoxy; amino(Cl-<br>
C4)alkyl; (C2-C4) alkenyl; halo; -0-(CI-C4) alkyl; chiorophenethyl; acetonitrile; phenyl;<br>
or an optionally substituted phenyl; wherein the substitution may be one or more of the<br>
following: (CI -C6)alkoxy, halo, carboxy, or (C1 -C6)alkoxycarbonyl;<br>
with the proviso that R7' cannot be aryl; heteroaryl; fused aryl; or fused heteroaryl.<br>
and the pharmaceutically acceptable salts, esters and prodrugs thereof.<br><br><br><br><br>
is a five or six membered ring;<br>
R6 may be one or more of the following: hydrogen, (Cl-C6)alkyl, (C2-<br>
C6)alkenyl, (C2-C6)alkynyl, (Cl-C6)*lkoxy, (C2-C6)alkenyloxy, (C2-C6)alkynyloxy&gt;<br>
(C1 •C6)a!kylthio, (C1 -C6)alkylsulphii iyl, (C1 -C6)alkylsulphonyl, (C1 -C6)alkylamino,<br>
di-[(Cl-C6)alkyl]amino, (Cl-C6&gt;lko&gt;;ycarbonyl, N-(C1-C6&gt;lkylcarbamoyl, N,N-di-<br>
[(CI-C6)alkyl]carbamoyl, (C2-C6)alkanoyJ, (C2-C6)alkanoyk&gt;xy, (C2-<br>
C6)alkanoylamino, N-(C1-C6)alkyl-(C2-C6)alkanoylamino, (C3-C6)alkenoy)amino, N-<br>
(Cl -C6)alkyl-(C3-C6)alkenoylammo, :C3-C6)alkynoylamino, N-(C1 -C6)alkyl-(C3-<br>
C6)alkynoylamino, N-(C1-C6)alkylsulphamoyl, N,N-di-[(Cl-C6)alkyl]sulphamoyl, (Cl-<br>
C6]alkanesulphonylamino, N-(C1-C6)ulkyl-(C]-C6)alkanesulphonylamino, carboxamide,<br>
ethylene, thiophenyl, aminophenyt tri fluoromethyl, halo, trifluoromethoxy,<br>
hydroxymclhyl, N-pyrrolidino, N-morftholino, phenylthio, dialkylaminomcthyl,<br>
methoxyphenyl, amino, hydroxy, carboxyl, phenyl, arylalky,<br>
R2" is unsubstituted or substituted quinoline-8-yl; unsubstinited or substituted<br>
quinoline-6-yl; unsubsiituted or substituted 1-naphthyl; unsubstituted or substituted 2-<br>
naphthy); unsubsiituted or substituted 3,4-methylenedioxyphenyl; unsbustituted or<br>
substituted 3,4-cthylcncdioxyphenyl; unsubstituted or substituted benzolhiophen-2-yl;<br><br>
wherein the substitution may independently be one or more of the following: (CI -<br>
C6)alkyl, (C2-C6)alkenyl, (C2-C6)»lkynyl, (CI-C6) alkylhalide, (Cl-C6)alkoxy, (C2-<br>
C6)alkenyloxy, (C2-C6)alkyny!oxy, (CI-C6)aJkylthio, (C1-C6)alkylsulphinyl, (Cl-<br>
C6)alkylsulphonyl, (Cl-C6)alkylaiwno, di-{(Cl-C6)alkyl]amino, (Cl-<br>
C6)alkoxycarbonyl, N-(C1 -C6)alkylcarbamoyl, N,N-di-[(Cl -C6)alkyl]carbamoyl,<br>
aminooxy, N-(C1 -C6)alkyl aminooay, N,N-di-((CI -C6)alkyl)amindoxy, (C2-<br>
C6)alkanoyl, (C2-C6)a]kanoy]oxy, iC2-C6)alkanoyJamino, N-(CI-C6)alkyl-(C2-<br>
C6)a1kanoylamino, (C3-C6)alkenoylamino, N~(Cl-C6)alkyl-(C3-C6)alkenoylamino, (C3-<br>
C6)alkynoylamino, N-(C1-C6)alkyl-(C3-C6)alkynoylaniino, sulphamoyl, N-(C1-<br>
C6)a!kylsulphamoyl, N,N-di-[(Cl-C6)alkyl]sulphamoyl, (Cl-C6)alkanesulphonylamino,<br>
N-<cl-c6 carboxamide ethylene phenyl></cl-c6>
thiophenyl, aminophenyl, phenylthw, halo, cyano, pyridinyl, arylalkyl, hydroxy, N-<br>
pyrrolidino, N-morpholino, carboxyl, [5-phenyl-l,2,4-oxadiazole-3-yl]methoxy, 6-<br>
methyl-pyrida2in-3-yloxy, (5-oxo-2 -pyrrolidinyl)methoxy, 2-(4,5-dihydro-l H-<br>
imidazolyl), N, N-dialkylcarbamoyloxy, 1 -hydroxy-1-methylethyl, 4-fluorophenyl, 3,4-<br>
methylenedioxyphenyl, trifluoromethyl, trifluoromethoxy,<br>
or a group of the formula<br><br>
wherein: Xf is O, N, S, SO2.NRn, C(O), or bond; Qi is hydrogen, phenyl, 5-(2,2-<br>
difluoro-l,3-benzodioxolyl), C(O)Q.i, or pyridyl when m and n are independently 0-2,<br>
except when one is 0 the other cannot be 0; Qi is ORM, NR,,R|2, halo, N-morpholino,<br>
N-piperazino-N'Ri3, N-imidazolyl, N-pyra2olyl, N-triazolyl, N-(4-piperidinylpipcridine),<br>
SO3R14, SORM, NHSOJRIJ, acetamido, N-phtbalimido, N-oxa2olidino, N-imidazolino, N-<br>
benzoxazolidino, N-pyrolidinonyl, N(N*-methylbenzimidazolino), N,N-di(CI-<br><br>
C4)alkylamino(Cl-C4)alkoxy, N-benzimidazolino; when m and n are independently 0-2,<br>
but one or the other of m or n is not 0; Qs is hydroxy, methoxy, amino, diethylamino,<br>
dimethylamino; R,o is hydrogen, halo, (Cl-C6)alkyl; Ru and R,2 are independently<br>
hydrogen, (Cl-C6)alkyl, (C1-C6&gt;alkoxy, arylalkyl, cycloalkyl, cycloalkylmethyl, 4-(N-<br>
methylpiperidinyl), pyridyl, or Ru and R10 can be taken together to form a 4,5,6, or 7<br>
membered ring, or R, \ and Ru am be taken together to form a 3,4, 5,6, or 7 membered<br>
ring; Ru is hydrogen, (Cl-C6)alkyl, 2-methoxyphenyl; R)4 is 2-pyrimidinyl, N-mcthyl-2-<br>
imidazolyl, 4-chlorophenyl; 2-pyridylmethyl; R15 is (Cl-C6)alkyl, N-methyl-4-<br>
imidazolyl; R!6 is hydrogen, halo, arylalkyl, aryl,<br><br>
wherein: Qi is hydrogen, 4-imidazolyl, or C(O)NRj4Rj5 when o and p arc independently<br>
0-2; Q3 is OR2J, NR24R2S, or N-niorpholino, when o and p arc independently 0-2, but one<br>
or the other of o or p is not 0; R^ is hydrogen, or (Cl-C6)alkyl; R2) is hydrogen, (C1-<br>
C6)alkyl, or R2i and R30 can be taken together to form a 4, S, 6, or 7 membered ring; R22<br>
is hydrogen, (Cl-C6)alkyl, arylaikyl, aryl, or R21 and R22 can be taken together to be a 3,<br>
4,5,6,7 membered ring; R2? is hydrogen or (CI -C6)alkyl; R24 is hydrogen, (C1 -<br>
C6)alkyl, or R24 and R2j can be taken together to form a 3,4, 5,6, or 7 membered ring, or<br>
R24 and R20 can be taken together to form a 6 or 7 membered ring; R2J is hydrogen, (Cl-<br>
C6)alkyi, or acetyl,<br><br><br><br><br><br>
5. A compound as claimed in claim 1, wherein the compound is selected from the<br>
group comprising:<br>
a)	6-Bromo-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-3-yl)-<br>
quinoline,<br>
b)	3-Pyridin-4-yl-2-pyridin-2-yl-5,6-djhydro-4H-pyiTOlo[ 1,2-b]pyrazole,<br>
c)	2-(6-Mcthyl-pyridin-2«yl)-3-p-tolyl-5,6-dihydro-4H-pyrrolo[I,2-<br>
bjpyrazole,<br>
d)	4-[3-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pym&gt;lo[ 1 ,2-b]pyrazol-2-yl]-<br>
quinolinc,<br>
e)	2-(6-Methy!-pyr»din-2-yl&gt;3-naphthalen-l-yI-5,6-dihydro-4H-pyrTolo[l,2-<br>
b]pyrazolc,<br>
f)	2-(6-Mcthy]-pyndin-2-yl)-3-pyridin-3-yl-5t6-dihydro-4H-pyrTolo[ 1,2-<br>
b]pyrazole,<br>
g)	3-(4-FIuoro-naplithalcn-1 -yl)-2-(6-methyl-pyridm-2-yl)-5,6-dihydro-4H-<br>
pyrTolo[ 1,2-b3pyrazole,<br>
h) 3-(3,4-Difluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazolc,<br>
i) 1 -(2-
cth yl ideneaminoj-pyrrol id in-2n)ne,<br>
j) 7-Meihoxy-4-
quinolinc,<br>
k) 7-Bcn2yloxy-6-rncthoxy-4-
b]pyra2ol-3-yl)-quinoline,<br>
I) 6-(2-Pyridin-2-y
m) 6-(2-(6-Mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazo1-3-yl]-<br>
quinolinc,<br>
n) 3-Naphthalen-2-yJ-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ I ^-b]pyrazolc,<br>
o) 2-(6-Mcthyl-pyridin-2-yl)-3-naphthalcn-2-yl-5,6-dihydro-4H-pym)lo[ 1,2-<br>
b]pyrazolc,<br>
p) 3-(4-Fluoro-phenyl)-2-(6-trif1uoromcthyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo( 1,2-b]pyrazole,<br><br>
q) 4-(Quinolin-4-yl)-3-(5-fluoropyridin-2-yl)-5,6-dihydro-4H-pynrolo(l,2-<br>
b]pyrazolc,<br>
r) 4-(7-BromoquinoIin-4-yl&gt;3-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-<br>
bjpyrazole,<br>
s) (Quinolin-4-yl&gt;3-(2,4-diJ7uorophcnyl}-5,6-dihydro-4H-pyrrolo{l,2-<br>
bjpyrazole,<br>
0 4-(2-Pyrazin-2-yl-5,6-dihydro-4H-pyTTolo[ 1,2-b]pyrazol-3-yl&gt;quinoline,<br>
u) 4-(5-Mcthyl-2-oyridin-2-yI-5,6-dihydro-4H-pym&gt;lo[l ,2-b]pyrazol-3-y])-<br>
quinoline,<br>
v) 6-BroTno-4-[2-|6-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pym)Ioll^-<br>
b]pyrazol-3-yl]-quinolinc,<br>
w) 4-[2-(6-Methyl pyridin-2-yl)-5,6-dihydro-4H-pyrr6lo[ 1,2-bJpyrazol-3-yl]-<br>
6-trifluoromcthyJ-quinoline,<br>
x) 3-(3-Chloro-4-lluoro-phenyl)-2-(6-mcthyl-pyridin-2-yl&gt;-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-bjpyrazolc,<br>
y) 3-(2-Chloro-4-/luoro-phenyl)-2-(6-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-bjpyrazolc,<br>
z) 3-(4-Fluoro-3-tiifluoromethyl-phcnyJ)-2-(6-mcthyl-pyridin-2-yl)-5,6-<br>
dihydro-4H-pyrrolo(! ,2-bjpyrazolc,<br>
aa) 2-(6-Mcthyl-pyiidin-2-yl)-3-(2,4,5-trifluoro-phenyI)-5,6-<jihydro-4h-></jihydro-4h->
pyrrolo( 1,2-b)pyrazoJc,<br>
bb) 8-FluOTO-4-[2-(('-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pym&gt;lo{ 1,2-<br>
b]pyrazol-3-y)]-quinolinc,<br>
cc) 7-Bromo-4-[2-(loI! ,2-<br>
b]pyrazol-3-yJ]-quinolinc,<br>
dd) 4-[2-(6-Methy!-pyridin-2-yl)-5,6-dihydro-4H-pyfTolo{ 1,2-b]pyrazol-3-yl]-<br>
6-lrifluoromethoxy-quinolinc,<br>
ce) 4-(2-(6-MeJhy!-(»yridin-2-yl)-5,6-dihydro-4H-pyrrolo{ 1,2-b)pyTazol-3-yI]-<br>
7-trifluoromethyl-quinoline,<br>
0) 7-Mcthoxy-4-[2(6-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyrTolo[l,2-<br>
b]pyrazol-3-yl]-quinolinc.<br><br>
gg) 3-(2-Chloro-pyrid«n-4-yl)-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b)pyrazole,<br>
hh) [2-(6-MethyJ-pyridin-2-yl)-3-<juinolin-4-yl-5></juinolin-4-yl-5>
b]pyrazol-6-yl]-methanol,<br>
«0 [3-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrTO lo[ 1,2-b]pyrazol-6-yl]-methanol,<br>
jj) 4-[2-(tf-Chloro-pyridin-2-yl&gt;-5-(4-fluorophenyl)-5,6-dihydro-4H-<br>
pyrro lo[ 1,2-b]pyrazol-3-yl]-quit»oHnc,<br>
kk) 4-[2-(6-Ethoxy-pyridin-2-yl)-5-(4-fluoro-phenyl&gt;5,6-dihydro-4H-<br>
pyrrolo[J,2-b]pyrazol-3-yl]-qumoline,<br>
11) (S)-4-[6-Bcnzyloxymcthyl-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-3-yl]-7-chloro-quinolinc,	'<br>
mm) (S)-4-[6-BenzyIa«ymcthyl-2-(6-chloro-pyridin-2-yl)-5,6-djhydro-4H-<br>
pyrro] o[ 1,2-b]pyrazol-3-yl)-quii«)Hnc,<br>
nn) 4-{2-(6-Mcthyl-pyridin-2-yl)-3-quinolin-4-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-5-yl].bcnzoic acid ethyl ester,<br>
oo) 3-(4-Fluoro-phenyI)-5,5-dimclhyl-2-(6-inethyl-pyridin-2-yl)-5,6-dihydro-<br>
4H-pyn-olo[ 1,2-b)pyrazole,<br>
pp) (R)-6-Benzyloxyinethyl-3-(4-fluoro-pbenyl&gt;2-(6-inethyl-pyridin-2-yl)-<br>
5,6-dihydro-4H-pyrTolo[ 1,2-b]pyrazole,<br>
qq) 5-(4-Chloro-phenyl)-3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-5,6-<br>
dihydro-4H-pynolo[ 1,2-b]pyrasx&gt;le,<br>
rr) 4-[2-(3-Trifluorc4nethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[ 1,5-<br>
ajpyrid in*3-yl]-quinoline,<br>
ss) 4-[2-(4-Trifluore«nethyl-phenyl)-4.5,6,7-tctrahydro-pyrazolo( 1,5-<br>
ajpyrid in-3-yI]-quinolinc,<br>
tt) 4-[2-{4-Chloro-iihenyl)-4,5,6,7-tetrahydro-pyrazolo[ 1,5-a3pyridin-3-yl)-<br>
quinoline,<br>
ou) 4-[2-(3-Chloro-j)hcmyl&gt;4,5,6,7-ielrahydro-pyrazo)o( 1,5-alpyridin-3-y)-<br>
quinoline,<br>
w) 4-[2-
b)pyrazol-3- y]]-quinol ine,<br><br>
ww) 4-{2-(3-Fluoro-! -irifluoromethyJ-phenyl)-4,5,6,7-tetrahydro-pyrazolo[ 1,5-<br>
a]pyridin-3-yl]-quinoline,<br>
xx) 4-(2-Phenyl-4,5,6,7-tctrahydro-pyrazo1o[ 1,5-a)pyridin-3-yl)-quinoline,<br>
yy) 4-(2-Pyridin-2-yl-4,5,6,7-teirahydro-pyrazolo[ 1,5-alpyridin-3-yl)-<br>
(l,10]phenanthroline,<br>
22) 4-[2-(4-FIuoro-phenyl)-4,5,6,7-tetrahydro-pyrazolo[ 1,5-a]pyridin-3-yl]-<br>
quinolinc,<br>
aaa) 4-[2-(3-Tri fluon imcthoxy-phenyl)-4,5,6,7-tetrahydro-pyra2olo[ 1,5-<br>
a]pyridJn-3-yl]-quinolinc,<br>
bbb) 4-[2-(2-Fluoro-phenyl)-4,5,6,7-tetrahydro-pyrazolo[ 1,5-a]pyridin-3-yl]-<br>
quinolinc,<br>
ccc) 4-(2-QuinoIin-2- yl-4,5,6,7-tctrahydro-pyra2olo[ 1,5-a]pyridin-3-yl)-<br>
quinolinc,<br>
ddd) 4-[2-(4-Ethyl-pyridin-2-yI)~4,5,6,7-tetrahydio-pyrazolo( 1,5-a]pyridin-3-<br>
yl]-quinolinc,<br>
ccc) 4-(2-Quinolin-2- yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
ffT) 2-(3-Quinolin-4- yl-4,5,6,7-tetrahydro-pyra2olo[ 1,5-a]pyridin-2-yl)-<br>
[l,8]naphthyridine,<br>
ggg) 4-(5-(4-Fluoro-phcnyl)-2-p:yridin-2-yl-5,6-dihydro-4H-pym)lo[l,2-<br>
b]pyrazol-3-yJ]-quino!inc,<br>
hhh) 4-(6-Hydroxymcthyl-2-pyridin-2-yl-5,6-dihydro-4H-pynolo[Ir2-<br>
b]pyrazol-3yl)-quinolinc,<br>
in) 4-(3-Pyridin-2-y-5,6-dihydro-4H-pytTolo[l,2-b]pyrazol-2-yl)-quiiK&gt;line,<br>
jjj) 4-(4-Melhyl-2-pwidin-2-yl-5,6-dihydro-4H-pyrrolo[l^-b]pyrazoI-3-yl)-<br>
quinoline,<br>
kkk) 4-(5-Bcnzyl-2-p:Tidin-2-yl-5,6-dihydro-4H-pyrrolo[ J ^-b]pyrazol-3-yl)-<br>
quinoline,<br>
111) 4-(5-Phenethyl-2-pyridin-2- yl-3,6-dihydro-4H-pyrTolo[l ^-b]pyrazol-3-<br>
yl)-quinolinc,<br>
mmm) 4-(5-Phcnyl-2-p)Tidin-2-yl-5,6-dihydro-4HpyrTob[l,2-b]pyrazol-3-yl)-<br>
quinolinc,<br><br>
nnn) 4-{2-(3-Trifluorom»:ihylphcnyt)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yl]-quinoline,<br>
ooo) 4-[2-(4-Trifluoromtthyl-phenyl&gt;5,6-dihydro-4H-pym&gt;lo[ 1,2-bJpyrazol-3-<br>
yl]-quinoline,<br>
PPP) 4-(2-Phcnyl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
qqq) 2-Chloro-4-(2-pyrHlin-2-yl-5,6-dihydro-4H-pyrroIo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline,	.<br>
mr) 6,8-Dimethoxy-4-(7-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo(l,2b]pyra2ol-3-yI]-quinolwe,<br>
sss) 4-[2-(6-Bromo-pyridin-2-yl)-5,6-dihydro-4H«pyrrolo(l ,2-b]pyr«zol-3-yl]-<br>
quinoline,<br>
ttt) 6,8-DimcJhoxy-4-(;-pyridin-2 -yl-5,6-dihydro-4H-pyrn&gt;k)[ 1,2b]pyrazol-3-<br>
yl]-quinoline,<br>
uuu) 3-(4-FluorophcnyJ&gt;2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b}pyrazole,<br>
wv) 3-(4-Meihoxy-phcnyl)-2-pyridin-2-yl-5,6-dihydro-4H-pyrTolo[l,2-<br>
b]pyrazole,<br>
www) 3-(4-Fluorophcnyl&gt; 2-(6-methy)pyridin-2-yl)-5,6-dihydro-4H-pyrTolo[ \ ,2-<br>
bjpyrazole,<br>
xxx) 3-2-(6-mcthylpyridin-2-yl)-5.6-dihydro-4H-<br>
pyrroJo[ 1,2-b)pyrazole,<br>
yyy) 4-
zzz) 4-{2-(6-Propylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo{l,2-b]pyra2ol-3-yl]-<br>
quinofine,<br>
aaaa) 4-[2-(6-lsopropylpyridin-2-yl)-5,6-dihydro-4H-pyTTolo{ 1,2-b]pyrazol-3-<br>
yljquinolinc,<br>
bbbb) 4-[2-(6-E«hy)-pyridia.2-yl)-5,6-dihydro-4H-pyrn&gt;lot 1,2-b)pyrazol-3-<br>
yl]quinoline,<br>
cccc) 4-{2-(6-Mcthyl-pyhdio-2-yl)-5,6-dihydro-4H-pyiTolo[l,2-b]pyra2ol-3-yl]-<br>
quinoline,<br>
dddd) 4-[2-(3-Fluorophcnyl&gt;-5,6-dihydro-4H-pyiTolo[ 1,2-b)pyrazol-3-yl]-<br>
quinoline,<br><br>
eccc) 4-[2-(2-Fluoro-phenyl)-5,6~dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-<br>
quinoline,<br>
ffil) 4-[2-(4-Fluoro-phenyI)-5,6-dihydro-4H-pyrrolo[l,2-b)pyrazol-3-yl]-<br>
quinolinc,<br>
gggg) 4-(2-{3-Trifluoromcthoxy-phcnyl)-5,6-dihydrt&gt;-4H-pym&gt;lol 1,2-b]pyrazol-<br>
3-yl]-quinoline,<br>
hhhh) 4-(2i(4-Chloro-p:yridin-2-yl&gt;5,6-dihydro-4H-pyrrolol 1,2-b)pyittol-3-yl]-<br>
quinolinc,<br>
iiii) 4-[2-(4-Fluoro-3- trifluoromclhyl-phcnyl)-5,6-dihydro-4H-pyrrolo(l ,2-<br>
bJpyrazol-3-yl]quinoline,<br>
iiii) 4.[2-(2-nuoro-3-trifluoromethyl-phenyl)-5,6-dihydro-4H-pyrrolo[I^-b]-<br>
pyrazol-3-yl]-quinolinc,	;'<br>
kkkk) 4-[5-(3-Mcthoxyphcnyl&gt;-2-pyridin-2-yl-5,6'dihydro-4H-pyrroIo[l^-<br>
b}pyra2ol-3-yl]-quinoline,<br>
U1I) 4-{2-(4-Fluoro-3-irinuoromcthyl-phcnyl)-5-(3-methoxy-phcnyl)-5,6-<br>
dihydn -4H-pyrrolo[l,2-bJpyrazol-3-yl]-ijuinoline,<br>
mmmm) 4-(7-Chlo'o-quinolin-4-yl)-3-(6-methylpyridin-2-yl)-5,6<lihydto-></lihydto->
4H-pyrrolo{ 1,2-bJpyrazolc,<br>
nnnn) 4-(7-EthoxyquinclJn-4-yl)-3-(6-mcthylpyridin-2-y))-5,6-<jihydfo-4h-></jihydfo-4h->
pyrrolof 1 ^-bjpyrazok,<br>
oooo) 6-(3-Quinolin-4-&gt; l-5,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazol-2-yl)-pyridine-<br>
2-carboxylic acid hydrochloride,<br>
pppp) 6,7-Difluoro-4-[2 (6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo(l,2-<br>
b]pyra2ol-3-yl]-quinoline,<br>
qqqq) 6,7-Dimcthoxy-4- (2-(6-mclhyl-pyridin-2-yI)-5,6-dihydio-4H-pynolo( 1,2-<br>
b}pyrazoJ-3-yl}-quinoline,<br>
nnrr) 3-Benzo[ 1,3]dioxol-5-yl-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyra2Olc,<br>
ssss) 6-(4-Fluoro-phenyl)-4-[2-(6-mcihyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyra2ol-3-yl]-quiiK)line,<br>
tttt) 6-Benzo[ 1,3]dioxol-5-yl-4-[2-(6-methyl-pyridin-2-yJ)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyra2Ol-3-yI]-quin«3line,<br><br>
uuuu) 4-{2-(6-Methyl-[iyridin-2-yl)-5,6-dihydro-4H-pyrTolo[ 1,2-b]pyrazol-3-yl]-<br>
6-thiophen-2-yl-quinoline,<br>
vwv) 4-[2-(6-McthyU(»yridin-2-yl)-5,6-dihydro-4H-pyrrololl,2-b]pyrazoI-3-yl]-<br>
6-phenyI-quinol inc.<br>
wwww)	8-(2-(6-niethyl-pyridin-2-y1)-5,6-dihydro-4H-pym&gt;J
b]pyra2ol-3-y!]-quinoline,<br>
xxxx) 3-Benzo(b]«hiophcn-2-yl-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazole,<br>
yyyy) 4-{2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo{ 1,2-b]pyrazol-3-yl)-quinoline-6-<br>
carboxyltc acid methyl ester,<br>
7777) 4-[2-(6-Meihyl-f&gt;yridin-2-yi)-5,6-dihydro-4H-pyrrolo[ 1 ,2-b]pyra2ol-3-yl]-<br>
quinoline-6-carboxylic acid methyl ester,<br>
aaaaa) 4-[2-(6-Meihyl-pyridin-2-y|)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl]-<br>
quinoline-7-carboxylic acid methyl ester,<br>
bbbbb) 4-[2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-3-y(]-quinoline-7-<br>
carboxylic acid methyl ester,<br>
ccccc) 2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo[5,l-c]morpholine,<br>
ddddd)2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo[5,l-cJmorpholin-4-one,<br>
eeeee) Dimethyl- {3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyra2Ol-3-<br>
yl)-quinolin-7-yloxy]-propyl}-8»minc,<br>
ffTTf) {3-(6-Methoxy-4-(2-pyridiir&gt;.2-yl-5,6-dihydro-4H-pyrTolo{l ^-b]pyra2ol-3-<br>
yl)-quinoIin-7-yloxy]-propyl}-<iimethyl-amine></iimethyl-amine>
ggggg) Cyclopropylmetfjyl-propyl- {3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-propyl}-amine,<br>
hhhhh) Dicthyl- {3-[4-
quinolin-7-yIoxy]-propyl} -amine,<br>
iiiii) Ethyl-methyl-{3-{4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrok&gt;fl,2-b]pyrazol-<br>
3-yl)-quinolin-7-yloxy]-propyl -amine,<br>
iiiij) 3-[4-(2-Pyridin- 2-yl-5,6-dihydro-4H-pyrrolol 1,2-b]pyrazol-3-yl)-quinolin-<br>
7-yloxy]-propylamine,<br>
kkkkk) 7-[3-(4-Methyl-j)iperazin-1 -yl)-propoxy]-4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b3pyrazol-3-yl)-quinoline,<br><br>
Hill) Benzyl-meihyl-,3-l4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolollt2-<br>
b]pyrazo!-3-yl)-quinolin-7-yIo&gt;,yJ-propyl}-aminc,<br>
mmmmm) 7-(3-P iperidin-1 -yl.propoxy)-4-(2-pyridin-2-yI-5,6-dihydro-4H-<br>
pynrolo[ 1,2-b]pyrazol-3-yl)-qu.noltne,<br>
nnnnn) 4-(2-Pyridin-2-yi-5,6-dihydro-4H-pyrrolo[l ,2-b]pyra2ol-3-yl)-7-(3-<br>
pyrrolidin-l-yl-propoxy)-quino1ine,<br>
ooooo) 7-(3-A^epan-1 -yl-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pynolo[l ,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
ppppp) 7-(3-Imidazol-l -yl-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-q\iinoline,<br>
qqqqq) 7-(3-Pyf azol-1 - yl-propoxy )-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
rmrr) I1- {3-[4-(2-Pyridin-2.y|.5,,6-dihydro-4H-pyrTolol 1,2-b]pyrazol-3-yl&gt;<br>
quinolin-7-yloxy]-propyl} -[ 1, 4*]bipiperidinyl,<br>
sssss) Cyclopropyl-(1 -methyl-piperidin-4-yl)-{3-[4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[l^-b]pyrazo!-3-y;)-quinolin-7-yloxy]-propyl}-aminc,<br>
Uttt) 4-(2-Pyridin-2- yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(3-<br>
[ 1,2,3]triazol-1 -yl-propoxy)-quinoline,<br>
uuuuu) Dimcthyl-(3- {4-(2-
b]pyrazol-3-y1]-quinolin-7-yloxy}-propyl)-aminc,<br>
vww) Diethyl-(3- {4- [2-
bjpyrazol- 3-yl]-quinolin-7 -yloxy) -propyl)-am i ne,<br>
wwwww) CyclopropylmcthyK3- {4-(2-(6-mcthyl-pyridin-2-yl)-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-3-&gt; 1]-
xxxxx)Eihyl-mcthyl-(3-{4-[2-(6-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyirolof 1,2-b]pyrazol-3-yl]-cuinolin-7-yloxy}-propy!)-aminc,<br>
yyyyy) DimcthylH2-|4-(2-pyridin-2-yl-5,6-dihydro-4H-pyTTolo[1,2-b]pyrazol-3-<br>
yl)-quinolin-7-yloxy]-cthyl}-amh»e,<br>
zzzzz) Dicthyl- {2-[4 (2-pyridin- 2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yI)-<br>
quinolin-7-yloxy]-ethyl}-aminc,<br>
aaaaaa)7-{2-Piperidir -1 -y*-«thoxy)-4^2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br><br>
bbbbbb) Ethy)-m«hyl-{2.[4-(2-pyridin-2-yJ-5,6-dihydro^H-pyiTo]otl,2-<br>
b]pyrazol-3-yl)-quinolin-7-yloxy)elhy)}-amine,<br>
cccccc)4-(2-Pyridin-2-yl-:5,6-dihydro-4H-pyrrolo[1,2-b)pyra2ol-3«y})-7-(2-<br>
pyrrolidin-1 -y1-ethoxy&gt;quinolim,<br>
dddddd) 7-[2-(4-Methyl-piperazin-1 -yl)-ethoxy]-4-(2-pyridin-2-yl-5,6-<br>
dihydro«4H-pyrTOlo[ 1,2-b]pyrazctl-3-yl)-quinoline,<br>
ecceee)Dimetkyl- {3-[ 1 -OKy-4-(2-pyridin-2-yl-5,6-dihydro-4H-pynolo( 1,2-<br>
b)pyrazol-3-yl)-quinolin-7-ylox}]-propyl}-amine,<br>
ffflff) 7-M«thylsulfanyi-4-(2-pyridin-2-yl-5,6-dihydro-4H-pytTolo(1,2-b]pyrazol-<br>
3-yl)-quinoline,<br>
gggggg) 7-Ethylsulfanyl-4-(2-pyridin-2-yl-5,6-dJhydra-4H-pyiTOlo[l,2-<br>
b]pyrazol-3-yl)-quinolinc,	:<br>
hhhhhh) 6-Meihylsulfanyl-4-(2-pyridin-2-y|.5,6^iihydro-4H-pyiToJo[l ,2-<br>
b]pyrazol-3-yl)-quinolinc,<br>
iiiiii) 7-Bcnzylsulfanyl-4-(2-pyridin-2-yI-5,6-dihydro-4H-pyrrolo[l,2-b)pyrazol-<br>
3-yl)-quinoline,<br>
Jiijjj) 3-(4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-<br>
7-ylsulfanyl]-propan-1-ol,<br>
kkkkkk) Dimcthyl-{2-[4-(2-pyridm-2-yl-5,6-dihydro-4H-pyiTOlon,2-<br>
b]pyrazol-3-yl)-quinolin-7-yJsulfcnyl]-«thyl}-aminc,<br>
IIIIII) Dimethyl [C-CS-^inolin-^yl-S^-dihydro^H-pytTolof 1,2-blpyrazol-2-yl)-<br>
pyridin-2-yl-mcthyl]aminc,<br>
mmmmmm) 7-(2-Propoxy-ethoxy)-4-
pyrrolofl ,2-b]pyn»2ol-3-yl)-qninoUne,<br>
nnnnnn) N,N-Dimrthyl-N'-f4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrTolo[l ,2-<br>
b}pyrazol-3-yl)-pyridin-2-yl]-ethane-1,2-diaminc,<br>
oooooo) N,N-Din»ethyl-N'-[4-
b]pyrazol-3- yl)-pyridin-2-yI]- propane* 1,3-diamine,<br>
PPPPPp) 3- {3-[«»-
yl)-quinolin-7-yloxy]-propyl)-oxazolidin-2-one.<br>
qqqqqq)	I - {3-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyTTolo[ 1,2-b]pyrazol-3-<br>
yl)-quinolin-7-yloxy]-propyl | -iraidazolidin-2-onc,<br><br>
m-nr) 3-{3-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyra2ol-3-yl)-<br>
q u i nol in-7-yloxy]-propyl}-3 H-bciJ20oxazol«2-one,<br>
ssssss) Dimethyl-{2- {4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-pyridin-2-ylsulfanyl}-ethyl-amine,<br>
utttt) 4-(2-Pyridin-2-yl-5,6-dihydro~4H pyiTolo[ 1,2-b]pyrazol-3-yl)-2pym&gt;lidin-<br>
1-yl-quinoline,<br>
uuuuuu) 2-PhcnylsulfanyJ-4-{2-pyridin-2-yl-5,6-dihydro-4H-pyTTolo[ 1,2-<br>
b]pyrazol-3-yl)-quinol i ne,<br>
www)	2-MorphoIin-4-yl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[lt2-<br>
b]pyrazol-3-yl)-quinoline,<br>
wwwwww) 2-Ethylsulfanyl-4-(2-pyridin-2-yl-5,6-dihydn&gt;-4H-pyrrolo[l £•<br>
b]pyrazoI-3-yl)-quinoline,	;<br>
xxxxxx)	Phcnyl-[4-(:2-pyridin-2-yl-5,6-dihydro-4H-pytTOlo{l,2-b]pyra20l-3-<br>
yl)-quinolin-2-yl]-amine,<br>
yyyyyy)	2-Methoxy-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrTOlo[ 1,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
zzzzzz)2-Ethoxy-4-(2-pyridin-2-yl-5,6-dihydTO-4H-pyrrolo(l,2-b]pyrazol-3-y])-<br>
quinoline,<br>
aaaaaaa) • 4-[2-(6-Phenylsulfanyl-pyridin-2-yl)-S,6-dihydro-4H-pyrTolo[l ,2-<br>
b]pyrazo!-3-yl]-quinoline,<br>
bbbbbbb) Phcnyl-[6-{ J-quinolin-4-yl-5,6-dihydro-4H-pyiTOlo[ 1 J!-b]pyrazol-<br>
2-yI)-pyridin-2-y]]-aminc,<br>
ccccccc) 4- {2-[6-(4-Mcthoxy-phenyl)-pyridin-2-ylJ-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-bJpyrazol-3-yl }-quinolinc,<br>
ddddddd) 4-[2-(6-Pho»yl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l ,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
eeeeeee) 4-[2-
b]pyrazol-3-yl]-quinolinc,<br>
frfTffT) 4-(2-(6-Pyrrolidin- l-yI-pyridin-2-yl)-5,6-dihydro-4H-pyrroloI 1,2-<br>
b]pyrazol-3-yl]-quinolinc,<br>
ggggggg) 4-[2-(6-Me«hoxy-pyridin-2-yl)-5,6-dihydro-4H-pyiTolo[l ,2-<br>
b]pyrazol-3-yl]-quinolin€,<br><br>
hhhhhhh) 2-{3-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrTolo[l,2-b]pyrazol-3-<br>
yl)-quJnolin-7-yloxy]-propyl}-soindolc-l ,3-dionc,<br>
iiiiiii) 7-(3-Fluoro-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro«4H-pynolo[l,2-<br>
b]pyrazol-3-yl)-quinoline,<br>
Ijijiii) 7-(3-Fluoro-propoxy)-4-(2 -pyridin-2-yl-5,6-djhydro-4H-pyrrolo[ 1,2-<br>
b]pyrarol-3-yl)-quinolinc,<br>
kkkkkkk) ' 7-(3-Ch»oro-propoxy)-4-(2-pyridin-2-yl-5,6-dihydfO-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
1IH11I) 7-(3-Chloro-propoxy&gt;6-methoxy-4-(2-pyridin-2-yl-5,6-<lihydto-4h-></lihydto-4h->
pyrrolo[ 1,2-b]pyra2ol-3-yl)-q««nolinc,<br>
mmmmmmm) 7 -
4H-pyrrolo{ 1,2-b]pyrazol-3-yl]-
nnnnnnn) (1 - {3-["'-(2-Chloro-elhoxy)-quinolin-4-yl]-5,6-dihydio-4H-<br>
pyiroioj 1,2-b]pyrazol-2-yl} &gt;propenyl)-inethylenc-amine,<br>
ooooooo) N,N-Diethyl-2-[4-(2-pyridin-2-yI-5,6-dJhydro-4H-pym&gt;Jo[ 1,2-<br>
b]pyrazo)-3-yl)-quinolin-7-yl<ixy></ixy>
PPPPPPP) 7-[2-((2R)-l-Mcthyl-pyrTolidin-2-yl)-ethoxyH-(2-pyridin-2-yl-<br>
5,6-dihydro-4H-pyrrolo( 1,2-b |pyiazo1-3-yl)-quinoHne,<br>
qqqqqqq) DimcthyJ-{4-{4-(2-pyndin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-<br>
b]pyrazoI-3-yl)-pyridin-2-ylo:{y]-butyl}-aminc,<br>
rrmrr) 1 - (3-[4-
pyridin-2-yloxyJ-propyl} -pyr-olidin-2-one,<br>
sssssss)	7-( I -Metbyt-piperidin-3-ylmethoxy)-4-
dihydro-4H-pyrrolo[l,2-b]pyra2ol-3-yl)-quinoHnc,<br>
tntttt) 7-(3-N ,N -Dime(hyi«minQ-2-methyl-propyloxy)-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrro!o[ 1,2-b]pyiazol-3-yl)-quinolinc,<br>
uuuuuuu) 4-[2-(6-M«lh&gt;1-pyridin-2-yl&gt;5,6-dihydro-4H-pyTTolot 1,2-<br>
b]pyrazol-3-yl]-7-propoxy-qninoline,<br>
vvwvvv) 4-[6-Bcnzyioxynic(hy|.2-(6-methyl-pyridin-2-yI)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl]-cuinolii&gt;c,<br>
wwwwwww) {4-[2-i6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrTolo[l ,2-<br>
b]pyrazol-3-yl]-quinolin-7-yioxy}-acetic acid methyl ester,<br><br>
xxxxxxx) 7-lsopropoxy-4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl]-quinoline,<br>
yyyyyyy) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrroU&gt;[l ,2-<br>
b]pymolO-yl]-7-(3-morpholin-4-y)-propoxy)&gt;quinoline,<br>
Z2Z2ZZZ) 4-(6-Benzyloxymcthyl-2-pyridin-2-yl-5,6-dihydro-4H-pynolo[ 1,2-<br>
b]pyra2ol-6-yl)-quinolinc,<br>
aaaaaaaa) 7-Benzylox y-2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo{ 1,5-<br>
a]pjpcridinc,<br>
bbbbbbbb) 2-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-aceiamide,<br>
cccccccc) 7-(5-Phcnyl-[ 1,2,4]oxadiazol-3-ylmcthoxy&gt;-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinoHnc,	:<br>
dddddddd) 7-(2,2-Difluoro-benzo{ 1,3]dioxol-5-ylmcthoxy)-4-(2-pyridin-2-yl-<br>
5,6-dihydro-4H-pyrrolo[ 1,2-b]pyiazol-3-yl)-quinolinc,<br>
eceeeeee) 7-[2-((2S&gt; I -Mcthyl-pyrrolidin-2-yl)-cthoxy]-4-(2-pyridin-2-yl-<br>
5,6-dihydro-4H-pynrolo[ 1,2-b]pyj-azol-3-yl)-quinoline,<br>
nTffTTfY)5-[4^2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazoI-3-yI)-quinolin-<br>
7-yloxymcthyl]-pyrrolidin-2-one)<br>
BSfiggggg) 4-(6-Phcnoxymethy!-2.-pyridin-2-yl.5,6-dihydro-4H-pyrro!o[ 1,2-<br>
b]pyrazol-3-yl).quinolinc,<br>
hhhhhhhh) 4-(6-Mcthylcne-2-pyridin-2-yl-5,6-dihVdro-4H-pyirolo[ 1,2-<br>
b]p&gt;Tazol-3-yl)-quinolinc,<br>
iiiiiiii) 3-(4-Fluoro-phenyl)-6-mclhylene-2-(6-methyl-pyridin-2-yl)-5,6-dihydTO-<br>
4H-pym)lo[ 1,2-b]pyrazolc,<br>
iiiiijjj) 7-(1-Mcthyl-pipendin-2-ylmelhoxy)-4-(2-pyridin-2-yl-5,6-dihydfX&gt;-4H-<br>
pyrrolo{ I ^-b]pyrazol-3-yl&gt;quinoline hydrochloridc,<br>
kkkkkkkk) 7-[2-(l-Mrthy!-pyiToHdin-2-y1)-cthoxy]-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[l ,2-b]pyrazcl-3-yl)-quinolinc hydrochloridc,<br>
IIIIIIII) 4-[2-(6-McthyM-wy-pyridin-2-yI)-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl]-quinoline 1 -oxide:,<br>
mmmmmmmm) 4-[ 2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrTolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoIinc 1 -oxidt:,<br><br>
nnnnnnnn) 4-[2-(6-McthyJ-l-oxy-pyridin-2-yl)-5,6-dihydro-4H-pyrroJoll,2-<br>
b]pyra2ol-3-ylJ-quinolinc,<br>
oooooooo) 7-(3-Chloro-propoxy)-4-(2-pyr«'Jin-2-yl-5,6-dihydro-4H-<br>
pyrrolof) ,2-b]pyrazol-3-yl)-quinoIine 1 -oxide,<br>
PPPPPPPP) 7-Mcth»nesulfonyl-4-{2-pyTJdin-2-yl-5,6-dihydro-4H-pym)lo{l,2-<br>
b]pyrazol-3-yl)-q\iinolinc,<br>
qqqqqqqq) 3-(4-Flwwo-phenyl)-2-
4H-pyrroIot I »2-b]pyrazole,<br>
rrrrnTr)4-(Quinolin-N-1 -oxide-4-yI&gt;3-(6-me!hylpyridin-2-yl)-3,6-dihydro-4H-<br>
pyrrolo[l,2-b] pyrazole,<br>
ssssssss) 6-Mcth4nesulfonyl-4-(2-pyridin-2-y!-5,6-dihydro-4H-pyrrolo{ 1,2-<br>
b]pyrazol-3-yl)-quinoline,	;<br>
tttttttt) 7-Ethancsulfor yl-4-
3-yl)-quinoline,<br>
uuuuuuuu) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyiTolo[) ,2-b]pyrazol-3-yl)-7-{3-<br>
(pyrimidinc-2-sulfonyl)-prop«xy)-
vvwvwv) 7-{3-( I -Methyl-1 H-imida2olc-2-sulfonyl)-propoxy]-4-(2-pyridin-2-<br>
yJ-5,6-dihydro-4H-pyrrolo[ 1,2«bJpyrazoI-3-yl&gt;quino]ine,<br>
www ww www)	7-[3-(4-Chloro-bcnzencsul fony))-propoxy]-4 »(2-pyridin-2-<br>
yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolinc,<br>
xxxxxxxx) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrroJo[ J ,2-b]pyrazoJ-3-yl)-7-[3-<br>
(pyridin- 2-yl methancsul fony )-propoxy]-quinoline,<br>
yyyyyyyy) 4-(2-P yridin-2-yl- 5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-7-[3-<br>
(pyridin-2-yJ mcthancsu I finyl )-propoxy]-quinoline,<br>
»yy»&gt;777) 4*<quinolifi-1></quinolifi-1>
5,6-dihydro-4H-pyrrolo {1,2 b]pyrazole,<br>
aaaaaaaaa) 3-{4-[2-{6-Meihyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolot 1,2-<br>
b]pyrazol-3-yl]-quinolin-7-yl}-acfylic acid methyl ester,<br>
bbbbbbbbb) 3- {4-|2-(6-MethyIpyTdin.2-yl-5,6-<lihydro-4h-pyrrolo></lihydro-4h-pyrrolo>
bjpyr a2o)-3-y)]qui no) i n-7-yl} -1 -piperidin-1 -yl-propenonc,<br>
ccccccccc) 3- 
b]pyrazol-3-yl]-quinolin-6-yl}-acrylic acid methyl ester,<br><br>
ddddddddd) 4-[2-(6-Meihyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolol 1,2-<br>
b]pyrazol-3-yl]-7-vinyl-quinolinc,<br>
eeccceeee) 4-[2-(6-Ben2yl-pyridin-2-yl)-5,6-dihydro-4H-pyrroIo[l ,2-<br>
b)pyrazol-3-yl]-quinoline,<br>
TfTfffffT) 7-Benzyl-4-[2-(6-mcthyl-pyridin-2-yl)-5&gt;6-dihydro-4H-<br>
pyrro1o[ 1,2-b]pyrazol-3-yl]-qukno!Jnc,<br>
ggggggggg) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl]-quinoline-7-cai-boxyIic acid,<br>
hhhhhhhhh) 4-[2-(6-M«hyI-pyridin-2-yl)-5,6-dihydro^H-pyrTok&gt;{ 1,2-<br>
b]pyrazol-3-yl]-quinoline-6-caifboxyHcacid,<br>
iiiiiiiii) 3- {4-(2-(6-Mcihy!-pyridin~2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yl]-quino!in-7-yl}-acrylic acid,	:<br>
iiiiiijjj) 3- {4-[2-(6-Melhyl-pyridiiv-2-yl)-5,6-dihydror4H-pyiTolo{ 1,2-b]pyrazol-3-<br>
yl]-quinolin-7-yl}-propionic acid,<br>
kkkkklcJckk) 4-[2-(6-iVjethy]-pyridin-2-yl).3.quinolin-4-y!-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-5-yl]-benzoic acid,<br>
IIIIIIIII) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoHne-7-<br>
carboxylic acid cyclopentylamide,<br>
mmmmmmmmm) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yl)-quinoline-7-carboxylic acid (2-morpholin-4-yl-cthyl)-annide,<br>
nnnnnnnnn) 4-(2-Py)idin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid [2-(lH-imidazol-4-yl)-cthyl]-ainide,<br>
ooooooooo) 4-(2-Pyndin-2-y]-5,6-dihydro-4H-pym&gt;lo[ 1,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid (2-methylamino-ethyl)-amide,<br>
PPPPPPPPP) 4-(2-Pyiidin-2-yl-5,6-dihydro-4H-pyrrolo(l ,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid (3-methylamino-propyl)-amide,<br>
qqqqqqqqq) 4-(2-Pyddin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid (2-dimethylamino-ethyl)-amide,<br>
rnrmTr)	(4-MetKyl-pipcrazin-l-yl)-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyiTolof 1,2-b]pyrazol-3-yl)-qiiinolin-7-yl]-inclhanone,<br>
sssssssss) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid cyclobuiylamide,<br><br>
ttuuKt)4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2.b]pyra2ol-3-yl)-quinolinc-7-<br>
carboxyiic acid cyclopropylamidc,<br>
uuuuuuuuu) 4-(2-Pyiidin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid (1 -e hyl-propyll)-amide,<br>
vvvwvvvv) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrTolo[ I t2-bJpyrazol-3-yi)-<br>
quinoline-7-carboxylic acid ethylamide,<br>
wwwwwwwww) 4-{2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l ,2-b]pyrazol-3-<br>
yl)-quinoline-7-carboxy1ic acid isobutyl-arnide,<br>
xxxxxxxxx) 4-(2-Pyri4in-2-yl-5,6-dihydTO-4H-pyrrolo[l,2-b]pyTa2ol-3-yl)-<br>
quinoline-7-carboxylic acid tcrt-buiylainide,<br>
yyyyyyyyy) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyTrolo[l ,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid isopropylamidc,	;<br>
7Tm7rr7) 4-(2-Pyr din-2-yl-5,6-dihydro-4H-pytT0lol 1,2-b)pyrazol-3-yl)-<br>
quinolinc-7-caiboxylic acid prtipylamidc,<br>
aaaaaaaaaa) 4-(2-Pyndin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid (2 mcthyl-butyl)-amidc,<br>
bbbbbbbbbb) 4-(2-Pyiidin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid ((l!S)-2-methyl-butyl)-ainide,<br>
cccccccccc) 4-(2-Pyiidin-2-yl-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid (2S)-sec-butyiamide,<br>
dddddddddd) 4-(2-Pyridin-2-yI-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid (2R&gt;scc-butylamide,<br>
cecceeeece) 4-(2-Pyridin-2-y]-5,6-dihydro-4H-pyTTOlo( 1,2-b)pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid -1,2-dimethyl-propyl)-amide,<br>
nrrffiT!!) 4-(2-P)Tidin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazo!-3-yl)-<br>
quinolinc-7-carboxylic acid (pyridin-4-ylmethyl)-ainide,<br>
gggggggggg) 4-(2-P:/ridin-2-yl-5,6-dihydro-4H-pyrTolol 1,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid (pyridin-3-ylmethyl)-ant'<le></le>
hhhhhhhhhh) 4-(2-P&gt;ridin-2-yl-5,6-dihydro-4H-pyrrolo{ 1,2-bJpyrazol-3-yi)-<br>
quinolinc-7-carboxylic acid (pyridin-2-ylmcthyl)-amide,<br>
iiiiiiiiii)	6-(3-C'uinolin-4-yl-5,6-dihydro-4H-pyTTolo[l,2-b]pyrazol-2-yl)-<br>
pyridine-2-carboxylic acid amide,<br><br>
jjjjiiiijj)	1 -(4-Meihyl-piperaztn-1 -yl)-2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl)-qu&gt;nolin-7-yloxy]-ethanone,<br>
kkkxkkkkkk) N-(2-Ditn«hyIamino-eihyl)-2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pym&gt;lo( 1,2-b]pyrazol-3-yl)-quHnolin-7-yloxy]-acctamide,<br>
nilllllli)	N-(2-Diinediylamino-ethy1)-N-njethyl-2-[4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pynrolo{ 1,2-bJpyraz
mmmmmmmmmm) N,N-Diinethyl-3-t4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b}pyrazol-3-yl)-quNnolin-7-yIoxy]-benzamide,<br>
nnnnnnnnnn) 4-(2-Pyiidin-2-yl-5,6-dihydro-4H-pyrToIo[ 1,2-b]pyrazol-3-yl)-<br>
quinoIinc-7-carboxylic acid amide,<br>
oooooooooo) 4-(2-Pyiidiii-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-H]pyrazol-3-yl&gt;-<br>
quinoline-7-carboxylic acid (2-dimethylamino-€thyl)-mcthyl-amidc,<br>
PPPPPPPPPP) 4-(2-Pyiidio-2-yl-5,6-dihydro-4H-pyrrolo( 1,2-H]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid (3"dimethylaTnino-propyl)-mcthyl-amide,<br>
qqqqqqqqqq) 4-(2-Pyridm-2-yl-5,6-dihydro-4H-pyrrolo(1,2-H]pyrazol-3-yl)-<br>
quino1in«-7.carboxylic acid dimethylamide,<br>
nuiuiii) 4-(2-Pyridm-2-yl-5,6-dihydro-4H-pyrrolo( 1 f2-H]pyrazol-3-y1)-<br>
quinolin€-7-carboxylic acid nwthylamidc,<br>
ssssssssss) 4-{2-Pynd«-2-yl-5,6-dihydro-4H-pyiTolo[ ] ,2-b]pyrazol-3-yl)-<br>
quinoline-7-carboxylic acid p&gt;ri<iio-2-ylamide></iio-2-ylamide>
tttttttttt)	N-(2,2-Dii«elhylarnino-ethyl)-N-me!hyI-3-{4-[2-
pyridin-2-yl)-5,6-da«ydro-4H-})ynok)[ 12- b]pyrazol-3-yl]-quinolin-7-yl} -propionamidc,<br>
uuuuuuuuuu) 2-(6-Mcihyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b}pyrazol-<br>
3-yJ]-quinolinc-6-carboxylic acid (2-dimethylamino-cthyI)-amide,<br>
vvvwvwvv) 4-[2-
b]pyrazol-3-y]]-quinoIinc-6-carb0xylic acid(3-dimcthylamino-propyl)-amidc,<br>
wwwwwwwwww) *l-{2-(6-Methyl-pyridin-2-yl)-5t6-dihydro-4H-pyiTolo[ 1,2-<br>
b]pyrazol-3-y|]-quinoline-6-C3rboaiylicacid(2-morpholin~4-yl-cthyl)-amid€,<br>
xxxxxxxxxx) 1 [2-(Quinohn-4-yl)-1 -(6-methyl-pyridin-2-y1)-5,6-dihydro-4H-<br>
pyTTolo[ 1,2-b]pyrazol-3-yl] quinoHne-7-carboxylic acid N.N-dimethylaminoethylamide,<br>
yyyyyyyyyy) 4-[2-(6-M«ihy]pyridin-2-yl)-5,6-dihydro4H-pyn-olo(l,2-bJpyrazol-<br>
3-yl]quinoWne-7-c«rbox-ylic ticid(2-pip€ridin-l-yl-cthyl)aniide,<br><br>
zzz2zzzzzz) N-(2-Dimcthylamino-cthyl)-3-{4-[2-(6-methyl.pyridin-2-yl)-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolin-7-yl}-propionamide,<br>
aaaaaaaaaaa) 4-[2-(6-Mcthyl-pyridin-2-yl)-5,6-dJhydro-4H-pyrroloIl,2-<br>
b]pyrazol-3-yl]-quinolinc-7-carbo&gt;ylicacid(3-dimc(hylamino-propyl)-ainidc,<br>
bbbbbbbbbbb) 4-[2-(6-Methyl-pyridin-2-y!)-5,6-dihydio-4H-pym&gt;lo[1,2-<br>
b]pyrazol-3-yl)-quinoline-7-carboji ylic acid (3-pyirolidin-1 -yl-propyl)-amidc,<br>
ccccccccccc) 4-t2-(6-Mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-<br>
b)pyrazol-3-yl]-quinoline-7-carbo*ylic acid (3-morpholin-4-yl-propyl)-amide,<br>
ddddddddddd)3-{4-[2-(6-Mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyiTolo[l,2-<br>
b)pyrazol-3-yl]-quinoIin-7-yl} -propionamidc,,<br>
ececcccccee) 4-(2-Pyridin-2-yl-5,6-<lihydro-4h-pyno1o></lihydro-4h-pyno1o>
quinoline-6-carboxylic acid (2-diroethylamino-ethyl)-amide,<br>
mrrmTH) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pym&gt;lo[l ,2-bJpyrazol-3-yl)-<br>
quinolinc-6-carboxylic acid (2-moipholin-4-yl-clhyl&gt;amidc,<br>
Kgggggggggg) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyra2ol-3-yl)-<br>
quinoline«6-carboxylic acid,<br>
hhhhhhhhhhh) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo( 1,2-b)pyrazol-3-yl)-<br>
quinolinc-6-carboxylic acid hydra:ide,<br>
iiiiiiiiiii)	4.(2-Pyridin-2-yl-5,6-dihydro-4H-pyiTolo[l,2-b]pyrazoI-3-yl&gt;<br>
quinolinc-6-carboxylic acid amide<br>
iiiiiUJiiJ)	4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolinc-6-carboxylic acid (3-mdhylamino-propyl)-amide,<br>
kkkkkkkkkkJc) 4-{2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolinc-6-carboxylic acid amide<br>
IIIIIIIIIII) 4-(2-Pyridin-2-yl-5,6-dihydro-4H.pyrTolo[l,2-b)pyrazol-3-yl)-<br>
quinoline-6-carboxylic acid (2-hydroxy-ethyl)-amide,<br>
mmmmmrnrnrtimrnm)4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-<br>
y1)-quinoline-7-carboxylic acid hylrazidc,<br>
nnnnnnnnnnn)4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo(l,2-b]pyrazol-3-yl)-<br>
qutnoline-7-carboxylic acid hydroxyamide,<br>
OCK&gt;OOOOOOOO) 4-(2-Pyridin-2-yl-5, 6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-cart&gt;oxylic acid (2-am no-ethyl)-amide,<br><br>
ppppppppppP)4-(2-Pyrid»n-2-yl-5,6dihydro-4H-pyrrolo[l,2-b)pyra2o|.3-yl)-<br>
quinolinc-7-carboxylic acid (2-hydroxy-elhyl)-amide,<br>
qqqqqqqqqqq) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrTolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-sulfonic acid amide,<br>
iiiiiimn) 4-(2-Pyridin-2-yl-S,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl&gt;<br>
quinoline-7-sulfonic acid methylamide,<br>
sssssssssss) 4-(2-Pyridm-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinoline-7-sulfonic acid dimethylamide,<br>
ttttttttttt) 4-(2-Pyridin-2-yJ-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl&gt;<br>
quinoline-7-sulfonic acid (3-dim«hylamiiio-propyl)*amide,<br>
uuuuuuuuuuu) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl&gt;<br>
quinoline-7-sulfonic acid diethysamidc,	;<br>
vvwvwww) 4-(2-Pyridoi-2-yl-516-<lihydro-4h-pyitojo></lihydro-4h-pyitojo>
quinoline-7-sulfonic acid (2-pjperidin-1-yl-«thyl)-amidc,<br>
wwwwwwwwwww) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-3-<br>
yl)-quinoline-7-sulfonic acid (2-hydroxy-ethyl)-amidc,<br>
xxxxxxxxxxx) 4-(2-Pyri(Iio-2-yl-5,6-dihydro-4H-pynolo[1,2-b]pyiBZol-3-yl)-<br>
quinolin-7-ylamJne,<br>
yyyyyyyyyyy) 2-Dimcthylaniino-A/-[4r(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-3-yl)-quinolin-7-yl]-acctamidc,<br>
2Z22Z2Z2ZZZ) 3-Dimcthylamino-N-[4-(2-pyridin-2-yI-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-qumolin-7«yl]propionamide,<br>
aaaaaaaaaaaa) N-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo(l,2-b)pyra2ol-3-yl)-<br>
quinolin-7-yl]-mcthanesulfonariide,<br>
bbbbbbbbbbbb)	M -{4-(2-Pyridin-2-y»-5,6-dihydro-4H-pyrrolo( 1,2-<br>
b]pyrazol-3-yl)-quinolin-7-yl]-acetamide,<br>
cccccccccccc) 4-<br>
quinolinc-7-carboxylic acid (2-acelylamino-ethyl)-amide,<br>
dddddddddddd) N- {3-(4-(2-Pyridin-2.yl-5,6-dJhydro-4H-pynolo{ 1,2-<br>
b)pyrazol-3-yl)-quinolin-7-yloxy]-propyl}-methancsulfonamidc,<br>
ceeecceccccc) l-Mcthyl-IH-imidazole-4-sulfonic acid {3-[4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrTolo{l,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-propyI}-amidc,<br><br>
fmrflr/TfO l-(2-DJmethylamino-ethyl)-3-[4-(2.pyridin-2.y|.5t6-dihydro-4H-<br>
pyrrolol 1,2-b]pyrazol-3-yl)-quJi»Iin-7-yll -urea,<br>
gggfigggggggg)	1 
dihydi©-4H-pyrrolo[ 1,2-bJpyraz»I-3-yJ&gt;quino)in-7-yl)-urca,<br>
hhhhhhhhhhhh) I 
pyrrolof 1,2-b]pyrazol-3-yl)-qui»tolin-7-ylJ-urea,<br>
*«(«tiiiiaii&gt; (4-(2-Pyridin-2-yf-5,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazoJ-3-yI)-<br>
quinolin-7-y))-carbamic acid methyl ester,<br>
iiiiiiiiijjjt [4-(2-Pyndin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b)pyra2ol-3-yl)-<br>
quinoiin-7-yl]-carbamic acid 2-hydroxy-elh&gt;1 ester,<br>
kkkJdckkkkJckk) [4
yl)-quinolin-7-yl]-carbamic acid 2-methoxy-ethyl ester,	■<br>
Illlllllllll) 1,3-Bis-[4-(2-pyridin.2-yl-5,6-dihydro-4H-pyrrolo[ 1 ^-bjpyrazoi-<br>
3-yl)-quinoJin-7-yl]-urca,<br>
mmmmmmmmmmmrn) Dimethyl-carbamic acid 4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo( 1,2-b]pyraz«»l-3-yl)-quinolin-7-yI ester,<br>
nnnnnnnnnnnn) 7-Bromo-2-isopropyl-4-(2-pyridin-2-yl-5,6-dibydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl)-quinolinc,<br>
oooooooooooo)	2-{4-[2-(6-Methyl-pyridin-2-yI&gt;5,6-dihydro-4H-<br>
pyrrolo( 1,2-b]pyrazoJ-3-yJ)-quinolin-6-yl} -propan-2-ol,<br>
PPPPPPPPPPPP) 7-C»-Chloro-propyJsulfanyl)-4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-3-ylH*«noline,<br>
qqqqqqqqqqqq)	7-Bromo-4-(4-chloro-2-pyridin-2-yJ-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl&gt;-quinoline,<br>
ininuifti) 8-ChJoro-4-(2-pyrJdin-2-yl-5,6-dihydro-4H-pyiTolo[ J ,2-b]py»a2ol-<br>
3-yI)-quinolin-7-ol,<br>
ssssssssssss) 8-Bromo-4 (2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-<br>
3-yJ)-quinoIin-7-ol,<br>
tttttmtttt) 3-(7-Bromc-quinoIin-4-yl)-2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo{] ,2-b]pyrazol-4-o),<br>
uuuuuuuuuuuu) 7-Biomo-4-(4-me(hoxy-2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl)-quinoiine,<br><br>
vvvvwvvvvvv)	[3-(7-Bromo-quinolin-4-yl)-2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ ] ,2-b]pyra2ol-4-yl]-meihyl-amin€,<br>
wwwwwwwwwwww)3(7-Broino-quinolin-4-yl)-2-pyridin-2-yl-5,6-d&gt;hydro-<br>
pyrrolo[ 1,2-b]pyrazol-4-one,<br>
xxxxxxxxxxxx)	3{4-
3-yl)-quinolin-7-yloxy]-benzamide,<br>
yyyyyyyyyyyy) #^-DimcthyW-[4K2-pyridin-2-yl-5,6<lihydio-4h-></lihydio-4h->
pyrTolof 1,2-b]pyrazol-3-yl)-quiix&gt;Iin-7-yloxy]-thiobenzamide1<br>
777777777777) Dime(hyl-{3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pynrolo[l,2-<br>
b]pyrazol-3-yl)-quinol in-7-ylox yj-benzyl} • aminc,<br>
aaaaaaaaaaaaa)	4-{2-
b]pyrazol-3-yI]-lH-quinolin-2-««K,	:<br>
bbbbbbbbbbbbb) 4-(2-Pyridin-2-yl-5,6-dJhydro-4H-pynrolo[l^-b]pyra2ol-3-<br>
yl)-quinolin-7-ol,<br>
ccccccccccccc)	4- (2-(6-Mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo{ 1,2-<br>
b]pyrazol-3-yl]-quinolin-7-ol,<br>
ddddddddddddd) 6-Mcthoxy-4-(2-pyridin.2-y]-5.6-dihydro-4H-pyiTolot 1,2-<br>
b]pyrazol-3-yl)-quinolin-7-ol,<br>
cceceeeeeeeee)	3-{4-(2-1)-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-3-yl]-quiiiolin-7-yl}-propionic acid methyl ester,<br>
fffiYnrffffr) 4-(6-Me0iyl-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-<br>
3-yl)-quinoline,<br>
ggfiggggggeege) 3- (4-{2-(6-Meihyl-pyridin-2.yJ)-5,6-dihydro-4H-<br>
pyrTolo[l,2-b]pyrazol-3-yl]-qui«olin-6-yl}-propionic acid methyl ester,<br>
hhhhhhhhhhhhh) 7-Amino-4-(2-(6-Mcthyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl]-quiaoline,<br>
iiiiiiiiiiiii) N,N-Dimethyl-3-{4-[2-(6-methyi-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo( 1,2-b]pyrazo1-3-yl]-quii»Hn-7-yl}-propionamide,<br>
JiiUJjjjjjjj) N- (3-[4-
ylVquinolin-T-yloxyj-propylJ-acelamide,<br>
kkkkkkkkkkkkk) N Acetyl-N-{4-[2-(6-methyI-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazol-3-yl]-qui»olin-7-yl}'acetamide,<br><br>
lllIllllJllll) 2-Pyridin-2-yl-3-quinolin-4-yI-pyrazolo[l,5-a]piperidin-7-ol,<br>
mmmmmmmmmmmmm) 7-Acctoxy-2-pyridin-2-yl-3-quinolin-4-yl-<br>
pyrazolo[ 1,5-a)pipcridine,<br>
nnnnnnnnnnnnn) Methyl- {3-f4-(2-pyridin-2-yl-5,6-dihydro-4H-pyiTo!o[ 1,2-<br>
b]pyrazol-3-yl)-quino)in-7-yloxy]-propyl}-amine,<br>
ooooooooooooo) 7-(Piperidin-4-yloxyH-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazoi-3-yl)-qi)iinoline,<br>
ppppppppppppp) 4^2-(6-McthyI-pyridin-2-yl)-5,6-dihydra-4H-pyiTolo[l ,2-<br>
b]pyrazol-3-yl]-quinoline-7-caiboxylic acid (2-amino-l .l-dimcthyl-ethyl^amidc,<br>
qqqqqqqqqqqqq) {6-(3-
b]pyrazol-2-yl]-pyridin-2-yl}-tiKthanol,<br>
iniiiimiu) [6-(3-Quinolin-4-yl-5,6-d Jhydro-4H-pyrroio[ J ^-b]pyra2o1-2-yl)-<br>
pyridin-2-yl]-mcthanol,<br>
sssssssssssss) 4-[2-(6-(neihyl-pyridin-2-yl)-5,6-dJhydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-yl]-phenol,<br>
nnmntttt) 7-( I -Mcthyl-pyiTolidin-3-ylmcthoxy)-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrro!o[ 1,2-b]pyr*zol-3-yl)-quinolinc,<br>
uuuuuuuuuuuuu) 7-<i-methyl-piperidin-4-ylmethoxy>4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyi*»&gt;M-yO-quino!ine,<br>
vvvvwvvvww) 4-{2-
b]pyra2ol-3-yl]-quinoline-7.cai*ootylic acid(2-dimethylamin6-1,1 -dimcthyl-eihyl&gt;amide,<br>
wwwwwwwwwwwww) (5)-(3-2-(6-inethyl-pyridin-2-yl)-<br>
5,6-dihydro-4H-pyrrolo[ 1,2-b]pyiaiol-6-yU-incthanol,<br>
xxxxxxxxxxxxx) («&gt;.{3-(4-Fluoro-phcnyl)-2-(6-methyl-pyridin-2-yl)-5,6-<br>
dihydro-4H-pyrrolo[ 1 ^-bJpyraaol-^-yn-nwthanol,<br>
yyyyyyyyyyyyy) (,sH3-(4-Fi|io'ro-PhenyJ)'2-(6-methyl*pyr'<j>5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyraiol-6-yl]-acetonitrile,<br>
zzzzz2Z2zzzzz)	(^H3-
dihydro-4H-pyn-olo[l,2-b]pyra«&gt;l-6-yI]-acetonitrile,<br>
aaaaaaaaaaaaaa) 4
y])-quinoline,<br><br>
bbbbbbbbbbbbbb) 4
quinolinc,<br>
cccccccccccccc) 3(4-(2-Pyridin-2-y!-5,6-dihydro-4H-pyirolo[I^-b)p)razol-<br>
3-yl)-quinolin-7-yl}-oxazo)idin-2-one,<br>
dddddddddddddd) I [4-(2-Pyridin-2-y!-5,6-dihydro-4H-pyTrolo{lr2b]pyra2oi-<br>
3-yl)-quinolin-7-yl]-imidazolidm-2-one,<br>
cccecceeeeeecc) 4
yl)-7-(pyridin-4-ylinethoxy)-quiK&gt;linc,<br>
ffiTimrfrfnO 4-
pyridin-3-yl-propoxy)-quinolin«:,<br>
KBgegggggggggg) 7- (4,5-Dihydro- \ H-imidazol-2-yl)-4-(2-pyridin-2-yl-5*6-<br>
dihydro-4H-pyirolo( 1,2-b]pyra2ol-3-yl)-quinolinc,<br>
hhhhhhhhhlihhhh) 4-[5-(4-F)uoro-phcnyl)-2-(6-mcthyl-pyridin-2-yl)-5,6-<br>
dihydro-4H-pyrrolo[l ,2-b]pyra2oI-3-yl]-quinolinc (Enantiomer A),<br>
iiiiiiiiiiiiii) 4-[5-(4-Fluoro-phenyl&gt;2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo{ 1 ^-b]pyrazol-3-yl]-quinolinc (Enantiomer B),<br>
jjjijuiiijiiijj) 2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo(5,l-c]mofpholinc,<br>
kkkkkkkkkkkkkk) 4-[2-
b]pyrazol-3-yl]-quinoline,	.<br>
IIIIHIHIIII!) 3-{4-{2-(<i-methyl-pyridin-2-yl></i-methyl-pyridin-2-yl>
b]pyrazol-3-yl]-quinolin-6-yl} -acrylic acid,<br>
mmmmmmnimmmmmrfim) 7-(6-Methyl-pyridazin-3-yloxy)~4-(2-pyridin-2-yl-<br>
5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
nnnnnnnnnnnnnn) 4-{2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-bJpyrazol-3-<br>
yl)-7-(4-(4-pyriinidin-2-yl-pipcrazin-l-yl)-butoxy3-quinolinc,<br>
oooooooooooooo) 7-[3-[4-(2-Methoxy-phenyl)-pipcrazin-l-yI]-propoxy}-4-<br>
(2-pyridin-2- yl-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-3-yl)-quinoline,<br>
PPPPPPPPPPPPPP) Py ridin-2-yI- {3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyiTolof 1,2-b]pyrazol-3-yl)-quinolin-7-ylo*y]-propyl}-amine,<br>
qqqqqqqqqqqqqq) 4-| 2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrok&gt;[ \ ,2-<br>
b]pyrazol-3-yl]-quinoline-7-carboxylic acid (2-dimethyiamino- J -methyl-ethyl)-amidc,<br><br>
uiiTiiniiiii) 4-[2-(6- VfethyI-pyridin-2-yl)-S,6-dihydro-4H-pyrrolo( 1,2-<br>
b}pyrazol-3-ylJ-quinolinc-7-carboxylic acid amide,<br>
ssssssssssssss) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolinc-7-carboxylic acid (3 dimethylamino-propyl&gt;amidc,<br>
uutntmttt) 4-(2K6-Methyl-pyridin-2-yl&gt;5,6-dihydro^H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline-7-carboxylicacid(2-dimcthylamino-ethyl)-methyl-ainide,<br>
uuuuuuuuuuuuuu) N,N-Dimcthyl-3- {4-[2-
dihydro-4H-pyrro1o( 1,2-b]pyrazol-3-yl]-quinoKn-7-yI}-acrylamide,<br>
vvwvvvvvvvvw) *-{2-Pyridin-2-yl-5&gt;6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yl)-quinoline ]-oxide,<br>
wwwwwwwwwwwwww) 7-Benzyloxy-4-(2-(6-mclhyl-pyridin-2-yl)-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyrjtzol-3-yl]-quinoline,	:<br>
xxxxxxxxxxxxxx) ♦-(2-olo loro-pyridin«2-yl)-5<br>
[1,2-b]pyrazo]-3-yl]-quinoline,<br>
yyyyyyyyyyyyyy) (&gt;-(3-Quinolin-4-yl-5,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazol-<br>
2-yl)pyridine-2-carboxylic acid methyl ester,<br>
zzzzzzzzzzzzzz) ^K7-Chloroquinolin-4-yl)-3-(pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[l ,2Db]pyrazole,<br>
aaaaaaaaaaaaaaa) *-
yl)-quinoline,<br>
bbbbbbbbbbbbbbb) 3 - {4-[2-(6-Mcthyl-pyridin-2-yl)-5,6^ihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl]-quinoIin-6-yl}-acrylic acid methyl ester,<br>
ccccccccccccccc) 4~(2-(2-Methyl-thiazol-4-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
ddddddddddddddd) 3-(4-Fluoro-phenyl)-2-(2-methyl-thiazoI-4-yl)-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazole,<br>
eeeceeeceeeeeec) 4-(2-(2-Methyl-2H-pyrazol-3-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazoI-3-yl]-quinoline,<br>
fffffffffffffTO 4-(2-Thiazol-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-<br>
quinoline,<br>
ggggegggfiggeegg) "•[2-(l-Methyl-lH-imidazol-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl]-quinoline,<br><br>
hhhhhhhhhhhhhhh) 6/f-DichIoro-4-[2-(6-methyi-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ l,2-b}pyrazol-3-yl)-qumoline,<br>
iiiiiiiiiiiiiii) (S)-6-Bcn2yloxymcthyl-3-(4-fluoro-phenyl)-2-(6-methy1-pyridin-<br>
2-yl)-5,6-dihydro-4H-pynolo[ 1,2-b]pyr azoic,<br>
iiiiiiiiii^lip N,N-Dim<thyj-3-></thyj-3->
pyrrolo{ 1,2-b]pyrazol-3-yl]-quinolin-7-yl }~acrylamide,	^,———«=^jv<br>
and the pharmaceutical! y acceptable salts, esters ffflfVpniHintg* thercoOU<br>
6. A compound as claimed In claim 2, wherein the compound is selected from<br>
the group comprising:<br>
a)	7-mcthoxy-4-(2-i&gt;yridin-2-yl-5,6-dihydro-4H-pyrrolol 1,2-b]pyrazol-3-y1)-<br>
quinolinc,<br>
b)	7-benzy]oxy-6-methoxy-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrTOlo{ 1,2-<br>
bJpyrazol-3-yl)-quinoline<br>
c)	7-Bromo-4-[2-{6-inethyI-pyridin-2-y()-5,6-d ihydro-4H-pyrTolo{ 1.2-<br>
b]pyrazol-3-yl)-quinoline<br>
d)	7-Methoxy-4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyirolo[l,2-<br>
b]pyra2ol-3-y!]-quinoUnc<br>
c) [3-(7-Bromo-quinolin-4-yJ)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo( 1,2-bJpyrazol-6-yl]-mei;hanol<br>
0 4-(7-Bromoqui5alin-4-yJ)-:i-(pyTidin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
bjpyrazole<br>
g) 4-(7-Chloro-qui!tolin-4-yl)-3-(6-methylpyridin-2-yl)-5,6-dihydro-4H-<br>
pyrroJo[ ] ,2-b]pyrazole,<br>
h) 6,7-Diftuoro-4-[ 2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrToJo[ J ,2-<br>
b]pyrazol-3-yl]-quinoline,<br>
i) 6,7-Dimcthoxy-4-[2-(6-methyl-pyridin-2-yl&gt;5,6-dihydro-4H-pyfTolo{ \ ,2-<br>
b]pyrazol-3-y|].quinolin«<br>
j)	4-[2-(6-Mcihyl- (jyridm-2-yO-5,6-dihydro-4H-pyrrolo( 1,2-b)pyrazol-3-yl]-<br>
quinolinc-7-carboxylic acid methyl ester<br>
k) Dirnelhyl- {3-(4 
yl)-quinolin-7-yloxy]-propyl}-jmine,<br><br>
1)	{3-(6-methox:y-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazol-3-<br>
yl)-quinolin-7-yloxy]-propyl f-dimcthyl-amine,<br>
m) Cyclopropylnrieihyl-propyl- {3-I4-(2-pyridJn-2-yl-5,6-dihydro-4H-<br>
pyrro)o[ 1,2-b]pyTa2ol-3-yl)-t|uinolin-7-.vloxy]-propyl}-amine,<br>
n) Diethyl- {3-{4 (2-pyridin-2-yl-5,6-dihydro-4H-pynolo[ 1,2-b)pyrazol-3-yl)-<br>
quinolin-7-yloxy]-propyl} -ainine,<br>
«<br>
o) Ethyl-methyl- {3-[4-(2-pyridin-2-yI-5,6-dihydro-4H-pyrrolo{ 1,2-b]pyra2ol-<br>
3-yl)-quinolin-7-yloxy]-propy1}-aminc,<br>
P) 3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrroIo[ 1,2-b)pyra2ol-3-yl)-quinolin-<br>
7-yloxy]-propytamine,<br>
q) 7-[3-(4-mcthjl-pipcra2in-1 -yl)-propoxy]-4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrro1o( 1,2-b]pyra2ol-3-yl)-quinolinc,<br>
r) B€n2yl-methyI-{3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyiTolo(l,2-<br>
b]pyrazol-3-y|)-quinolin-7-yloxy]-propyU-amine,<br>
s) 7-
pyrrolo[ 1,2-b]pyrazol-3-yl)-quino!ine,<br>
0 4-{2-pyridin- 2-yl-5,6-dihydro-4H-pyrrolo{ J ,2-blpyrazo1-3-yO-7-(3-<br>
pyrrolidjn-1 •yl-propoxy)-quinoline,<br>
u) 7-{3-azepan- -yI-propoxy)-4^(2-pyridin-2-yl-5,6-dihydro-4H-pyrTolo[l,2-<br>
b]pyrazoJ-3-y|)-quinolinc,<br>
v) 7-(3-imidazol-l-yl-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pynrolo[l,2-b]pyrazoJ-3-yl)-quinoline,<br>
w) 7-(3-pyrazol-1 -yI-propoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo( 1,2-<br>
b]pyrazol-3-yl&gt;quinolinc,<br>
x) ]t-{3-[4-(2-p)aidin-2-yl5,6-dJhydro-4H-pyrTololl,2-blpyra2ol-3-yl)-<br>
quinolin-7-yloxy]-propyI} -(1,4*)bipipcridinyl,<br>
y) Cyclopropyl( 1 -mcthyl-pipcridin-4-yl)- {3-[4-
4H-pyrTolo[ 1,2-b]pyrazol-3 yl&gt;quinolin-7-yloxy]-propyl}-amine,<br>
2)	4-(2-pyridin- 2-yl-5,6-dihydro-4H-pyn-oIo( 1,2-b]pyTazol-3-yl&gt;7-(3-<br>
[I,2,3]tria2ol-l-yl-propoxy)-quinoline,<br>
aa) Dimethyl-(3 {4-[2-(6-methyl-pyridin-2-y!)-5,6-dihydro-4H-pynolo[ 1,2-<br>
b]pyrazol-3-yI]-quinolin-7-yloxy}-propyI)-amine,<br><br>
bb) Dicthyl-(3- {4-[2 (6-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l ,2-<br>
b]pyrazol-3-yl]-quinolin-7-yloxy}-propyl)-amine,<br>
cc) CyclopropylmcihyK3-{4-(2-{6-meihyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl]-qui«olin-7-yloxy) -propyl)-propyl-amine,<br>
dd) Ethyl-mcthyl-5,6-dihyd«&gt;-4H-<br>
pyrro)o[ 1 ^-b]pyrazol-3-yl]-quinolin-7-yloxy}-propyl)-amin€,<br>
ce) Dimcthyl-{2-[4-{2-pyridin-2-yl-5,6-dihydro-4H-pym&gt;Io[lt2-b]pyra2ol-3-<br>
yl)-quinolin-7-yloxy)-ethyl} -aniinc,<br>
fl) Dieihyl- {2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b)pynaol-3-yl)-<br>
quinolin-7-yIoxy)-ethyl)-amiiK,<br>
88) 7-(2-piperidin-l yi-ethoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l ,2-<br>
b]pyrazol-3-yl)-quinolinc,<br>
hh) Ethyl-methyl- {2 -{4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo(l ^-b]pyrazol-<br>
3-yl)-quinolin-7-yloxy]ethyl} -umine,<br>
ii) 4-
pyrro)idin-l-yl-cthoxy)-quinol nc,<br>
JLJ) 7-[2-(4-mcthyi-pipcrazin-l-yl)-cthoxy]-4-{2-pyridin-2-yJ-5,6-dihydro-4H-<br>
pyrrolof! ,2-b]pyrazol-3-yl)-quinoline,<br>
kk) Dimethyl-{3-[I-oxy-4-(2-pyridin-2-y]-5,6-dihydro-4H-pyrrolo[l,2-<br>
bJpyrazol-3-yl)-quinolin-7-ylony]-propyl}-amine,<br>
H) 7-Methylsulfan/)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo(l,2-b3pyrazol-<br>
3-yl)-quinolinc,<br>
mm) 7-Ethylsulfanyl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrTolo[l,2-b]pyra2ol-<br>
3-yl)-quinoline<br>
nn) 7-Benzylsulfanyl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-yl)-quinoline,<br>
oo) 3&gt;[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo{ 1,2-b]pyrazol-3-yl)-quinolin-<br>
7-ylsulfanylJ-propan-l -ol.<br>
pp) Dimethyl- {2-[* -(2-pyridin-2-yl-5,6-dihydro-4H-pyTTolo(1^-b]pyrazol-3-<br>
yl)-quinolin-7-ylsulfanyl]-ethyl}-amine,<br>
qq) 7-(2-Propoxy-«tho&gt;y)-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-<br>
3]pyrazol-3-yl )-quinoline<br><br>
rr) 3- {3-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrro!o( 1,2-b)pyrazo1-3-yl)-<br>
quinolin-7-yloxy)-propyl}-oxazolidin-2-one,<br>
ss) 1 - {3-[4-(2-PyrJdin-2-yl-5,6-dihydro-4H-pynrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-propyl}-imidazolidin-2-one,<br>
tt) 3- {3-(4-(2-Pyridin-2-yl-S,6-dihydro-4H-pyrTolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-propyl) -3H-benzooxazol-2-one,<br>
uu) 2- {3-l'4-(2-Pyridin-2-yl-5,,6-dihydro-4H-pyiTolo[ 1,2-b]pyrazo!-3-yl)-<br>
quinolin-7-yloxy]-propyl} -isoindole-1,3-dione,<br>
vv) 7-(3-Fluoro-propoxy)-4-(2-pyridtn-2-yI-5,6-dihydro-4H-pyiToIo[ 1,2-<br>
blpyrazoI-3-yl)-quinolinc,<br>
ww) 7-(3-Chloro-p opoxyH-l^-pyridin2-yl-5,6-dihydro-4H-pynoloI 1,2-<br>
b]pyrazol-3-yl).quinoline,<br>
xx) 7-(3-chIoro-piopoxy)-6-methoxy-4-(2-pyridin-2-yI-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyra2ol-3-yl)-quinoline,<br>
yy) 7-(3-chloro-propoxy)-4-[2-(6-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyra2ol-3-yl]-quinoHne,<br>
zz) (1 - {3-[7-(2-chloro-ethoxy)-quinoIin-4-yl]-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-2-y|} -propenyl)-niethylcnc-amine,<br>
aaa) N,N-Dicthy1-2-[4-{2-pyridin-2-yl-5t6-dihydro-4H-pynx)lo[l,2-b]pyrazol-<br>
3-yl)-quinolin-7-yloxy]-acetamidct<br>
bbb) 7-[2-((2R&gt; 1 • Methyl-pynolidin-2-yl)-€thoxyH-(2-pyridin-2-y!-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-qumolinc,<br>
ccc) 7-( 1 -Mcthyl-piperidin-3-ylmcthoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl&gt; quinoline,<br>
ddd) 7-(3-N,N-Dimethyiamino-2-methyl-propyloxy)-4-(2-pyridin-2-yl-5,6-<br>
d ihydro-4H-pyrrolo[ 1,2-b](»yrazol-3-yl)-quinolinc,<br>
eec) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolot 1,2-b]pyrazol-3-yl]-<br>
7 -propoxy-quinolinc,<br>
ffO {4-[2-(6-Me thyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-<br>
yl]-quinolin-7-yloxy}-acetic acid methyl ester,<br>
ggg) 7-lsopropo&gt; y-4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyTTolo[ 1,2-<br>
b]pyra2ol-3-y|).quinoline,<br><br>
hhh) 4-(2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrro)o[l,2-b]pyra2ol-3-yl]-<br>
7-(3-morpholin-4-yl-propoxy)-Quinoline,<br>
iii) 7-Benzyloxy-2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo[ 1,5-a]piperidine,<br>
jij) 2-[4-(2-pyridin-2 -yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoJin-.<br>
7-yloxy]-acetatnide,<br>
kkk) 7-(5-Phenyl-[ 1,2,4]oxadiazolO-ylmcthoxyH-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrTOlo[ 1,2-b]pyrazol-3-yl&gt;quinolinc,<br>
HI) 7-(2^-Difluoro«benzo[l,3]dioxol-5-yImcthoxy)-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[! ,2-b)pyrazol-3-yl)-quinoline,<br>
mmm) 7-[2-((25)-1 -Mcthyl-pyrrolidin-2-yl)-cthoxy)-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyra2ol-3-yl)-quinoline,<br>
nnn) 5-[4-
7-yloxymclhyl]-pyrrolidin-2-oiH:,<br>
ooo) 7-( I -Mcthyl-pipendin-2-ylincthoxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo(l,2-b]pyrazol-3'yl)-quino!ine hydrochloride,<br>
PPP) 7-[2-{ 1 -Methyl-pyrrolidin-2-yl)-cthoxy]«4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrro)o[ 1,2-b]pyrazo)-3-yl)-<juinoline hydrochloride></juinoline>
b]pyrazol-3-yl)-quinoline 1 -oxide,<br>
rrr) 7-Methanesulfonyl-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazoI-3-yl)-quinoline,<br>
sss) 7-Ethanesulfonyl"4-(2-pyridin-2-y]-5,6-dihydro-4H-pyrrolo[ 1,2-b)pyrazol-<br>
3-yl)-quinoline,<br>
ttt) 4-(2-Pyridjn-2-yl-5,6-dihydro-4H-pyiTolo[l,2-b)pyrazol.3-yl)-7-[3-<br>
(pyrimidine-2-sulfonyl)-propoxy|-quinoline,<br>
uuu) 7-[3-( I -McthyI-lH-imidazole-2-suIfony])-propoxy]-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pynolo[ 1,2-b)pyraz€il-3-yl)-quinolinc,<br>
vvv) 7-[3-(4-Chloro-benzenesulfonyl)-propoxy]-4-(2-pyridin-2-yJ-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<i></i>
www) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyTazol-3-yl)-7-[3-<br>
(pyridin-2-ylnr»ethanesulfonyl)-propoxy]-quinolinc,<br><br>
xxx) 4-(2-Pyridin-2-y|-5f6-dihydro-4H-pyrrolo(J,2-b]pyra2ol-3-yI)-7-(3-<br>
(pyridin-2-ylmcthanesulfinyl)-pn)poxy]-quinolinc,<br>
yyy) 3- {4-[2-(6-Methyi-pyridin-2- yl&gt;5,6-dihydro-4H-pyrrolo{ 1,2-b]pyrazol-3-<br>
yl]-quinolin-7-yl}-acrylic acid methyl ester,<br>
222) 4-[2-(6-Methyl-pyridin-2-yl)"5,6-dihydro-4H-pyTToIo[ J ,2-b]pyrazol-3-yl]-<br>
7-vinyl-quinoline,<br>
aaaa) 3-{4-[2-(6-Mcihylpyrdin-2-yl-5,6-dihydro-4H-pyiTolo[I,2-b]pyrazol-3-<br>
yl]quinolin-7-yl}-I -piperidin-1-yl-propenonc,<br>
bbbb) 7-Bcn2yl-4-[2-(6-inethyI-pyridin-2-yl)-5,6-dihydro-4H-pyn-oIolJ,2.<br>
b)pyrazol-3-yI]-quinol ine,<br>
cccc) 4-[2-(6-M"cthyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo(l^-bJpyrazol-3-yl]-<br>
quinolinc-7-carboxylic acid,	:<br>
dddd) 3-(4-{2-(6-Methyl pyridin^-yl^S^-dihydTcMH-pyrrolofl^-bJpyrazol-3-<br>
yl]-quinolin-7-yl) -acrylic acid,<br>
eeee) 3- {4-[2-(6-Mcthyl pyridin-2-yl)-5,6-dihydro-4H-pynrolo( 1,2-b)pyrazol-3-<br>
yl]-quinolin-7-yl}-propionicacid,<br>
ftTf) 4-(2-Pyridin-2-yl-.',6-dihydro-4H-pyrrolo[l ,2-b]pyrazol-3-yl)-quinoline-7-<br>
carboxylic acid cyclopentylamidc,<br>
gggg) 4-(2-Pyridin-2-yl-! ,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazpl-3-yl)-quinolioe-7-<br>
carboxylic acid (2-morpholin-4-yl-ethyl)-amide,<br>
hhhh) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-quinoline-7-<br>
carboxylic acid [2-(lH-imidazoI-A-yl)-cthyl]-amide,<br>
iiii) 4-(2-Pyridin-2-yl-3,6-dihydro-4H-py«Tolo[ 1 ^-b)pyra2ol-3-yI)-quinoJine-7.<br>
carboxylic acid (2-methylamino-e(hyl)-ainide,<br>
jiij) 4-{2-Pyridin-2-yI-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoHne-7-<br>
carboxylic acid (3-methylamino-piopyl)-aiiiide,<br>
kkkk) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b}pyrazol-3-yl)-quinoline-7-<br>
carboxylic acid (2-dimethylamina-€thyl)-amidc,<br>
1111) (4-Methyl-pipcrazin-l-yl)-[4H;2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-<br>
b]pyrazol-3-y))-quinolin-7-yl]-meirhanone,<br>
mmmm) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrTolo(l ,2-b]pyrazol-3-yI)-<br>
quinoline-7-carboxylic acid cyclobutylamide,,<br><br>
nnnn) 4-(2-Pyridin-2-yl -5,6-dihydro-4H-pyrrolo(1,2-b]pyrazol-3-yl)-quinoline-7-<br>
carboxyfic acid cyclopropylamkle,<br>
oooo) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline«7-<br>
carboxyiic acid (l-ethyl-propyl)-amide,<br>
PPPP) 4-(2-Pyridin-2-yf-5,6-<lihydro-4h-pyrrolo></lihydro-4h-pyrrolo>
carboxyljc acid eihylamidc,<br>
qqqq) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pynrolop ,2-b]pyrazol-3-yl)-quinoline-7-<br>
carboxylic acid isobutyl-amide<br>
mr) 4-(2-Pyridin-2-&gt; l-5,6-dihydro-4H-pym&gt;lo( 1,2-b)pyn«ol-3-yJ)-quJnoHne-7-<br>
carboxylic acid tert-butylamidt,<br>
ssss) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo(l,2"b]pyra20l-3-yI)-quinolinc-7-<br>
carboxylic acid isopropylamide,<br>
««) 4~(2-Pyridin-2- /l-5,6-dihydro-4H-pyrrololl ^-bJpyrazol-S-yO-quinoline-?-<br>
carboxylic acid propylamidc,<br>
uuuu) 4-(2-Pyridin-2-yJ-5,6-d<hydro-4h-pyrrolo i t2-b></hydro-4h-pyrrolo>
carboxylic acid (2-methyl-butyl)-amidc,<br>
vwv) 4-(2-Pyridin-2 yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolinc-7-<br>
carboxylic acid ((2S)-2-mcth,vl-botyJ&gt;aroide.<br>
wwww)	4-(2-P widin-2-yI-5,6-d&gt;hydro-4H-pyTrolo[ 1,2-b]pyTazol-3-yl)-<br>
quinolinc-7-carboxylic acid (2S)-scc-b«)iylamidc,<br>
xxxx) 4^2-Pyridin-2-y!-5,6-dihydro-4H-pyrroJo[ 1,2-b]pyrazoI-3-yl&gt;-quinoIinc-7-<br>
carboxylic acid (2R)-sec-buty!amide,<br>
yyyy) 4-(2-Pyridin-i -yJ-5,6-dihydro-4H-pynro)o( 1,2-b]pyrazol-3-yl&gt;quinoHne~7-<br>
carboxylic acid ((IR)-1,2-diriiethyl-piopyl)-amide,<br>
2222) 4-(2-Pyridin-:.'-yN5,6'dihydro-4H-pyrro?of 1,2-b]pyra2ol-3-yl)-quinolinc-7-<br>
carboxylic acid (pyridin-4-y!mcthyl)-amidc,<br>
aaaaa) 4-(2-Pyrtdin- 2-yi-5,6-dihydro-4H-pyrrolof 1,2-b]pyra2Ol-3-yl)-quinoline-7-<br>
carboxyh'c acid (pyridin-3-yimeihyl)-amide,<br>
bbbbb)4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyTTolo[l,2-b]pyrazol-3-yl)-quino)inc-7-<br>
carboxylic acid (pyridin-2-&gt;Ime«hyl)-amide,<br>
ccccc) l-(4-MeihyI-pipera2in-l-yI)-2-(4-(2-pyridin-2-yI-5,6-dibydro-4H-<br>
pyrrolof 1,2-b3pyrazol-3-yJ)-quinoHn-7-yloxy]-ethanone,<br><br>
ddddd)N-(2-dimeihylamino-ethyl)-2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yI)-quir«oiin-7-yloxy]-acetamide,<br>
eeeee) N-(2-dimcthylamino-cthyl)-N-methyl-2-[4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-3-yl&gt;qginolin-7-yloxy)-acetamidc,<br>
fffTif) N.N-Dimeihyl-3 (4-(2.pyridin-2-y!-5,6-dihydro-4H-pyiTolo(1,2-b]pyrazol-<br>
3-yl)-quinolin-7-yloxy]-bcnzarnidc,<br>
ggggg) 4-(2-Pyridin-2-yi-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-y1)-quinoline-7-<br>
carboxylic acid amide,<br>
hhhhh) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo{ 1,2-H]pyrazol-3-yl)-quinoUnc-<br>
7-carboxylic acid (2-dimethylamino-eChyljhmethyl-amide,<br>
iiiii) 4-(2-Pyridin-2-&gt;l-5,6-dihydro-4H-pyTTolo[l,2-H)pyrazol-3-&gt;i)-quinoline-<br>
7-carboxylic acid (3-dimethyia,nino-propyl)-methyl-amide, :<br>
jijjj) 4-(2-Pyridin-2-j'1-5,6-dihydro-4H-pyrrolo[ 1,2-H]pyrazol-3-yl)-quinoline-<br>
7-carboxylic acid dimcthylamiie,<br>
kkkkk) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrroloI 1,2-H]pyrazol-3-yl)-quinolinc-<br>
7-carboxylic acid mcthylamidi:,<br>
1111!) 4-(2-Pyridin-2- /l-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quino!ine-7-<br>
carboxylic acid pyridin-2-yIanudc,<br>
mmmmm) 1 -[2-<q ainolin-4-yl></q>
pyrrolo( 1,2-b]pyrazol-3-yll qt inoline-7-carboxyiic acid N.N-dimcthylaminocthylamidc,<br>
nnnnn) 4-[2-
yl]quinolinc-7-carbox-yIic acid (2-pipcridin-l-yl-ethyI)amidc,<br>
ooooo)N-(2-Dimethylamino-cthyl)-3-{4-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-<br>
4H-pyTTolo(l,2-b]pyrazol-3-yl]-quinolJn»7-yl}-propionatnidc,<br>
ppppp) 4-{2-
quinoline-7-carboxylic acid (J-dimcthylamino-propyl)-amidc,<br>
qqqqq)4-{2-(6-Mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyiroJo[l,2-b]pyrazol-3-yi]-<br>
quinoline-7-carboxylic acid (J-pyrrolidin-l-yl-propyl)-amide,<br>
mn) 4-[2-(6-Meth&gt;l-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo(l,2-b]pyrazol-3-yn-<br>
quinolinc-7-carboxylic acid (3-morphol«n-4-yl-propy1)-amide,<br>
sssss) 3-{4-(2-(6-M«uhyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo(l,2-b]pyrazol-3-<br>
yl]-quinolin-7-y|)-propionamide,<br><br>
UtM) N-(2,2-Dime«hyl*mino-ethyl)-N-methyl-3-{4-[2-(6-methyl-pyridin-2-yl)-<br>
5,6-dihydro-4H-pyrrolo[l,2-b]p)Tazol-3-yl]-quinolin-7-yJ}-propionamide,<br>
uuuuu) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrroIo[ 1,2-b]pyra2oJ-3-yJ&gt;-quinoline-7-<br>
carboxylic acid hydrazidc,<br>
wvvv) 4-(2-Pyridin-2-yl- 5,6-dihydro-4H-pyrTolo[ 1,2-b]pyrazol-3-yl)-quinoline-7-<br>
carboxylic acid hydroxyamide,<br>
wwwww) 4-(2-Pyrid«n-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyra2ol-3-yl)-<br>
quinolinc-7-carboxylic acid (2-amino-ethy|)-amide,<br>
xxxxx) 4-(2-Pyridin-2-yJ- 5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazoJ-3-yl)-quinoJine-7-<br>
carboxyJic acid (2-hydroxy-ethyl&gt;amide,<br>
yyyyy) 4-(2-Pyridin-2-yl-5,6-dihydro-4H-pynrolo[] ,2-b]pyrazol-3-yl)K|uinolinc-7-<br>
sulfonic acid amide,<br>
Z2222) 4-(2-Pyridin-2-yl-.*),6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-3-yl}-quinolinc-7-<br>
sulfonic acid mcthylamidc,<br>
aaaaaa)4-(2-Pyridin-2-y]-."i,6-dihydro-4H-pyrToIo(l,2-b]pyrazol-3-yl)-quinoline-7-<br>
sulfonic acid dimcthylamide,<br>
bbbbbb)	4-(2-Pyridi i-2-yl-5,6-dihydro-4H-pyrrolo(; ] ,2-b]pyrazol-3-yI)-<br>
quinoline-7-sulfonic acid (3-dimeihylamino-propyl)-amide,<br>
cccccc)4-(2-Pyridin-2-yl-5,6-dihydro-4H-pynrolo[ 1,2-b]pyrazoJ-3-yl)-
sulfonic acid diethylamide,<br>
dddddd)	4-(2-Pyriditi-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl&gt;-<br>
quinoline-7-sulfonic acid (2-pipendin-l-yl-ethyl)-amide,<br>
cceccc)4-(2-Pyridin-2-yl-5 (6-dihydro-4H-pyrTolo[ 1,2-b]pyrazoI-3-y!)-quinoh"ne-7-<br>
sulfonic acid (2-hydroxy-ethyl)-aniidc,<br>
ffTTIflf) 4-(2-Pyridin-2-yJ-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-3-yl)-<juinolin-7-></juinolin-7->
ylaminc,<br>
ggggfig)	2-DimcthyIamino-A^-{4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo( 1 »2-b]pyrazol-3-yl)-quinolin-7-yl]-acetainide,<br>
hhhhhh)	3-Dimcthylamino-N-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolin-7-yl]propionamide,<br>
iiiiii) N-[4-(2-Pyridin-2-&gt;l-5,6-dihydro-4H-pyrrolo[l,2-b)pyrazol-3-yl)-<br>
quinolin-7-yl]-methanesulfonamid
 <br>
JMJ) N-[4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl)-<br>
quino!in-7-yl]-acetamide,<br>
kkkkkk) 4-(2-Pyridin-2-yl-S,6^ihydro-4H-pyTTolo{1,2-b)pymol-3-yl)-<br>
quinoline-7-carboxy)ic acid (2-acctylamino-ethyl)-amide,<br>
111111) N-{3-[4-(2-Pyridin-2-yl-5.6-dlihydro.4H-pyrrolotl,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-propyl}-methanesulfonarnide,<br>
mmmmmm) 1 -methyl-1 H-imidazole-4-sulfonic acid {3-{4-(2-pyridm-2-yN5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pymol-3-yl)-quinolin-7-yloxy]-propyl}-ainidef<br>
nnnnnn)	I •(2-Dimcthylamino-ethyl)-3-t4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolin-7-yl]-urea,<br>
oooooo)	1 -(3-Dimcthylamino-propyl)-3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolo[l,2-b]pyrazo1-3-yl)'qainolin-7-yl]-urca,	;<br>
PPPPPp)	1 -(2-H ydroxy-cthyl)-3-[4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyuolo{ ] ,2-b]pyTazol-3-yl)-quinolin-7-yl}-urea,<br>
qqqqqq) [4-(2-Pyridin-2-yl-5,6-dihydro-4H-pyiTolo[l,2-bJpyra2ol-3-y))-<br>
quinolin-7-y|]-carbamic acid methyl ester,<br>
mrrr) [4-(2-Pyridin-2-yl-5,6-<lihydro-4h-pyttolo></lihydro-4h-pyttolo>
yl]-carbamic acid 2-hydroxy-ethyl ester,<br>
ssssss) [4-(2-Pyridin- 2-yl-5,6-dihydro-4H-pyTTolol 1,2-b]pyrazol-3-yl)-quinolin-7-<br>
yl]-carbamic acid 2-methoxyethyl ester,<br>
ttmt) 1 ,3-Bis-[4-(2- pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b}pyrazol-3-yl)-<br>
quinolin-7-yl)-urca,<br>
uuuuuu)	Dimethyl-carbamic acid 4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrTolo[ 1,2-b]pyrazol-3-yl)-quinolin-7-yl ester,<br>
vvvvvv)	7-Broino-2-isopropyl-4-(2-pyridin-2-yl.5,6-dihydro-4H-<br>
pyrrolo[ 1.2-b}pyrazoi-3-yl)-quinoHoe,<br>
wwwwww) 7-(3-Chloro-propylsulfanyl)-4-(2-pyridin-2-yl-S,6-dihydro-4H-<br>
pyrrolo[ 1,2-b)pyrazol-3-yl)-tjuinoline,<br>
xxxxxx)	7-Bromo-4-(4-chloro-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazol-3-y|)-quinoline,<br>
yyyyyy) 8-Chloro-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-<br>
3-yl)-quinolin-7-ol,<br><br>
zzzzzz)	8-Bromo-4(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-<br>
3-yI)-quinolin-7-ol,<br>
aaaaaaa) 3-(7-Brotmo-quinolin-4-yl)-2-pyTidin-2-yl-5,6-dihydro-4H-<br>
pyrrolot 1,2-b)pyrazol-4-ol,<br>
bbbbbbb) 7-Bromo-4-(4-melhoxy-2-pyridin-2-yI-5,6-dihydro-4H-<br>
pyrrolo( 1,2-b]pyrazol-3-yl)-quinaKne,<br>
ccccccc) (3-(7-Bromo-quinolin-4-yl)-2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrTolo[ 1,2-b]pyrazoI-4-yl )-mcthyl-aminc,<br>
ddddddd) 3-(7-Bronio-quinolin-4-yI)-2-pyridin-2-yi-5,6-dihydro-pym)lo[ 1,2-<br>
b)pyrazol-4-onc,<br>
ceeeeee) 3-[4-(2-P)fidin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yloxy]-benzamide,<br>
fffffff) N,N-Dimethyl-3-|4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrololl,2-b)pyrazo1-<br>
3-yl)-quinolin-7-yloxy]-thiobcnzamidc,<br>
ggggggg) Dimethyl{3-(4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-<br>
b]pyrazo!-3-yl)-quinolin-7-yloxy]-benzyl}-amine,<br>
hhhhhhh) 4-(2-Pyri«lin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-ol,<br>
iiiiiii) 4-(2-(6-MethyI-pyridin-2-yl)-5,6-dihydro-4H-pynro!o[ 1,2-b]pyrazol-3-yl]-<br>
quinolin-7-ol,<br>
jjjjjjj) 6-Methoxy-4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-ol,<br>
kkkkkkk) 3- i4-[2-(6-Mcthy|.pyridin-2-y1)-5,6-dihydro-4H-pyrrolo[l ,2-<br>
b]pyrazol-3-yl)-quinolin-7-yl}-propionic acid methyl ester,<br>
IIIIIII) 7-Amino-4-[2-(to-Mcthyl-pyridin-2-yl)-5,6-dihydro-4H-pyfTolo( 1,2-<br>
b]pyrazol-3-y|]-quinoIinc,<br>
mmmmmmm)N,N-Dinielhyl-3-{4-t2-(6-mcthyl-pyridin-2-yl)-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazol-3-yl]-qu»nolin-7-y|} -propionamidc,<br>
nnnnnnn) N-
yl)-quinolin-7-y|oxy]-propyl}-acciamide,<br>
ooooooo) N-Acctyl-N- {4-{2
pyTrolo[l,2-b]pyrazol-3-yl]-quinoHn-7-yl}-acetamide,<br><br>
ppppppp) 2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo( 1,5-a]piperidin-7-ol,<br>
qqqqqqq) 7-Acetoxy-2-pyridin-2-yl-3-quinolin-4«yl-pyrazolo[l,5-<br>
a]piperidine,<br>
rnrmr) Methyl- {3-[4-(2-pyridin-2-yI-5,6-dihydro-4H-pynrolo[ 1,2-b]pyrazol-3-yI)-<br>
quinolin-7-yloxy]-propyl}-amine,<br>
sssssss)	7-(Piperidm-4-yloxy)-4-(2-pyridin-2-yl-5,6-dihydro-4H-<br>
pyrrolof 1,2-b]pyrazoU3-yl)-quinolinc,<br>
ttmtt) 4.[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl]-<br>
quinolinc-7-carboxylic acid (2-amino-l,1-dimethyl-ethyl)-amide,<br>
uuuuuuu) 7-(l-Methyl-pyrrolidin-3-ylmcthoxy)-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
vvvvvv) 7-(l -Mcthyl-pipcridin-4-ylmethoxy)-4-(2-pyridin-2-yl-5,6-<br>
dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinolinc,<br>
wwwwwww) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyiTolo{ 1,2-<br>
b]pyrazol-3-yl]-quino!ine-7-carboxy)icacid(2-dimethylamino-l,I-ditncthyl-eihyl)-amidc,<br>
xxxxxxx) 4-(6-Pyridin-2-yl-2,3-dihydro-pyrazolo[5,l-b]oxazol-7-y))-<br>
quinoline,<br>
yyyyyyy) 3-[4-(2-Pyridin-2-yI-5,6-dihydro-4H-pyrrolo( 1,2-b]pyrazol-3-yl)-<br>
quinolin-7-yl]-oxazolidin-2-one,<br>
zzzzzzz)	I -[4-(2-Pyridin-2-yl -5,6-dihydro-4H-pyiTolo[ 1,2b]pyrazol-3-yI)-<br>
quinolin-7-y|]-imidazolidin-2-ortc,<br>
aaaaaaaa) 4-(2-Pyriclin-2-yl-5,6-dihydro-4H-pyrrolo[l,2-b)pyrazol-3-yl)-7-<br>
(pyridin-4-ylmethoxy)-quinolin«,<br>
bbbbbbbb) 4-(2-Pyridin-2.yl-516-dihydro-4H-pyTTolo[U-b]pyrazol-3-yl)-7-(3-<br>
pyridin-3-yl-propoxy)-quinolinc,<br>
cccccccc) 7-(4,5-Dihydro-1 H-imidazol-2-yl)-4-(2-pyridin-2-yl-5,6-dihydro-<br>
4H-pyrrolo[ 1,2-b]pyrazol-3-yl)-quinoline,<br>
dddddddd) 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b}pyrazol-<br>
3-yl]-quino)inc-7-carboxylic acid (2-dimcthylamino-1-methyl-cthyl)-amide,<br>
eeeeeece) 4-[2-(6-Methyl-pyridin-2-yl)5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-<br>
3-yl]-quinoline-7-carboxylic acid amide,<br><br>
fffTfffl) 4-(2-Pyridin-2-yl 5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-3-yl)(-<br>
quinolinc-7-carboxylic acid (3-dimeThylamino-propyl)-amidc,<br>
gggggggg) 4-[2-(6-Mcthyl-pyridIn-2-yl)-5,6-dihydro-4H-pyrrolo[ 1,2-b]pyrazol-<br>
3-yI]-quinolinc-7-carboxylicacid(2-dimethylamino-cthyl)-mcthyl-amidc,<br>
hhhhhhhh) N,N-Dimethyl-3-{4-[2
pyrTolo[ 1,2-b3pyrazol-3-yl]-quinolin-7-yl}-acrylafnidc,<br>
iiiiiiii) 7-BenzyIoxy-4-[2-(6-methyI-pyridin-2-yl)~5,6-dihydro-4H-pyrrolo{ 1,2-<br>
b]pyrazo!-3-yI]-quinoline,<br>
jiijjlijj) N,N-Dimethyl-3-{4-[2-(6-methy1-pyridin-2-yI)-5,6-dihydro-4H-<br>
pyrrolo( 1,2-b]pyTazol-3-yl3-quinolin-7-yl}-acryIamidc,<br>
and the pharmaceutically acceptable salts and esters.<br>
7.	A pharmaceutical formulatian comprising a compound as claimed in claim 1 to 6, or<br>
the pharmaceutically accep :abie salt ester thereof with a pharmaceutically acceptable<br>
diluent or carrier.<br>
8.	A compound as claimed in claim 1, wherein compound is 3-bromo-2-(6-methyl-<br>
pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrrazole.<br><br>
Novel pyrrazole compounds and their<br><br>
use as pharmaceutical agents, in particular their use as TGF-beta signal transduction<br>
inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (1) is a<br>
four, five, or six membered saturated ring and X is C, O or S.</j></i-methyl-piperidin-4-ylmethoxy></:></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1LT0xOUC0yMDAzLSgwNC0wMS0yMDEzKS1GT1JNLTI3LnBkZg==" target="_blank" style="word-wrap:break-word;">1359-KOLNP-2003-(04-01-2013)-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1LT0xOUC0yMDAzLSgwNS0wMS0yMDEyKS1GT1JNLTI3LnBkZg==" target="_blank" style="word-wrap:break-word;">1359-KOLNP-2003-(05-01-2012)-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1LT0xOUC0yMDAzLUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">1359-KOLNP-2003-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1LT0xOUC0yMDAzLUZPUk0gMjcucGRm" target="_blank" style="word-wrap:break-word;">1359-KOLNP-2003-FORM 27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtYXNzaWdubWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtY2xhaW1zLnBkZg==" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtY29ycmVzcG9uZGVuY2UucGRm" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZGVzY3JpcHRpb24gKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZm9ybSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZm9ybSAxMy5wZGY=" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZm9ybSAxOC5wZGY=" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZm9ybSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZm9ybSAyNi5wZGY=" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-form 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZm9ybSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZm9ybSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtZ3BhLnBkZg==" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtcmVwbHkgdG8gZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTM1OS1rb2xucC0yMDAzLWdyYW50ZWQtc3BlY2lmaWNhdGlvbi5wZGY=" target="_blank" style="word-wrap:break-word;">1359-kolnp-2003-granted-specification.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="228786-method-for-increasing-the-capacity-of-an-installation-used-to-carry-out-an-industrial-process.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="228788-authentication-between-device-and-portable-storage.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>228787</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1359/KOLNP/2003</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>07/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>13-Feb-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>11-Feb-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>22-Oct-2003</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ELI LILLY AND COMPANY</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>LILLY CORPORATE CENTER, CITY OF INDIANAPOLIS, STATE OF INDIANA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>SAWYER, JASON, SCOTT</td>
											<td>5718 NORTH WINTHROP AVENUE, INDIANAPOLIS, IN 46220</td>
										</tr>
										<tr>
											<td>2</td>
											<td>BEIGHT, DOUGLAS, WADE</td>
											<td>3468 SOUTH COUNTY ROAD 600 WEST, FRANKFORT, IN 46041</td>
										</tr>
										<tr>
											<td>3</td>
											<td>CIAPETTI, PAOLA</td>
											<td>39, DOMAINE DE L&#x27;ILE, F-67400 ILLKIRCH-GRAFFENSTADEN</td>
										</tr>
										<tr>
											<td>4</td>
											<td>DECOLLO, TODD, VINCENT</td>
											<td>15028 REDCLIFF DRIVE, NOBLESVILLE, IN 46142</td>
										</tr>
										<tr>
											<td>5</td>
											<td>GODFREY, ALEXANDER, GLENN</td>
											<td>176 INNISBROOK TRAIL, GREENWOOD, IN 46142</td>
										</tr>
										<tr>
											<td>6</td>
											<td>GOODSON, THEODORE, JR.</td>
											<td>4045 DEVON DRIVE, INDIANAPOLIS, IN 46226</td>
										</tr>
										<tr>
											<td>7</td>
											<td>HERRON, DAVID KENT</td>
											<td>5945 ANDOVER ROAD, INDIANAPOLIS IN 46220</td>
										</tr>
										<tr>
											<td>8</td>
											<td>LI, HONG-YU</td>
											<td>1268 SULLIVANS RIDGE. ZIONSVILLE, IN 46077</td>
										</tr>
										<tr>
											<td>9</td>
											<td>LIAO, JUNKAI</td>
											<td>50 JUNIPER LANE, TEWKSBURY, MASSACHUSETTS 01876</td>
										</tr>
										<tr>
											<td>10</td>
											<td>MCMILLEN, WILLIAM, THOMAS</td>
											<td>5823 BEATLE DRIVE, APARTMENT. B, INDIANAPOLIS, IN 46216</td>
										</tr>
										<tr>
											<td>11</td>
											<td>MILLER, SHAWN, CHRISTOPHER</td>
											<td>8329 EAST ASH DRIVE, MORGANTOWN, INDIANAPOLIS, IN 46160</td>
										</tr>
										<tr>
											<td>12</td>
											<td>MORT, NICOLAS, ANTHONY</td>
											<td>3582, NORTH OAKLAND AVENUE, APT. 3, MILWAUKEE WISCONSIN 53211</td>
										</tr>
										<tr>
											<td>13</td>
											<td>YINGLING, JONATHAN, MICHAEL</td>
											<td>10679 MISTY HOLLOW LANE, FISHERS, IN 46038</td>
										</tr>
										<tr>
											<td>14</td>
											<td>SMITH, EDWARD, C., R.</td>
											<td>9969 PARKWAY DRIVE, FISHERS, IN 46038</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 487/04</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2002/11884</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2002-05-13</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/293,464</td>
									<td>2001-05-24</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/228787-pyrrole-compound by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:24:44 GMT -->
</html>
